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ABSTRACT 
Mesenchymal stem cell (MSC) has an immense potential for use in clinical 
applications, however, there is still paucity in the fundamental knowledge in the 
techniques and processes involved in MSCs differentiation, especially tenogenic 
differentiation. Growth and differentiation factor 5 (GDF5) is a potential inducer which 
may induce tenogenic differentiation response in MSC. The aims of this current study 
were: (1) to investigate the tenogenic differentiation in human and rabbit MSCs 
(hMSCs and rbMSCs respectively) in response to GDF5 treatment; (2) to investigate the 
potential of GDF5-induced rbMSCs in tendon repair in in vivo rabbit model; and (3) to 
investigate the differentially expressed genes between GDF5-induced hMSCs and the 
untreated hMSCs compared to the native tenocytes (hTeno). In this study, both hMSCs 
and rbMSCs were isolated and characterized following the ISCT guidelines. Upon 
GDF5 (0, 5, 25, 50, 100 and 500 ng/ml) treatment, the results demonstrated that there 
was (i) no significant differences in the proliferation rate between the hMSCs cultured 
at different concentrations of GDF5; (ii) a significant increase in total collagen levels 
comparable to that of hTeno culture (p<0.05) when hMSCs were cultured at 100 ng/mL 
of GDF5, (iii) a significant increase in total collagen levels in 500 ng/ml GDF5-induced 
rbMSCs to a level comparable to rbTeno (rabbit tenocyte) cultures, however there were 
no significant difference in total collagen levels between rbMSCs treated with 
100 ng/ml and 500 ng/ml of GDF5; (iv) a significant (p<0.05) up-regulation in the 
expression of candidate tenogenic marker genes (Scleraxis (Scx), tenascin-C and type-I 
collagen (Col-I)) whilst a significant (p<0.05) down-regulation of the non-tenogenic 
marker genes (runt-related transcription factor 2 and sex determining region Y (SRY)-
box 9) at day 7 upon 100 ng/mL GDF5 treatment in hMSCs; (v) a significant increase in 
Scx and Col-I gene expression levels were also detected in 100 ng/ml GDF5-induced 
rbMSC; (vi) increase in COL-I expression at protein level in rbMSCs cultures treated 
iv 
 
with 100 ng/ml GDF5. In the in vivo study to investigate the potential use of tenogenic 
rbMSCs (TMSC, 100 ng/mL of GDF5-induced rbMSCs), the quality of the 
infraspinatus tendon repair in New Zealand white rabbits using TMSCs and other 
methods were evaluated, which showed significant improvement in the cell based 
treated groups compared to the non-cell-based treated groups. A significant up-
regulation in expression of tenogenic marker genes (Scx and Col-I) in TMSCs group as 
compared to other treatment groups were also observed. Furthermore, microarray 
analysis showed: (i) significant differences in 954 genes in GDF5-induced hMSC and 
tenocytes compared to control hMSCs; (ii) the differentially expressed genes were 
involved in specific pathways (i.e. cytoskeleton remodeling, cell adhesion, and 
extracellular matrix related genes) that are closely related to the native behavior of 
hTeno in vivo. The findings of this study demonstrate that concentration of GDF5, 
≥100 ng/mL is able to induce tenogenic differentiation in both hMSCs and rbMSCs. 
These data suggest that tenogenic MSCs may potentially provide similar function to that 
of native tenocytes e.g. during tendon repair. These findings provide evidence of 
potential use of GDF5-induced MSCs in the clinical applications in future. 
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ABSTRAK 
Sel stem mesenkima (MSC) merupakan sel yang berpotensi tinggi untuk aplikasi 
klinikal. Namun, pengetahuan asas dalam teknik dan proses pembezaan MSC masih 
amat kekurangan, khususnya pembezaan tenogenik. Dalam pembezaan tenogenik pada 
sel MSC, faktor pertumbuhan dan pembezaan 5 (GDF5) berpotensi tinggi untuk 
merangsangkan gerak balas ini. Objektif kajian ini ialah untuk: (1) mengkaji kesan 
pembezaan tenogenik sel MSC manusia dan arnab (hMSCs dan rbMSCs) akibat cetusan 
GDF5; (2) mengkaji potensi sel tenogenik rbMSC (sel rbMSC yang dicetus GDF5) 
dalam pembaik pulihan tendon terkoyak dengan menggunakan model in vivo arnab; dan 
(3) mengkaji gen terungkap pada aras yang berbeza pada sel hMSC cetusan GDF5 
berbanding dengan sel hMSC tanpa rawatan dan sel tenosit asli (sel tendon daripada tisu 
tendon; hTeno). Dalam kajian ini, kedua-dua hMSC dan rbMSC diasingkan dan 
dicirikan mengikuti garis panduan ISCT. Dalam eksperimen cetusan GDF5 (pada 
kepekatan 0, 5, 25, 50, 100 dan 500 ng/ml) didapati: (i) tiada perbezaan yang signifikan 
dalam kadar pembahagian sel antara sel hMSC yang dikultur pada kepekatan 
GDF5yang berbeza; (ii) peningkatan aras jumlah kolagen yang signifikan dan setanding 
dengan aras sel hTeno (p<0.05) pada hMSC yang dikultur pada 100 ng/mL GDF5, (iii) 
peningkatan yang signifikan dalam aras gen calon penanda tenogenik (seperti scleraxis, 
tenascin-C dan kolagen jenis-I (Col-I)) dan pengurangan yang signifikan (p<0.05) 
dalam aras gen penanda bukan tenogenik (seperti runt-related transcription factor 2 and 
sex determining region Y (SRY)-box 9; pada hari ke-7 sel hMSC yang dicetus oleh 
100 ng/mL GDF5; (iv) perbezaan yang signifikan dalam 954 gen yang dikenal pasti 
melalui analisis mikroatur pada sel hMSC yang dicetus olah GDF5; (v) gen-gen 
terungkap pada aras yang berbeza didapati terlibat dalam tapak jalan tertentu (iaitu 
pembentukan semula cytoskeleton, perlekatan sel, dan gen yang berkaitan dengan 
matriks extraselular) yang berkait rapat dengan kelakuan sel tenosit asli dalam keadaan 
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in vivo. Dalam eksperimen in vitro rbMSC, didapati: (i) peningkatan yang signifikan 
(p<0.05) dan setanding dengan sel rbTeno (sel tenosit arnab) dalam aras jumlah kolagen 
pada sel rbMSC cetusan dengan 100 ng/ml GDF5; (ii) peningkatan yang signifikan 
dalam aras ungkapan gen scleraxis dan Col-I (p<0.05); (iii) peningkatan dalam aras 
pengekspresan protein COL-I pada sel rbMSC yang dirawat dengan 100 ng/ml GDF5 
berbanding sel MSC tanpa rawatan, melalui pewarnaan berpendafluor. Kajian in vivo 
untuk mengkaji potensi sel tenogenik rbMSCs (sel rbMSC yang dicetus oleh 100 ng/mL 
GDF5) dalam meningkatkan kualiti pembaik pulihan tendon infraspinatus terkoyak 
dalam arnab menunjukkan peningkatan kualiti pemulihan tendon dalam kumpulan arnab 
dengan rawatan yang berasaskan sel berbanding kumpulan yang dirawat tanpa sel. 
Selain itu, juga didapati peningkatan yang signifikan dalam aras gen penanda tenogenik 
(scleraxis dan Col-I) dalam kumpulan arnab yang dirawat dengan sel tenogenik rbMSCs 
berbanding kumpulan rawatan lain. Keputusan kajian ini menunjukkan bahawa 
≥100 ng/mL GDF5 dapat mencetuskan pembezaan tenogenik pada sel hMSC dan 
rbMSC. Pemerhatian kajian ini mencadangkan bahawa sel tenogenik MSC berpotensi 
untuk memainkan peranan yang sama seperti yang sel tenosit asli, contohnya semasa 
pembaik pulihan tendon. Penemuan ini memberikan bukti bahawa sel MSC yang 
dicetus oleh GDF5 berpotensi tinggi untuk digunakan dalam aplikasi klinikal pada masa 
hadapan. 
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1.0 GEERAL ITRODUCTIO 
1.1 Structure and Function of ormal Tendon 
1.1.1 Tendon, Tenocyte and Tendon Extracellular Matrix 
Tendon is dense connective tissue which connects muscle to bone and allows 
transmission of forces generated by muscle to bone, resulting in joint movement. It is a 
living tissue with mechanical adaptation ability that allows it to respond to mechanical 
forces (eg. high tensional loading). This is achieved through changes in the metabolism 
as well as its structural and mechanical properties (Kjaer, 2004; Provenzano & 
Vanderby, 2006; Wang, 2006). These critical biological and biomechanical roles of 
tendon are played through a reciprocal relationship between its two main components, 
i.e. cells and extracellular matrix (ECM) (Table 1.1).  
 
Table 1.1 Structural compositions of tendon (Sharma & Maffulli, 2005; Wang, 2006). 
Component 
 
Total (%) 
Cellular materials 
     Tenocytes and tenoblasts 
     Others (chondrocytes, synovial cells and vascular cells) 
 
20 
       90-95 
         5-10 
 
Extracellular matrix(ECM) 
     Water 
     Dry mass 
 
80 
       60-80 
       20-40 
 Collagen        75-85 
 Type I 95-99 
 Type III and V 1-5 
 
 
 
 
Others (Type II, VI, IX, X and XI) 
 
Ground substance (Proteoglycan, glycoproteins and etc.) 
 
Trace amount 
 
 
       15-25 
 
The overall cell content in tendon tissue is low (20%). Tenocytes and tenoblasts 
are the two main cell types which coexist in tendon. Both of these cells are of 
mesenchymal origin and they constitute about 90-95% of the cellular component of 
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tendons (Amiel et al., 1984). Tenoblasts are immature tendon cells. They are spindle-
shaped and have numerous cytoplasmic organelles. They have a high organelle content 
which reflects their high metabolic activity. As they mature, tenoblasts become 
elongated and transformed into tenocytes. Tenocytes have lower nucleus-to-cytoplasm 
ratio than tenoblasts. These cells lie between the collagen fibers along the long axis of 
the tendon (Kirkendall & Garrett, 1997). The remaining 5-10% of the cellular elements 
of tendon consists of chondrocytes at the bone attachment and insertion sites (Fukuta et 
al., 1998), synovial cells of the tendon sheath, and vascular cells, including capillary 
endothelial cells and smooth muscle cells of arterioles (Sharma & Maffulli, 2005). 
Recently, several studies have shown that multipotent tendon stem cells/tendon 
progenitor cells (TSC/TPC) also exist in human and animal tendon tissues (Bi et al., 
2007; Rui et al., 2010; Yin et al., 2010). Nevertheless, it remains unclear whether the 
TSC/TPC are the same population of cells as the tenoblast. It is also unclear as to 
whether tenoblast is in fact committed tenogenic progenitor cells and that these cells are 
different from TSC/TPC. Cell markers to differentiate between the tenocyte, tenoblast 
and TSC/TPC are at this point remains unknown. 
In normal tendon, tenocyte synthesizes a wide range of ECM proteins in a well-
ordered structure. Among the most abundant of these proteins is the type-I collagen. 
This protein is organized in a parallel arrangement providing a distinct hierarchal 
structure, which ultimately forms the tendon (Figure 1.1). The tenocyte secretes soluble 
trihelical tropocollagen that is assembled and cross-linked in parallel fibrillar arrays. 
Higher-order organization of these arrays is provided by the endotenon, which appears 
as a loose connective tissues layer that envelopes collagen fibrils to form tendon 
fascicles. Fascicles in turn are bundled together by the epitenon, a layer contiguous with 
the endotenon through which the microvasculature traverses and provides nutrients 
(Boyer et al., 2005; Fenwick et al., 2002). This multi-unit hierarchical structure aligns 
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fiber bundles parallel with the long axis of the tendon and affords the tendon high 
tensile strength (Wang, 2006). 
  
Figure 1.1   Schematic diagram of hierarchical structure of tendon (Silver et al., 2003). 
The fibril is the smallest tendon structural unit; it consists largely of rod-like 
collagen molecules aligned end-to-end in a quarter staggered arrays. Fibers 
form the next level of tendon structure. Fibers are composed of collagen 
fibrils and are bound by endotenons. Fiber bundles form fascicles, and 
bundles of fascicles are enclosed by the epitenon. Tendons are also 
surrounded by a third layer of connective tissue called paratenon (not shown 
in this figure).  
 
Normal tendon ECM is composed largely of collagen (predominantly type-I 
collagen, COL-I
1
), which provides structural integrity and mechanical strength 
(Benjamin et al., 2008). A small amount of ground substances (Table 1.1) is not only 
important in fibrillogenesis but also provides tendon its high resistance behaviour to 
                                                 
1 Please note that the abbreviation for the gene is given in italics and the abbreviation for the protein expressed by the gene is given 
in capital letters. 
Tenocytes 
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compressive and tensile forces (Yoon & Halper, 2005). COL-I constitutes about 60% of 
the dry mass of the tendon and about 95% of the total collagen in tendon (Evans & 
Barbenel, 1975). The remaining 5% consists of type III and V collagens. In a normal 
tendon, type III collagen (COL-III) is mainly located in the endotenon and epitenon 
(Becker et al., 1976; Duance et al., 1977). The ratio of COL-I to COL-III has been 
previously used as indicators of the tenogenic characteristics in tendon tissues and 
tenocyte cultures (Maffulli et al., 2000; Yao et al., 2006). Other collagens (type II, VI, 
IX, X and XI) are present in trace amount in tendons (Fukuta, et al., 1998). The ground 
substances of the tendon ECM network surrounding the collagens and tenocytes are 
composed of proteoglycans and several other small molecules (Sharma & Maffulli, 
2005). The proteoglycan content in a tendon (dry mass) is relatively lower (~6% in 
compression region and ~0.2% in tensional region) as compared to other 
musculoskeletal tissue (Yoon & Halper, 2005). The content varies at different sites of 
the tendon and is dependant on the mechanical loading conditions, eg. tension vs. 
compression (Berenson et al., 1996; Riley et al., 1994b; Waggett et al., 1998). A 
summary of the abundant proteoglycans in tendon is presented in Table 1.2. Although 
normal mechanical function of tendon depends on the precise alignment of collagen 
fibrils, it is proteoglycans that regulate collagen fibrillogenesis. This is achieved via the 
interactions between the positively-charged groups of collagen fibers and the 
negatively-charged groups of the glycosaminoglycans (GAGs) in a proteoglycan 
molecule (Yoon & Halper, 2005). This, indirectly affects a tendon’s functionality. 
Members of the small-leucine-rich proteoglycans (SLRP) family (eg. decorin, biglycan, 
fibromodulin and lumican) bind to collagen fibrils and actively participate in 
fibrillogenesis (Vogel & Heinegard, 1985). Depletion of biglycan and fibromodulin 
affects the TSP/TPC differentiation and impairs tendon formation in vivo (Bi, et al., 
2007). Other proteins, such as adhesive glycoproteins (eg. fibronectin and 
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thrombospondin) are involved in binding the tenocytes to the collagen fibers (O'Brien, 
1992). These, are important in the repair and regeneration process in tendon (Jozsa et 
al., 1991; Lawler, 1986; Miller & McDevitt, 1991). Apart from these ECM proteins, 
several polypeptide factors are important in regulating the expression of specific genes 
that are commonly found in tendons and the expression of these genes influences the 
ECM metabolism and subsequently modulates the composition and organization of the 
tendon ECM (Table 1.3).  
 
Table 1.2 Summary of most abundant tendon proteoglycans. 
Designation Class Role in Tendon 
 
Decorin SLRP Binds to fibrillar collagen, inhibits collagen 
fibrillogenesis, binds TGF‚ and EGF (Zhang et al., 
2006). 
 
Biglycan SLRP Binds to fibrillar collagen, absent in avian species 
(Vogel & Heinegard, 1985). 
 
Fibromodulin SLRP Binds to type I collagen, facilitates formation of mature 
large collagen fibrils, modulation of tendon strength 
(Iozzo & Murdoch, 1996). 
 
Lumican SLRP Binds to type I collagen, inhibits size of collagen fibrils, 
modulation of tendon strength (Iozzo & Murdoch, 
1996). 
 
Aggrecan Modular 
(lectican) 
Linked to hyaluronan, provides resiliency, low levels in 
tensional parts of tendon, high levels in compressed 
regions, particularly in fibrocartilage (Rees et al., 2000). 
 
Versican Modular 
(lectican) 
Linked to hyaluronan, low levels in tensional parts of 
tendon, somewhat higher levels in compressed regions, 
increases viscoelasticity, maintains cell shape (Scott et 
al., 2008). 
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Table 1.3 Genes involved in tendon development and repair (Adapted from (James et 
al., 2008). 
 
Gene Function in Development, Repair and Tissue Regeneration 
 
Scleraxis 
(Scx) 
Transcription factor specifically detected in tendon cell precursor 
populations and selectively expressed in later stages (Schweitzer et 
al., 2001; Shukunami et al., 2006; Wang et al., 2005). 
 
Tenomodulin 
(Tnmd) 
A type II transmembrane glycoprotein that been reported 
predominantly expressed in tendons and ligaments (Shukunami, et 
al., 2006). A regulator of cell proliferation, differentiation and 
collagen fibril maturation (Docheva et al., 2005). 
 
Tenascin C 
(Tnc) 
A mechano-responsive modulator of matrix formation expressed in 
high tensional loading tissue such as tendons and ligaments (Mehr 
et al., 2000). An ECM protein that is evident during embryonic and 
tendon development (Chiquet-Ehrismann & Tucker, 2004). 
 
Collagen I 
(Col-I) 
 
Mature and highly organized collagen fibrils (Lejard et al., 2007). 
 
Collagen III 
(Col-III) 
Early ECM collagen in wound repair (Maffulli, et al., 2000; 
Williams et al., 1984). 
 
Decorin 
(Dcn) and 
aggrecan 
(Acan) 
 
Proteoglycan interactions modulating collagen fibril orientation 
and alignment (Sini et al., 1997). 
 
Smad8 Tenocyte differentiation, phenotype modulation and intracellular 
signaling (Towler & Gelberman, 2006). 
 
1.1.2 Early Tendon Development 
The formation of musculoskeletal system from the somatic mesoderm requires 
the coordinated development of muscle, cartilage and tendon lineages. In the early 
somite development, muscle and cartilage emerge from two distinct compartments, the 
myotome and the sclerotome. This is in response to signals secreted from the 
surrounding tissues. As the somite matures, the tendon lineage is established within the 
dorsolateral sclerotome (or syndetome, the fourth somitic compartment (Brent et al., 
2003)), which is adjacent to and beneath the myotome. The formation of a scleraxis 
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(Scx)-expressing tendon progenitor (TP) population in the sclerotome is induced by a 
fibroblast growth factor (FGF) signal secreted from the myotome (Figure 1.2).  
 
Figure 1.2  Model of FGF-dependent activation of Pea3 and Erm, and subsequent 
induction of Scx in the Somite (Adapted from Brent et al. 2004). 
(A) FGF signaling leads to expression of Ets transcription factors Pea3 and 
Erm and inhibits Mkp3, Sef and Spry in the anterior and posterior 
sclerotome and dermomyotome. FGF secreted by myotome bind to and 
activate an FGFR (green arrow). Receptor activations results in series 
of phosphorylation events (red arrows), culminating in direct or indirect 
transcriptional activations (black arrow) of target genes such as Pea3, 
Erm, Mkp3, Sef and Spry. 
(B) Once Pea3 and Erm expression domains have been established, further 
FGF signaling triggers phosphorylation and subsequent activation of 
Pea3 and Erm, which, in turn, activate transcription of target genes 
resulting in Scx expression. 
(C) Schematic of four somites, frontal view: dermomyotomes are beige; 
myotomes are yellow; sclerotomes are aqua. FGF expressed in center of 
myotome (orange) can diffuse to surrounding dermomyotome, 
myotome and dorsal sclerotome (arrows). FGF signaling here results in 
expression of Pea3 (red) and Erm (green), in a nested pattern, within 
anterior and posterior dermomyotome and dorsal sclerotome. Scx 
expression (purple) is induced when myotomal FGFs signal to the 
Pea3- and Erm- expressing dermomyotome and sclerotome. 
 
The FGF transcription effectors (Pea3 and Erm) are necessary for TP marker 
Scx expression in the somite to be expressed (Brent et al., 2005; Brent & Tabin, 2004). 
The domain of Scx expression, or the location of the syndetome, is dependent on the 
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combined conditions of the restricted expression pattern of Pea3 and Erm within the 
anterior and posterior sclerotome, and the distances that FGFs secreted from the center 
of the myotome are able to travel. Brent and colleagues (2005) also suggested that the 
early myotome regulatory factors, Myf5 and Myod1 (previously known as MyoD) 
expressions are required for FGF protein expression in the myotome, which in turn is 
required for the induction of TP markers. In addition, they suggested that tendon and 
cartilage lineages arising from the sclerotome appear to be an alternative and mutually 
exclusive, where the loss of chondrocyte differentiation results in an expanded somitic 
TP population. This causes the Sox9-expressing mesenchymal condensations to begin 
expressing tendon markers. It worth noting that when the differentiation of one cell fate 
is blocked, the other is adopted.  (Brent, et al., 2005).  
In contrast to the differentiation of axial tendons, that of the cartilages or tendons 
of the appendicular skeleton arises in situ. The initiation of tendons differentiation in the 
appendicular skeleton does not seem to require the presence of muscle (Kardon, 1998). 
Nevertheless, the maintenance of distal tendons does require interaction with muscle 
because in the absence of muscle these tendons gradually degenerate (Kardon, 1998). 
Based on the observation of Scx expression in the subectodermal location of the 
appendicular skeleton, it has been postulated that ectodermal signals might play a role 
in the occurrence of Scx-expressing TPs (Liu et al., 2011). However, the signals that 
initiate the expression of Scx in the appendicular skeleton remain unknown. 
In addition to FGF signaling for inducing sclerotomal cells to become tendon 
progenitor cells (TPC), transforming growth factor - β (TGFβ) signaling is also a potent 
inducer of Scx both in organ culture and in cultured cells (Pryce et al., 2009). This is 
said to be essential for the maintenance of the early TPC and has been suggested to 
mediate the recruitment of additional tendon cells by the adjacent muscles and cartilage 
condensations. This recruitment is to establish the connections of tendon primordial 
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with these tissues, and it is an essential event for the subsequent differentiation and 
growth of mature tendons (Pryce, et al., 2009). In coordinating the cartilage and tendon 
differentiation in the developing limb mesenchyme, TGF-interacting factor, Tgif1, has 
been identified as one of the potential candidates which modulates the TGFβ signaling 
from chondrogenesis to fibrogenesis, and its expression pattern in the limb marks the 
developing tendons (Lorda-Diez et al., 2009). This reprogramming of TGFβ signaling 
provokes down-regulation of Sox9 and aggrecan and up-regulation of Scx and 
tenomodulin through the Smad pathway (Lorda-Diez, et al., 2009). A recent review on 
the musculoskeletal assembly in the vertebrate embryo postulated that the induction and 
differentiation of TPCs occur in  three distinct stages (Figure 1.3): induction, 
organization as well as aggregation and differentiation (Schweitzer et al., 2010).  In 
brief, the differentiation of tendon in the somite depends upon a combination of both 
activating and repressing signals from the other compartments of the somite.  
 
 
Figure 1.3 The three main stages and regulators of tendon induction and differentiation 
in vertebrate embryos (Adapted from Schweitzer et al. 2010).  
The Scx-expressing tendon progenitors (TPs) are represented in green and 
mesenchymal cells in white to show the different stages of tendon induction 
and differentiation. 
(A) Induction. The initial induction of Scx-expressing TPs is associated 
with FGF signaling, but the myotome in somites is the only identified 
source to date. In somites and digits, the progenitors are induced at or 
near their functional position between the myogenic and skeletogenic 
cells, but in the early limb bud and branchial arches the site of 
progenitor induction is not related to their final destination.  
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Figure 1.3, continued 
 
(B) Organization. In an E12.5 mouse embryo, TPs throughout the 
embryonic body organize as loose cellular aggregations between the 
differentiating muscle and skeletal tissues. This transition depends on 
TGFβ signaling, which mediates the recruitment of additional TPs by 
the muscle and cartilage tissue to position and integrate the TPs with 
their interacting musculoskeletal tissues (white arrows). In addition, 
TGFβ ligands expressed by the TPs are likely to contribute to the 
maintenance of the tenoblastic identity of the TPs (black arrow). 
(C) Aggregation and differentiation. By E13.5, the TPs condense and 
organize into structurally distinct tendons that connect to the muscle 
and cartilage. In some, but not all tendons, tenocyte differentiation 
depends on Scx function. In most tissue, tendon differentiation depends 
on the presence of muscle (arrow), but the extensor and flexor tendons 
that extend into the autopod differentiate as structurally distinct tendons 
even in the absence of muscles. 
 
However, little is known about other TGF-β family members, in particular the 
bone morphogenetic protein (BMP) family members in the musculoskeletal 
development. BMP5 is expressed in precise domains in the developing muscle masses 
and in the autopodial tendons. In the limb mesoderm, Smad and MAPK pathways act 
synergistically in the BMP pathway controlling limb development (Zuzarte-Luis et al., 
2004). Other BMP family members include growth and differentiation factor (GDF) 
isomers such as GDF5, -6 and -7 (also known as BMP 14, 13 and 12) have also been 
implicated in tendon development and healing (Mikic et al., 2009; Mikic et al., 2001; 
Settle et al., 2003). Mice deficient GDF5, -6 or -7 exhibit tendon ultrastructural, 
biological and/or biochemical abnormalities (Mikic, et al., 2009; Mikic, et al., 2001), 
whereas exogenous delivery of these factors causes ectopic tendon formation (Wolfman 
et al., 1997). In addition, as one of the earliest known markers of joint formation (Settle, 
et al., 2003; Storm & Kingsley, 1999), GDF5 dysregulation is strongly linked to various 
musculoskeletal malformations. GDF5 expression/activity is important in controlling 
different stages of skeletogenesis, in particular chondrogenesis in a GDF5 dose-
dependent manner (Francis-West et al., 1999). In cartilage development, GDF5 
signaling has a characteristic development pattern in pre-cartilage condensations and in 
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the developing cartilaginous joints (Settle, et al., 2003). Mutations in either GDF5 or its 
receptor BMP receptor 1B (BMPR1B) lead to similar skeletal malformation phenotypes, 
indicating that in chondrogenesis, GDF5 signaling seem to be exclusively mediated 
through BMPR-1B (Kotzsch et al., 2009). Many developmental processes, including 
limb skeletogenesis, also require the segregation of signaling molecules into gradient or 
the functional compartmentalization of one cell type from another to generate 
information for differentiation and morphogenesis. Although GDF5 has functional roles 
in both tendon and cartilage development, it remains unclear whether GDF5 plays a role 
similar to that of FGF. It may be the case that tendon and cartilage lineages develop in 
an alternative and mutually exclusive manner through the functional 
compartmentalization processes. 
 
1.2 Tendon Damage and Repair Mechanism 
1.2.1 Tendon Injury 
 Tendon injuries, specifically at the shoulder, are a common cause of morbidity 
and contribute a significant health burden to the society. It is defined as a loss of cells or 
ECM caused by trauma (Leadbetter, 1992). Injury represents a failure of cell and matrix 
adaptation to a mechanical loading, in excess of the tolerance level, which can be 
repetitive or prolonged. In these circumstances, there is an inadequate response from the 
cells or tissues to the mechanical loading applied. In other words, tendon is injured 
when it is exposed to forces that damage it. Tendon injury at the shoulder can be as the 
result from forces that cause elongation of the tendon tissue extending into the micro- 
and macro-failure region. Under physiological circumstances, tendons function in the 
toe and linear region of the stress-strain curve. Repeated and prolonged load application 
has been shown to alter the stress-strain curve of the tendon tissue, where tendon injury 
may result from repeated loading into what would normally be the higher linear region 
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of that curve (Wang, 2006). Rapid unloading has also been associated with tendon 
injury. Sudden force release is suggested to break interfibrillar adhesion because of 
shearing force within the tendon (Sharma & Maffulli, 2005). In lieu of forces that are 
too big for the tissue to withstand, tendon can also be injured when “normal” forces are 
applied. This occurrence can be seen in genetic disorders, aging, vascular changes, 
endocrine influences, nutritional deficiencies, inactivity, immobilization and exercise 
(Hess et al., 1989). 
 The cellular events in ruptured tendon (i.e. rotator cuff tendon) are closely 
related to the composition and integrity of ECM structure (Riley et al., 1994a; Riley, et 
al., 1994b; Wu et al., 2010). Tendon ECM transmits mechanical loads, stores and 
dissipates loading-induced elastic energy. Mechanical deformation in the ECM can 
transmit forces through tendon cell actin cytoskeleton and cause the remodeling of the 
actin cytoskeleton (Wang, 2000; Wang et al., 2001). The cytoskeleton remodeling in 
turn controls the cell shape, affects cell motility and mediates various cellular functions 
including DNA and protein synthesis (Janmey, 1991). Tendon cells sense mechanical 
force and convert them into biochemical signals via mechanotransduction mechanisms 
that ultimately lead to the physiological adaptiveness of tissue or conversely result in 
pathological changes.  
 
1.2.2 ormal Repair Mechanism 
 Tendon injury will initiate attempts of tissue repair, which has been defined as 
replacement of damaged or lost cells and ECM by new cells or new matrices 
(Leadbetter, 1992). In the natural healing process, tendon repair can be divided into 
different phases (Figure 1.4). Generally, they consist of an inflammatory phase, 
proliferation phase, differentiation phase and remodelling phase. In brief, the healing 
process starts with a hematoma, platelet activation and invasion of cells that form a 
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granuloma. Inflammation after injury protects the body by eliminating and diluting 
harmful agents, preventing further injury, supplying large quantities of oxygen and 
nutrients needed for repair, and allowing the entry of clotting agents. Inflammation is 
triggered by several chemical mediators such as histamines, kinins, prostaglandins, 
complement, and lymphokines (Frank et al., 1999).  
 
Figure 1.4  Schematic diagram of tendon repair (Aspenberg, 2007). 
(a) Haematoma with platelet activation (inflammatory phase). 
(b) Invasion of cells and proliferation of paratenon (proliferation phase). 
(c) Vascular and neuronal ingrowth. 
(d) Loose collageneous callus formation (differentiation phase). 
(e) Mechanical stimulation. 
(f) Maturation and remodeling (remodelling phase). 
 
During the repair process, the clot formed during inflammation is transformed 
into a granulation tissue. The circulating monocytes then differentiate into macrophages 
after entering the extravascular space. These macrophages are capable of digesting and 
removing the clot while providing a continuing source of growth factors, 
chemoattractants, and proteolytic enzymes as needed for tenocyte activation (Leadbetter, 
1992). The macrophage-derived growth factor and TGFβ cause the proliferation of 
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tenoblasts originated in the epitenon (Fyfe & Stanish, 1992). As tenoblasts infiltrate the 
wound, blood vessels are formed and facilitate RBC to carry oxygen and nutrients to the 
developing tissue. Tenoblasts rapidly produce COL-III, which is characterized by 
smaller fibrils lacking cross-links, which means that the tissue will be lacking tensile 
strength. At the later stage of this phase, the tenoblasts shift to produce COL-I. Initially, 
no cross-link occurs between the tropocollagen molecules. This facilitates the enzymatic 
breakdown and reorganization in the repaired tendon. Cross-links start to develop at 6-
14 days post injury increasing tensile strength to the area of injury. At approximately 48 
hours to 8 weeks post-injury, the disorganized collagen fibril deposition lies parallel to 
tensile forces within the tissue.  
 In the maturation and remodelling phase, cellularity and synthetic activity 
decreases in the tendon. However, the collagen production has been shown to be 15 
times of normal tendon. The granulation tissue is supplanted by new collagen synthesis 
and deposition, as well as by remodelling myofibroblasts (which derived from the 
tenoblast that migrated from the edge of wound) that contract the matrix along the axis 
of the tendon. The ECM becomes more organized at this stage. Wound healing cells and 
their matrix exist in a dynamic reciprocity whereby cells deposit new matrix and that the 
matrix modulates gene expression and cell-matrix receptors (Gurtner et al., 2008). 
Through cell-cell and cell-matrix interactions, collagen fibrils align with tenocytes and 
join end-to-end with other fibrils in the wound and at the margin via covalent crosslinks 
(Kjaer, 2004). Most cells (endothelial cells, macrophages and myofibroblasts) then enter 
apoptosis (programmed cell death), the ECM thereby undergoes a transition from a 
highly cellular granulation tissue to a less densely populated scar tissue (Gurtner, et al., 
2008). Consequently, tendons usually heal with fibrosis and scar tissue, which may 
regain only 70-80% of their original structural and biomechanical integrity for as long 
as one-year-post injury. The healed tendon (with suboptimal tensile strength) is prone to 
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reinjury, resulting in lifestyle changes with activity restriction. Poor vascularization 
(Hegedus et al., 2010) and histopathological changes (Maffulli et al., 2011) have been 
suggested as factors contributing to the resulting tendon thickening, fibrosis and being 
less resistant to tensile stress compared to its preinjured state. The origin of the cells 
responsible for repairing an injured tendon is controversial. Two mechanisms have been 
postulated: intrinsic and extrinsic. The former postulates that fibroblast populations 
come from the endotenon and epitenon, whereas the latter postulates that inflammatory 
cells and fibroblasts migrate in from surrounding tissues (Boyer, 2005). However, a 
recent report suggested that intrinsic repair may require a progenitor class with 
predominant tendon marker expression, while extrinsic repair may involve a progenitor 
class recruited from perivascular cells of the peritenon (Mienaltowski et al., 2013). 
Tendon TSC/TPC decreases with age and alludes to its association with the age-related 
reduction in tendon repair as seen in rotator cuff tears (Gulotta et al., 2012). Molecular 
mechanisms controlling these events, either via tenocytes, tenoblast or/and TSC/TPC, 
and whether a fully differentiated replacement tendon forms at these sites remains 
largely unclear. The understanding of molecular mechanism in tendon development 
could assist us in better understanding of tendon etiology and repair.  
 
1.2.3 Surgical Repair and Cell Based Therapy in Tendon Healing 
Clinically, tendons are repaired or reconstructed using a variety of traditional 
and innovative methods or surgical techniques that vary with tendon location. These 
techniques demonstrate various degrees of success. Tendon grafts are also used (Table 
1.4). In the light of current shortcomings of tendon repair, the current focus in tissue 
engineering research is to investigate a repair method which can restore the tissue 
defects with living cells, or a cell based therapy. A number of cell sources have been 
suggested (Table 1.5).  
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Table 1.4 The advantages and disadvantages of various type of tendon augmentation grafts. 
Graft Type Source Advantages Disadvantages 
Autograft Human 1. No disease transmission risk. 
2. No storage required. 
3. No preservation problem. 
 
 
1. Donor site complication (Aune et al., 2001; Comley & 
Krishnan, 1999). 
2. Limited availability. 
Allograft Human 1. No donor site complications. 
2. Availability. 
1. Immunogenicity problem (Minami et al., 1982; Nellas et 
al., 1996; Nutton et al., 1999). 
2. High risk of disease transmission (Nutton, et al., 1999). 
3. Required proper storage or preservation (Vangsness et al., 
2003). 
 
 
Xenograft Animal 1. As with allograft above. 1. As with allograft above. 
2. Ethical issue, i.e. inappropriate animal source such as 
porcine derived tissue graft. 
 
 
Prosthesis Human or animal 1. As with allograft above. 1. Low mechanical properties (often result in failure of 
surgery). 
2. Non-specific new tissue induction ability. 
3. Induce inflammatory response and rejection (Chen et al., 
2009).  
 
 
Synthetic  Chemical 
compounds 
1. Stronger mechanical strength and 
consistency in quality (Chen, et al., 
2009). 
1. Low biocompatibility. 
2. Induce inflammatory response and rejection (Chen, et al., 
2009). 
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Table 1.5 A summary of cell therapy of different cell origins. 
Cell Type Source Advantages Disadvantages Study model 
(Reference) 
Mesenchymal 
stem cells 
(MSCs) 
Bone 
marrow-
derived 
1. Multilineage potential.  
2. Hypoimmunogenecity. 
3. Increase rate of tendon healing and 
maturation. 
4. Improve biomechanical and histologic 
properties of the tendon. 
 
1. Cannot control differentiation into 
undesired tissue lineage such as bone, 
cartilage and muscle. 
2. Cell population diminished with age. 
Rabbit (Awad et al., 
1999; Chong et al., 
2007; Djouad et al., 
2003; Harris et al., 
2004) and Mice 
(Djouad et al. 2003) 
Adipose 
tissue-
derived 
1. Widely available. 
2. Simple to obtain. 
3. No morbidity to donor site. 
 
1. As with bone marrow derived MSCs above. 
2. Limited application in tendon therapy. 
Equine (de Malttos 
Carvalho et al., 2011; 
Del Bue et al., 2008) 
Synovium-
derived 
1. May promote bone-tendon regeneration. 1. As with bone marrow derived MSCs above. Nil (Chen et al., 2011) 
 
Muscle-
derived 
 
1. As with bone marrow derived MSCs 
above. 
 
1. As with bone marrow derived MSCs above. 
2. Limited evidence in tendon therapy. 
 
Nil (Rosenbaum et al., 
2008) 
Fibroblasts Skin 1. Great potential in tendon engineering and 
tendon repair. 
2. Widely available. 
3. Relatively noninvasive method for cell 
harvesting. 
4. No significant effect to the donor site. 
5. Potential source of cells for storage. 
1. Differentiated cells. 
2. Uncertainty about behavior in tendon 
environment. 
3. Unsubstantiated repair process. 
4. Qualitative repair.  
Human (Connell et al., 
2009) 
Tendon 
progenitor/ 
stem cells 
Tendon 1. Can develop into tendon like tissue. 
 
1. Morbidity to donor site. 
2. No tenocyte markers. 
3. No human studies. 
Rat (Gurkan et al., 
2010) 
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Cell based therapy seeks to enhance tissue repair by providing a cell and/or 
biological scaffold to a repair site in an attempt to elicit a healing response. In order to 
achieve this, investigators have seeded differentiated cells (mature cells or tenocytes) 
and undifferentiated cells (mesenchymal stem cells) on scaffolds to develop tissue 
engineered constructs. Various stimulations, either chemical (using growth factors and 
cytokines) or mechanical (by stretching), which can mimic the nature of normal tendon 
in vivo environment have been used to enhance the properties of the constructs. 
Advances in tendon tissue engineering approaches potentially yield a cell-based product 
that can markedly advance the repair of this soft tissue. 
Nevertheless, would tendon development events re-occur and regenerate tendon 
tissue, should the TP cells be transplanted to the defect site? In the course of cell-based 
therapy, would the TP, tenoblast and tenocytes together orchestrate cellular events of 
tendon regeneration? A better understanding in the cellular events involved in tendon 
development, differentiation and repair is needed in order to lead us to better outcomes 
for treating tendon injury. 
 
1.3 Mesenchymal Stem Cells and Their Potential Role in Tenogenesis 
1.3.1 Mesenchymal Stem Cells and Its Potential 
 Mesenchymal stem cells (MSCs, bone marrow stromal cells or multipotent 
progenitor stromal cells) are multipotent adult stem cells that are capable of 
differentiating into various cells of mesodermal lineage (Huang et al., 2012; Platt et al., 
2009). According to International Society for Cellular Therapy (ISCT), the three criteria 
used to define MSC are: (i) they adhere to plastic when maintained in standard culture 
conditions using culture flasks, (ii) there is a specific surface antigen (Ag) expression 
and (iii) presence of multipotent differentiation potential (Dominici et al., 2006). Firstly, 
MSCs must be plastic-adherent, as described by Friedenstein et al. in the 1970s 
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(Friedenstein et al., 1974). Secondly, more than or at least 95% of MSC population 
must express CD105, CD73 and CD90, as measured by flow cytometry. In addition, 
these cells must lack expression (not more than 2% positive) of CD45, CD34, CD14 or 
CD11b, CD79α or CD19 and HLA class II. Third, the cells must able to differentiate 
into trilineages (i.e. osteoblasts, adipocytes and chondrocytes) under standard in vitro 
differentiating condition. 
Although the traditional source of MSCs has been the bone marrow, there are 
other potential sources of MSCs (Beitzel et al., 2012; Pierini et al., 2012). These have 
included peripheral blood (Kassis et al., 2006; Roufosse et al., 2004), adipose tissue 
(Boquest & Collas, 2012; Choi et al., 2012; Nishiwaki et al., 2012) and cord blood 
(Joyce et al., 2012; Kim et al., 2012). The roles of these cells in an organism are to 
maintain and repair the tissue in which they are found. In recent years, the interest in 
MSCs have been growing immensely due to speculation that these cells, having both the 
ability for multipotency and self-renewal, have the potential to bring about tissue 
regeneration and repair. As such, in several conditions requiring tissue repair, MSCs 
have been shown to enhance the healing potential when these cells are placed directly 
into the defective site (Awad, et al., 1999; Lee et al., 2011; Schnabel et al., 2009). 
However, these findings have been received with some reservations. Many researchers 
have expressed their concern as to the validity of such findings mainly because the exact 
etiology as to why tissue regeneration occurs is still poorly understood. Furthermore, 
the existence of a mixed population in MSCs has been shown to lose its viability after 
being transplanted into tissues (Toma et al., 2002). It is speculated that such repair 
outcomes may be attributed to other factors such as the release of cytokines, interaction 
with the extracellular matrix (loss of attachment to ECM which cause anoikis), ischemia 
and other causes (Rodrigues et al., 2010). In addition, transplantation outcome has been 
worsened by conditions such as in situ ectopic bone formation which has been reported 
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in transplantation of undifferentiated MSCs (Harris, et al., 2004), although the opposite 
result has also been reported (Pacini et al., 2007). To overcome such issues, a number of 
tissue engineering approaches are presently being developed to induce differentiation in 
a specific lineage, i.e. tenogenic differentiation, prior to transplantation.  
 
1.3.1.1 Tenogenic Differentiation of MSC 
 One of the unique biological properties of MSC is the ability to differentiate into 
cells of multi-mesenchymal lineages (Caplan & Bruder, 2001). The tenogenic MSC 
lineage is one of the MSC lineages that have been of great interest to orthopaedic 
surgeons, especially for cell-based therapy in tendon disorders. In the case of 
tenogenesis (tendogenesis, ligamentagenesis), MSCs undergo lineage commitment into 
tenogenic MSCs and ultimately mature into tenocytes (Figure 1.5). In vitro 
differentiation of MSCs towards tenogenic lineage before transplantation has been 
postulated to be a good strategy to promote tendon healing apart from minimizing the 
chances of ectopic bone formation or tumour formation in tendons. Thus, a new 
enlightened era of stem cell research has been initiated with human and non-human 
MSCs, in vitro and in vivo, in relation to MSC tenogenic differentiation as well as its 
use in tendon repair. However, to date, neither tenogenic lineage transition sequence nor 
differentiation has been comprehensively discussed or widely reported, neither has it 
been compared to other lineage transition sequences such as osteogenesis, 
chondrogenesis or myogenesis.  
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Figure 1.5  Mesenchymal stem cells and tenogenic differentiation. Modified from Caplan 
& Bruder (2001). 
 
 The current focus of tendon tissue engineering is to develop an optimal method 
for MSC tenogenic differentiation, potentially to be used for tendon repair. To achieve 
this goal, various tissue engineering approaches have been applied to MSCs of various 
tissue sources in order to elucidate their effects in tenogenesis induction. Among the 
techniques that have been reported are; mechano-transduction (Farng et al., 2008; Kuo 
& Tuan, 2008; Lee et al., 2007), gene transfer (Wang, et al., 2005), co-culture systems 
(Lee, et al., 2007; Luo et al., 2009) and making use of biomaterials (Kishore et al., 
2012) as well as growth factors, either in the purified form (Lee, et al., 2011; Tan et al., 
2012) or the crude extract such as platelet-rich–plasma releasate (Zhang & Wang, 
2010). Nevertheless, the optimal method to induce tenogenic differentiation for 
maximal phenotypic expression has yet to be proven. Table 1.6 summarizes all the 
tenogenic differentiation studies that been reported thus far.  
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Table 1.6 Summary of methods for tenogenic differentiation in MSCs from various tissue origin sources. 
o Differentiation method 
(Reference) 
 
Cell type Tissue source Principle Findings 
(A) Gene transfer 
 
1 Transfection of BMP-12 gene 
by electroporation into rhesus 
MSCs (Wang, et al., 2005) 
i. Rhesus primary MSCs i. Adult rhesus bone marrow 
aspirates 
i. Transfected cells became more slender and their processes 
became thinner and were interwoven into a network. 
ii. More organelles were observed in transfected cells. 
iii. Transfected cells expressed BMP-12, Col-I and Scx, but 
not Col-III mRNA. 
 
2 Transfection of active Smad8 
variant into an MSC line that 
coexpressed BMP2 (Hoffmann 
et al., 2006) 
i. Multipotent mouse 
C3H10T1/2 cell 
ii. C3H10T1/2 constitutively 
expressing BMP2 
 
i. Transfection with pSV2pac 
followed by selection with 
puromycin (5µg/ml) 
(Moutsatsos et al., 2001) 
i. Smad8 inhibits the osteogenic pathway in MSCs, while 
promoting tendon differentiation. 
ii. Expression of BMP2 and Smad8 linker plus MH2 domain 
leads to tenocytic cell differentiation in C3H10T1/2 cells. 
iii. Smad8 plays a pivotal role in the signaling cascade that 
leads to tenocytic differentiation of MSCs, however, this 
cascade is not directly activated by BMP2 but by another 
factor, which is still unknown. 
 
3 hMSC cell line lentivirally 
transduced with FLAG-Scx 
cDNA (Alberton et al., 2012) 
i. Immortalized Bone marrow 
derived-hMSC cell line (SCP-
1) 
i. HMSCs were purchased from 
Cambrex Corporation (East 
Rutherford, NJ, USA) and 
transduced with hTERT 
lentivirus (Boker et al., 2008) 
i. Increased cell area. 
ii. Reduced self-renewal and restricted multipotentiality. 
iii. Gene expression of Col-I, decorin and tenomodulin were 
significantly increased. 
iv. Sox-9 gene expression was significantly decreased. 
(B) Mechanical stimulation 
 
4 
 
MSCs stretched at 10% strain, 
1 Hz for 48 hours or MSCs 
stretched after co-culture in 
1/1 ratio of anterior cruciate 
ligament (ACL) cells and 
MSCs (Lee, et al., 2007) 
 
i. Human MSC primary 
culture 
ii. Human ACL primary 
culture 
 
i. Human bone marrow 
ii. Human ACL 
 
i. ACL typical markers (Col-I, Col-III and tenascin C) were 
significantly increased in cell exposed to mechanical 
stress, either with or without co-culture with ACL cells 
prior to stretching. 
ii. Specific regulatory signals released from ACL cells 
appear to be responsible for supporting the selective 
differentiation toward ligament cells. 
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Table 1.6, continued 
 
5 Mechanical stimulation with 
cyclic uniaxial 10% strain at 
0.33 Hz for 48 hours applied 
to the scaffold administered 
with 1600ng of GDF5 (per 
scaffold) to the collagen 
coating (Farng, et al., 2008) 
 
i. Immortalized mouse bone 
marrow derived-MSC cell 
line (D1 ORL UVA) 
i. From ATCC (Manassas, 
VA) 
i. After 48 hours, both mechanical stimulation and GDF5 
increased mRNA production of Col-I, Col-II and Scx. 
ii. Tenascin C mRNA expression did not increase.  
iii. Combined stimuli did not change mRNA gene expression. 
6 Mechanotransduction in 3D 
dynamic model at 1%, 1 Hz 
for 30 min/day for 7 days 
(Kuo & Tuan, 2008) 
 
i. MSC primary culture i. Human bone marrow i. 3D MSC tenogenesis culture system upregulate scleraxis, 
but cyclic stretching was required to maintain expression 
of scleraxis. 
ii. Neo-tendon formation due to matrix deposition and 
remodeling activity (increased gene expression levels in 
scleraxis, Col-I, Col-III, elastin, MMP1, MMP3 and 
MMP13) under dynamic loading conditions. 
iii. Similar role for Wnt4 and Wnt5a in tenogenesis with 
cyclic stimulation. 
 
7 Substrate with mechanical 
property gradients and various 
extracellular matrix ligand 
(Sharma & Snedeker, 2010) 
i. Human bone marrow MSCs i. Human bone marrow MSCs 
from Dr Simon Hoerstrup’s 
lab (University of Zurich) 
i. Higher level of attachment on collagen substrate after 1 h 
and increase spreading and organization trends after 24 h.  
ii. Differentiation studies showed an increase in osteoblast 
differentiation on fibronectin substrates than collagen 
substrates. 
iii. Osteogenic differentiation decreased on substrates of 
lower stiffness and lower ligand density. 
iv. Tenoblast markers were detected on collagen substrates 
within a narrow range of stiffness. 
 
8 Mechanical stretching at 10%, 
1 Hz for 48 hours (Xu et al., 
2011; Xu et al., 2012) 
i. Immortalized bone marrow 
derived-hMSC cell line 
(UE6E7T-3) 
i. hMSC infected with 
recombinant retroviruses 
expressing the E6, E7 and 
hTERT; acquired from Health 
Science Research Resource 
Bank (Osaka, Japan) 
i. Stretched cells showed increased in Col-I, Col-III, 
tenascin C and Scx mRNA expression. 
ii. FAK signaling molecule plays an important role in 
regulating hMSCs cell realignment and mechanical 
stretch induced tenogenic differentiation. 
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Table 1.6, continued 
 
 
    iii. RhoA/ROCK and cytoskeletal organization were essential 
to mechanical stretch-activated FAK phosphorylation at 
Tyr397. 
iv. RhoA/ROCK, cytoskeletal organization and FAK 
compose a “signaling” network” that sense mechanical 
stretching and induced hMSCs tenogenic differentiation. 
 
(C) Co-culture system 
 
9 In 1:1 ratio co-cultured system 
with adult primary tenocytes 
cultured in transwell chambers 
and MSC plated onto the plate 
wells (Luo, et al., 2009) 
i. Rat primary MSC culture 
ii. Rat primary tenocyte culture 
i. Adult Sprague-Dawley (SD) 
rat bone marrow 
ii. Adult AD rat Achilles 
tendons 
i. MTT assay showed no significant growth difference 
between control and co-culture group at the first two days 
of co-culture, but after day 3, MSC in co-culture group 
grew significantly faster than control. 
ii. The mRNA expression level of c-fos gene was 
significantly up-regulated on day 4 and day 7 in co-
culture group. 
iii. On day 7, the co-culture group also showed significant 
up-regulation in tenascin C and Scx mRNA gene 
expression levels but no changes for Col-I and Col-III. 
iv. On day 14 and 21, up-regulation in Scx, tenascin C, Col-I 
and Col-III were also detected in the co-cultured group. 
 
10 In 50/50 ratio co-cultured of 
anterior cruciate ligament 
(ACL) cells and MSCs 
(Canseco et al., 2012) 
i. Porcine MSCs  primary 
culture 
ii. Porcine ACL primary 
culture 
i. Bone marrow from Yorkshire 
pig 
ii. ACL from 4-8 month 
Yorkshire pig legs 
i. Significant increase in Col-I and tenascin-C 
mRNA/protein expression levels. 
ii. Ratio of Col-I to Col-III is similar to native ligament 
levels. 
 
11 In 1:1 ratio co-cultured system 
with adult primary tenocytes 
cultured in transwell chambers 
and amnion epithelial cells 
(AEC) plated onto the plate 
wells (Barboni et al., 2012) 
i. AEC primary culture 
ii. Fetal tenocytes primary 
culture 
iii. Adult tenocytes primary 
culture 
i. Sheep Amnions 
ii. Sheep fetal calcaneal tendons 
iii. Sheep adult calcaneal tendons 
i. AEC exposed to fetal derived tenocytes/explants 
developed in vitro tendon-like three dimensional 
structures with expression of Col-I and Thsb4. 
ii. Significant increase in tendon related mRNA genes 
expression levels (Col-I, Scx and tenomodulin). 
iii. Increased COL-I, OCN and connexins (Cx32and Cx34). 
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Table 1.6, continued 
 
(D) Growth factor or other culture supplements 
 
12 With 50 ng/mL BMP-12 
(GDF-7) supplement for 14 
days (Violini et al., 2009) 
i. Equine primary MSCs i. Adult Dutch Warm blood 
mare bone marrow 
i. Equine MSCs expressed tenomodulin and decorin mRNA 
at day 14 of BMP-12 induction. 
ii. Upon tenogenic differentiation in BMP-12, equine MSCs 
exhibited heterogeneous morphology with most cells 
fibroblast-like and elongated. 
 
13 Treatment with GDF5 in 
monolayer (Park et al., 2010) 
i. Rat primary MSCs culture i. Fisher 344 rat adipose tissue i. GDF5 increased MSCs proliferation in a dose- and time-
dependent manner. 
    ii. The mRNA expression level of ECM (Col-I, decorin and 
aggrecan) and tenogenic marker (Scx, tenomodulin and 
tenascin C) in MSCs treated with 100 ng/mL of GDF5 
were significantly up-regulated. 
iii. Western blot analysis confirmed dose- and time- 
dependent increases in protein expression of tenomodulin, 
tenascin C, Smad-8 and matrix metalloproteinase-13. 
iv. GDF5 treatment induced cellular events leading to 
tenogenic differentiation in rat adipose tissue-derived 
MSCs. 
 
14 Spatial control of multiple 
differentiation fate with 
growth factors (BMP-2, 
FGF-4 and GDF-7) printed 
onto fibrin coated glass 
coverslips and growth factors 
as a supplement in culture 
medium (Ker et al., 2011) 
 
i. Multipotent mouse 
C3H10T1/2 cells 
ii. Mouse C2C12 cells 
iii. Multipotent muscle derived 
stem cells (MDSC) 
i. From ATCC (Manassas, VA, 
USA) 
ii. From ATCC (Manassas, VA, 
USA) 
iii. Primary mouse 
gastrocnemius muscle 
biopsies 
i. Fibroblast growth factor-2 (FGF-2) up-regulated Scx 
mRNA expression levels in C3H10T1/2 cells, mouse 
C2C12 cells and primary MDSC in dose dependant 
manner. 
ii. FGF-2 may direct stem cells toward a tendon fate via the 
Ets family members of transcription factors such as pea3 
and erm. 
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Table 1.6, continued 
 
15 Treatment with a single 
physiological dose of insulin 
(10
-10
 mol/L) (Mazzocca et al., 
2011) 
i. MSC primary culture i. Human bone marrow i. 10
-10
-mol/L insulin was determined as the optimal single 
dose for one time treatment to differentiate MSCs into 
tendon. 
ii. 1-time treatment with a physiologic dose of 10
-10
 mol/L 
insulin exhibit significantly higher transcript levels of 
Col-I, Col-III, Scx and tenascin C compared with 
untreated cells. 
iii. MSCs treated with 10
-10
 mol/L insulin also showed a 
significant increase in the protein levels of COL-I, COL-
III and tenascin C compared with the untreated cells and 
cells treated with the 10
-9
, 10
-12
, 10
-13
 mol/L insulin. 
 
16 Growth factor induction 
(10 ng/mL IGF-1, 10 ng/mL 
TGFβ1, IGF-1/ TGFβ1 
(5 ng/mL each), 10 ng/mL 
PDGF-BB, 10 ng/mL 
BMP-12), high density co-
culture of primary MSCs and 
tenocyte cultures, with spent 
media obtained from primary 
tenocytes (Schneider et al., 
2011) 
i. Canine primary MSCs  
culture 
ii. Canine primary tenocyte 
culture 
i. Canine adipose tissue 
biopsies 
ii. Canine tendon biopsies  
i. Tenogenesis was induced in MSCs through a combination 
of treatment with IGF-I and TGFβ1, in high density co-
cultures and through cultivation with the spent media 
from primary tenocytes. 
ii. Electron microscopy and immunoblotting demonstrate up-
regulation of COL-I, COL-III, decorin, tenomodulin, β1-
integrin, MAPKinase pathway (Shc, Erk1/2) and SCX in 
the co-cultures, and provide simultaneous evidence for the 
inhibition of apoptosis. 
iii. Cells actively exchanged vesicles suggesting the uptake 
and interchange of soluble factors produced by the MSCs 
and/or tenocytes. 
 
17 Use of recombinant human 
bone morphogenetic protein 
12 and bone morphogenetic 
protein 13 (rhBMP12 and 
rhBMP12) to induce the 
formation of tendon-like tissue 
or tendon-specific gene 
expression (Berasi et al., 2011) 
i. Murine MSC cell line 
C3H10T1/2 (clone 8) 
i. From ATCC (Manassas, VA, 
USA) 
i. Ectopic expression of rhBMP12 and rhBMP13 induces 
the formation of tendon-like tissue. 
ii. Treatment of C3H10T1/2 cells with rhBMP12 or 
rhBMP13 resulted in a dose-dependent induction of a 
tendon-specific gene (Thrombospondin, Thbs4) 
expression with no detectable activation of SMAD 1/5/8. 
iii. Differential regulation of Thbs4 and osteocalcin has 
potential utility as an in vitro biomarker for induction of 
tenogenic signaling. 
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Table 1.6, continued 
 
(E) Scaffold/substrate with or without growth factor 
 
18 MSCs seeded on basic 
fibroblast growth factor 
(bFGF) releasing nanofibrous 
scaffolds (Sahoo et al., 2010) 
i. Rabbit MSCs i. New Zealand white rabbits 
bone marrow 
i. bFGF incorporated in nanofibrous scaffolds released in 
bioactive form over 1 week.  
ii. The released bFGF activated tyrosine phosphorylation 
signaling within seeded MSCs. 
iii. bFGF releasing nanafibrous scaffold facilitated MSC 
proliferation, up-regulated mRNA gene expression levels 
of tendon/ligament-specific ECM proteins (Col-I, Col-III, 
biglycan and fibronectin) and induced tendon/ligament-
like fibroblastic differentiation. 
 
19 Human tendon 
stem/progenitor cells 
(hTSPCs) culture on aligned 
nanofibers (Yin, et al., 2010) 
i. Human tendon 
stem/progenitor cells 
i. Human foetal Achilles tendon 
from an aborted embryo 
(5months) 
i. The hTSPCs were spindle-shaped and well orientated on 
the aligned nanofibers.  
ii. The mRNA expression of tendon-specific genes (Eya2, 
Scx, Col-14 and Col-I) was significantly higher in 
hTSPCs growing on aligned nanofibers than those on 
randomly-oriented fibrous nanofibers in both normal and 
osteogenic media. 
iii. Aligned cells expressed significantly higher mRNA levels 
of integrin α1, α5 and β1 subunits, myosin IIB. 
iv. In vivo experiments, the aligned nanofibers induced the 
formation of spindle-shaped cells and tendon-like tissue. 
 
20 Collagen substrates with 
moderate rigidity (~30-50 kPa) 
(Sharma & Snedeker, 2012)  
i. Human primary MSCs i. Human bone marrow 
(Hoerstrup et al., 2002) 
i. Scx and tenomodulin mRNA expression observed only in 
cells cultured on the collagen substrate with moderate 
rigidity (~30-50kPa). 
ii. Smad8 and BMP-2 mRNA expression levels were 
increased on collagen substrate with moderate rigidity 
(~30-50kPa). BMP-2 secretion was confirmed by 
colorimetric assay. 
iii. BMP-2 supplementation was sufficient to arrest 
osteoblastic differentiation on substrate sections that were 
otherwise osteogenic.  
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1.3.2 Growth and Differentiation Factor 5 (GDF5) and Tenogenesis 
1.3.2.1 Growth and Differentiation Factor 5 (GDF5)   
Growth and differentiation factor 5 (GDF5) is also known as Cartilage-derived 
morphogenetic protein 1 (CDMP1) or BMP 14 (Chang et al., 1994). It is a growth factor 
of the BMP family, a subgroup of TGFβ superfamily secreted at the stage of 
pre-cartilageneous mesenchymal condensations in the perichondrium around the 
cartilaginous cores, especially in the joint inter-zones, and be observed clearly during 
the embryonic development (Chang, et al., 1994; Luyten, 1997). It is also expressed by 
fibroblast (You et al., 1999), articular chondrocytes (Erlacher et al., 1998) and 
odontoblasts (Morotome et al., 1998). It is initially synthesized as a large precursor 
protein (proGDF5) consisting of 501 amino acids including an N-terminal signal peptide 
of 27 amino acid length (Hotten et al., 1994). Inferring from studies reporting on other 
BMPs (Cui et al., 2001; Cui et al., 1998), the proGDF5 undergoes proteolytic cleavage 
at a cluster of basic residues [RX(K/R)R] at position 381. Consequently, a C-terminal 
mature protein is released from the N-terminal prodomain. The bioactivity and signaling 
range of this secreted mature protein is regulated by proteolytic cleavage (Herpin et al., 
2004). The mature GDF5 protein consists of 120 amino acids, which form homo- or 
hetero- dimers with other BMPs that are linked via a disulfide-bridge. The importance 
of GDF5 is underlined by a number of clinical syndromes associated with mutations in 
GDF5 or BMPR1B (Kornak & Mundlos, 2003; Schwabe & Mundlos, 2004). 
 
1.3.2.2 Tenogenesis Effects of GDF5 
The first published work which produced evidence of ectopic tendon formation 
by administration of GDF5, -6 and -7 (Wolfman, et al., 1997) has made it possible for 
GDF5, -6, and -7 to be used to augment tendon and ligament repair in a manner similar 
to the use of more traditional BMPs for fracture healing and bone fusion. Since then, 
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various studies have reported the use of GDF5 in tendon formation or functional repair 
(Table 1.7). These studies consistently demonstrated as well as evidenced the pivotal 
role of GDF5 in synovial joint formation, especially tendon formation, and in 
modulating tendon repair (Table 1.7). GDF5 is therefore being suggested as a viable 
candidate for eventual therapeutic use to augment tendon repair in human.  
 
1.3.2.3 Other Effects of GDF5  
The findings of tenogenicity using GDF5 induction are not without controversy. 
Several researchers have found that GDF5 is capable of inducing osteogenic (Shimaoka 
et al., 2004; Zeng et al., 2007) and chondrogenic (Coleman & Tuan, 2003; Hotten et al., 
1996; Nakamura et al., 1999). Such discrepancies may be explained by many factors. 
These have included different recombinant protein production processes, different 
delivery mechanisms as well as different culture conditions (monolayer, 3D culture, 
micromass culture, medium used etc.). Further, during early development, the 
progenitor cells differentiated into various types of mature cells, e.g. osteocytes, 
chondrocytes and tenocytes, in response to the amount of signal molecules received. 
Thus, different differentiation effects from different concentrations of GDF5 could be 
expected considering that gradient effect is an important mechanism in early 
development which compartmentalizes one cell type from another. As such, fine-tuning 
the factor amount or form of delivery may play an important role in achieving 
controlled healing of tendon tissue. 
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Table 1.7 A summary of tendon and GDF5 related studies. 
 
o Model Used Finding 
 
(A)  In vivo study 
 
1 Rodent Achilles tendon The tensile strength of the tendon repair with GDF5 increased in a dose-dependent manner (Aspenberg 
& Forslund, 1999). 
2 GDF5 deficient murine model GDF5 deficient Achilles tendons were structurally weaker than controls and structural strength 
differences appeared to be caused by compromised material properties. Mutant Achilles tendon 
contained 40% less collagen per microgram of DNA when compared to control (Mikic, et al., 2001).  
3 GDF5 deficient murine model Mutant tail showed 17% increase in the proportion of medium diameter (100-225 nm) collagen fibrils in 
tail tendon (at the expense of larger fibrils) when compared to controls (p<0.05). Mutants also exhibited 
a trend toward an increase in irregular-shaped polymorphic fibrils (33% more, P>0.05). In stress-
relaxation test, mutant fascicle relaxed 11% more slowly (p<0.05) than control tendons (Clark et al., 
2001). 
4 GDF5 deficient murine model Achilles tendon of GDF5 deficient mice contained significantly more fat within the repair tissue and was 
significantly weaker than control tissue after surgery. 
GDF5 may play an important role in modulating tendon repair (cell recruitment, migration/adhesion, 
differentiation, proliferation, and angiogenesis) (Chhabra et al., 2003). 
5 Rodent medial collateral 
ligament (MCL) laceration 
model 
Administration of GDF5 once at the time of surgery significantly improve ligament repair as observed in 
increased the ultimate tensile strength and stiffness of the femur-ligament-tibia complex. Quantitative 
PCR and in situ hybridization revealed enhanced type-I procollagen expression by GDF5. PCR analysis 
also revealed that the GDF5 treatment reduced the expression of type III procollagen relative to type I 
procollagen (Tashiro et al., 2006). 
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Table 1.7, continued 
6 Rodent Achilles laceration 
tendon 
Tendon transduced with BMP-14 exhibit less visible gapping, a greater number of neotenocytes at the 
site of healing and greater tensile strength than did either those transduced with GFP or the sham controls 
at two weeks after repair. No inflammatory response and ectopic bone formed in the tendon transduced 
with BMP-14 or GFP (Bolt et al., 2007). 
7 Rodent Achilles tendon Histological grading at 3 weeks showed improved healing (significantly higher ultimate tensile load and 
stiffness) in tendons repaired with GDF5 coated suture versus control (Dines et al., 2007). 
8 Murine distal flexor digitorum 
longus (FDL) tendon;  
recombinant adeno associated 
(rAAV)-Gdf5 vector & freeze-
dried mouse FDL tendon 
allografts with rAAV-Gdf5 
 
Recombinant adeno-associated vector (rAAV)-Gdf5 vector significantly accelerates wound healing in an 
in vitro fibroblast (Mouse embryonic fibroblast (NIH3T3)) scratch model, and when loaded onto freeze-
dried FDL tendon allografts significantly improves the metatarsophalangeal joint flexion compared to 
rAAV-lacZ controls (Basile et al., 2008).  
 
(B)  In vitro study 
 
9 Immortalized murine bone 
marrow stromal cell lines (from 
ATCC, Manassas, VA) 
GDF5 increased mRNA production of Col- I, II, and Scx compared to control; no additive synergism 
effect with mechanical stimulation (Farng, et al., 2008). 
10 Rodent adipose tissue-derived 
MSCs 
GDF5 treatment can induce cellular events leading to the tendonogenic differentiation of adipose-derived 
mesenchymal stem cells (Park, et al., 2010). 
11 Lagomorpha anterior cruciate 
ligament (ACL) and medial 
collateral ligament (MCL).  
ACL cells proliferation to GDF5 treatment was similar to that of MCL cells. GDF5 enhanced Col-1a1
expression in ACL and MCL fibroblasts. MCL fibroblasts showed stronger migration activities in 
response to GDF5, depended on the integrin α2-mediated adhesion on Col-I (Date et al., 2010). 
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Table 1.7, continued 
12 Lagomorpha MCL fibroblast bFGF/GDF5 treatment additively enhanced cell proliferation and migration in vitro. MCL repaired with 
bFGF/GDF5 hydrogel stimulated Col-IaI expression and deposition and organization of fiber alignment, 
induced better morphology of fibroblasts in healing MCL (Saiga et al., 2010). 
13 Primary rat adipose-derived 
stromal cells (ADSCs) 
Gene expression of Scx was upregulated at one week with GDF5 treatment when cultured on 3D 
electrospun scaffold compared to 2D films with or without GDF5 treatment. Expression of Col-I was 
increased at 1 week on treatment of 100 ng/ml GDF5 compared to 2D film (James et al., 2011). 
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Initial studies suggest that murine GDF5 play a role in osteogenesis via the 
process of endochondral ossification, i.e., bone formation. This process starts with 
mesenchymal cell condensations which forms a cartilage matrix that later calcifies to 
form mature bone (Chang, et al., 1994; Storm et al., 1994). The osteogenic effect of 
GDF5 in the in vivo model utilizing the hydroxyapatite (HA) implants has been reported 
in MSC/HA composites supplemented with GDF5 (Shimaoka, et al., 2004). Besides the 
in vivo studies, an in vitro study with rat adipose tissue derived stromal cells has also 
been reported. Based on the in vitro study, GDF5 not only promotes osteogenic 
differentiation, but also angiogenic activity of stromal cells. These findings suggest that 
several distinct regulatory mechanisms may exist in association with osteogenic 
differentiation, particularly in GDF5 induced differentiation processes (Zeng, et al., 
2007).  
Several studies have also demonstrated that the TGFβ superfamily of proteins 
induces chondrogenesis in cultured MSCs. In ATDC5 (the cell line which has 
differentiated to chondrocytes) culture, GDF5 has been shown to promote chondrocyte 
differentiation and activate p38 MAPK to promote chondrogenesis (Nakamura, et al., 
1999). In an in vitro high-density micromass culture of chick embryonic limb 
mesenchymal cells, GDF5 has been demonstrated to increase cellular condensation, 
which resulted in chondrocyte maturation. This is achieved via gap junction mediated 
cellular communication. However, it does not increase the cellular viability, 
biosynthetic activity, or function through enhanced N-cadherin mediated cellular 
adhesion (Coleman & Tuan, 2003). This finding is in contrary to previous study that 
demonstrated GDF5 causes the increase in cell adhesiveness. It has been postulated that 
through the cell adhesiveness mechanism, the GDF5 initiates condensation formation 
(Buxton et al., 2001). Recently, Trps1 (a novel transcription factor of GATA family) 
was demonstrated to act downstream of the GDF5 signaling pathway and promote the 
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differentiation and apoptosis of ATDC5 cells (Itoh et al., 2008). It has a synergistic 
dedifferentiating effect in expanded human and bovine chondrocyte primary culture 
when combined with 2.5 µg/ml insulin (Appel et al., 2009). 
 
1.3.2.4 Tenogenesis Signaling Pathways 
 In the Transforming Growth Factor β (TGFβ) signaling pathway, GDF5 has 
been shown to bind specifically to three different cell-surface transmembrane receptors: 
serine/threonine kinase receptor type 1 (BMPR-IB) or serine/threonine kinase receptor 
type 2 which could be either BMPR-II or ActR-IIA (Nishitoh et al., 1996). Generally, 
upon ligand (GDF5) binding, the type II receptor forms heterodimer with type I 
receptor. This then activates the type I receptor. The intracellular substrates of the 
activated type I receptors are Smads. Smads 1, 5 and 8 are phosphorylated and then 
translocate to the nucleus, where they participate in the transcriptional regulation of 
genes involved in tendon formation (Figure 1.6) (Prime et al., 2004; Roelen & Dijke, 
2003). The TGFβ signaling pathway is of key importance in the control of 
embryogenesis and tissue homeostasis. It plays an important role during the 
specification of early tendon progenitor cells as described in the earlier section (Section 
1.1.2, page 10). Besides, TGFβ1 has been demonstrated to mediate the production of 
COL-I in human tendon fibroblasts under in vitro cyclic uniaxial stretching conditions 
(Yang et al., 2004). However, the exact cellular and molecular downstream mechanistic 
pathway of GDF5 remains to be completely understood. 
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Figure 1.6  Transforming growth factor β (TGFβ) signaling pathway (Modified from 
Roelen & Dijke 2003). 
Ligand (GDF5) binding-induced heterodimerization of type II and type I 
receptors leads to type I receptor phosphorylation by type II receptor 
followed by receptor-regulated Smad (R-Smad: Smad 1, Smad 5 and Smad 
8 are substrate of BMP type I receptor; Smad 2, Smad 3 and Smad 7 are 
activated primarily in response to TGFβ1) phosphorylation by type I 
receptors. A complex is formed of phosphorylated R-Smad with the Co-
Smad, and this complex translocates to the nucleus where it regulates 
transcription. 
 
1.4 Aim and Objectives 
1.4.1 Aim of This Study 
Tenogenesis is a tightly controlled process in which several factors regulate 
discrete stages of the differentiation programme. Understanding the mechanism of cell 
commitment and further differentiation into particular lineage is of importance in the 
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development of therapeutic treatments of tendon lesions based on MSC transplantation 
techniques. This research aims to understand the GDF5 effect in tenogenic 
differentiation and function in the regulation of adult stem cells, particularly in MSC.  
The overall objective is to identify regulatory mechanisms in GDF5-induced 
tenogenic MSC. This would lead to a better understanding in the molecular and cellular 
events in early tenogenic differentiation processes induced by GDF5 in MSC, in 
particular, human MSC. This ultimately have a potential for future development of 
molecular therapeutic approaches to repair tendon lesions. 
 
1.4.2 Hypothesis 
The hypotheses are: 
I. GDF5 is involves in tenogenesis of MSCs;  
II. GDF5-induced MSCs is superior for tendon healing compared to the 
undifferentiated MSCs;   
III. Gene expression profile studies could reveal putative molecular pathways 
involved in tenogenesis of MSC. 
 
1.4.3 Specific Objectives 
The effects of GDF5 induced tenogenesis in adult MSC at cellular and transcriptional 
(mRNA) levels as well as in in vivo transplantation model were studied. To evaluate the 
hypothesis, the following objectives were established: 
I. To isolate human and rabbit mesenchymal stem cells (hMSCs and rbMSCs) 
from human and rabbit bone marrow respectively. 
II. To differentiate the hMSCs into tenogenic lineage using GDF5. 
i. To determine the effect of different concentration of GDF5 on MSC 
proliferation; 
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ii. To determine the optimal concentration of GDF5 for tenogenic  
induction in hMSCs (with comparison to native tenocytes from  tendon); 
iii. To determine tenogenic lineage commitment in hMSCs using gene 
expression analysis. 
III. To differentiate rbMSCs into tenogenic lineage using GDF5, in view of possible 
animal transplantation models being used in our later experiments. 
i. To optimize the best concentration of GDF5 for tenogenic induction in 
rbMSCs (in comparison to native tenocytes from tendon); 
ii. To confirm tenogenic lineage using gene expression analysis in 
tenogenic rbMSCs. 
IV. To determine the potential of GDF5 induced tenogenic MSCs in a rabbit tendon 
repair model. 
i. To create a defect on a rotator cuff tendon (infraspinatus tendon) in the 
New Zealand white rabbit model;  
ii. To determine the suitability of tenogenic MSCs in rabbit tendon repair. 
V. To compare the gene expression profile in GDF5 induced hMSC compared to 
untreated MSC control and native tenocyte from tendon. 
i. To generate the gene expression profiles of untreated MSCs, GDF5 
induced MSC and native tenocytes; 
ii. To compare the differentially expressed genes in untreated hMSC 
control, GDF5 induced MSCs and native tenocytes; 
iii. To determine the putative pathways potentially involved in the events of 
tenogenesis which could potentially contribute to the tendon repair 
mechanism. 
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CHAPTER 2  
METHODS 
 
 
 
 
 
 
 
 
Part of this chapter has been published in: 
Tan S.L., Ahmad T.S., Selvaratnam L. & Kamarul T. (2013) Isolation, characterization 
and the multi-lineage differentiation potential of rabbit bone marrow-derived 
mesenchymal stem cells. Journal of Anatomy 222: 437-450. 
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2.0  METHODS  
2.1 Materials 
2.1.1 General Chemicals 
All the chemicals used were either cell culture grade, analytical grade or 
molecular biology grade as stated in Table 2.1. 
 
Table 2.1 General chemicals used in this study. 
$o. Chemical $ame Grade Manufacturer, 
Country 
1 Absolute ethanol Molecular Biology grade 
Catalogue No: 
1.08543.0250 
 
Merck, Damstadt, 
Germany. 
2 Acetic acid (glacial) ACS grade 
Catalogue No: 1410-58 
 
R & M Marketing, 
Essex, UK. 
3 Agarose Molecular Biology grade 
Catalogue No: 75510-019 
 
Invitrogen, Carlsbad, 
California, USA. 
4 Ascorbic acid Not specify. 
Catalogue No: A5706-100G 
 
Sigma-Aldrich, 
Germany. 
5 BD CompBead 
 
Anti-mouse Ig kappa 
Cat No: 552843 
 
BD Pharmingen™, 
USA. 
 
6 β-mercaptoethanol,  Molecular biology grade 
(Catalogue No: 1.12006) 
 
Merck, Damstadt, 
Germany. 
7 Collagenase Type 
1A-S  
Cell culture grade. 
Catalogue No: C9722-
50mg) 
 
Sigma-Aldrich, 
Germany. 
8 Copper (II) sulphate ACS grade 
Catalogue No: 171-500G 
 
Univar Analytical 
Reagent, Australia. 
9 DEPC treated water Molecular Biology grade 
Catalogue No: 750023 
 
Invitrogen, Carlsbad, 
California, USA. 
10 Dimethyl sulfoxide Cell culture grade  
Catalogue No: 196055 
 
MP Biomedical, Santa 
Ana, CA, USA. 
11 Eosin Y Histology grade. 
Catalogue No: E-6003 
 
Sigma-Aldrich, 
Germany. 
12 Fast Green Histology grade. 
Catalogue No: F-7252 
Sigma-Aldrich, 
Germany. 
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Table 2.1 continued 
 
  
13 Formaldehyde Not specify. 
Catalogue No: FO 129-20 
 
System®, Italy. 
14 Formic acid Not specify. 
Cat No: FO 264-70 
 
System®, Italy. 
15 Glutaraldehyde 
 
Histology grade. 
Cat No: G6257- 1L 
Sigma-Aldrich, 
Germany. 
 
16 Haematoxylin Histology grade. 
Cat No: 1798-25G 
 
Laboratory Chemical, 
Australia. 
17 Isopropanol ACS grade  
Catalogue No: 4778-50 
 
R & D Chemical, UK.  
18 L-proline Not specify. 
Cat No: P5607-25G 
 
Sigma-Aldrich, 
Germany. 
19 Mayers 
Haematoxylin 
Histology grade. 
Catalogue No: S330930 
 
Dako, Denmark. 
20 Methanol ACS grade  
Catalogue No: ME313-50 
 
System®, Italy. 
21 Ficoll-Paque 
Premium  
Density: 1.077 g/mL 
Catalogue No: 17-5442-02 
 
GE Healthcare, 
Sweden. 
22 Oil-red-O Histology grade. 
Catalogue No: O0625-25G 
 
Sigma-Aldrich, 
Germany. 
23 RNase away Molecular Biology grade 
Catalogue No: 75510-019 
 
Molecular 
BioProducts, San 
Diego, CA. 
24 Safranin O Histology grade. 
Catalogue No: 3260-25G 
 
Laboratory Chemical, 
Australia. 
25 Sodium acetate 
anhydrous 
Not specify. 
Catalogue No: A679-500G 
 
Analytical Chemical, 
New Zealand. 
26 Sodium chloride Not specify. 
Catalogue No: 31434 
 
Sigma-Aldrich, 
Germany. 
27 Stabilizing fixative For immuno staining. 
Catalogue No: 338036 
BD Pharmingen™, 
USA. 
 
28 Stain buffer (FBS) 
 
For immuno staining. 
Catalogue No: 554656 
 
BD Pharmingen™, 
USA. 
29 50X TAE Molecular Biology grade 
Catalogue No: 129237 
Qiagen, USA 
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2.1.2 Cell Culture Consumables 
For cell culture procedures, sterile disposable plastic pipettes (Orange Scientific, 
Belgium), Pasteur pipettes (Copan, Italy), cell scrappers (TPP, Switzerland) and 
centrifuge tubes (Orange Scientific, Belgium) were used. Cell culture consumables such 
as petri dishes (Orange Scientific, Belgium), cell culture flasks (Nunc
TM
, USA), six-
well- and 96-well- plates (TPP, Switzerland) and chamber slide with cover (Lab-Tek II, 
Nunc, Japan) were used for in vitro experiment. All the general cell culture components 
were obtained from Gibco, Invitrogen, Carlsbad, California, USA, unless stated 
otherwise (Table 2.2). Due to the inavailability of recombinant rabbit GDF5 at time 
when the experiments were conducted, the recombinant mouse GDF5 was used for 
rbMSCs; whereas the recombinant human GDF5 was used for hMSCs. Althought the 
signaling and  mature domains of GDF5 is highly conserved among different species 
(Seemann et al., 2005), the recombinant human and mouse GDF5 were tested separately 
at diferent concentrations to determine their effective concentration towards the treated 
cells. The cell culture images were captured via digital camera (Xcam Alpha, 3M pixel) 
attached on the inverted phase contrast trinocular microscope (CKX41, Olympus, 
Tokyo, Japan). 
 
Table 2.2 Cell culture components used in this study. 
$o. Cell Culture Component 
 
Manufacturer, 
Country 
1 Dulbecco’s Modified Eagle Medium (DMEM) 
4.5 g/L D-glucose 
(Catalogue No: 11995-065) 
 
Invitrogen, Carlsbad, 
California, USA. 
2 Dulbecco’s Modified Eagle Medium (DMEM) 
1.0 g/L D-glucose 
(Catalogue No: 11885-065) 
 
Invitrogen, Carlsbad, 
California, USA. 
3 Dulbecco’s Modified Eagle Medium (DMEM) 
4.5 g/L D-glucose (without fenol red) 
(Catalogue No: 31053-036) 
 
Invitrogen, Carlsbad, 
California, USA. 
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Table 2.2 continued  
 
4 Dulbecco’s Modified Eagle Medium (DMEM) 
1.0 g/L D-glucose (without fenol red) 
(Catalogue No: 11054-020) 
 
Invitrogen, Carlsbad, 
California, USA. 
5 GlutaMAX
TM
-I Supplement 
(Catalogue No: 35050-061) 
 
Invitrogen, Carlsbad, 
California, USA. 
6 Fetal Bovine Serum 
(Catalogue No: 10270-098) 
 
Invitrogen, Carlsbad, 
California, USA. 
7 Sodium pyruvate  
(Catalogue No: 11360) 
 
Invitrogen, Carlsbad, 
California, USA. 
8 Antibiotic-Antimycotic (100x) 
(Catalogue No: 15240-062) 
 
Invitrogen, Carlsbad, 
California, USA. 
9 Penicillin-Streptomycin 
(Catalogue No: 15140-122) 
 
Invitrogen, Carlsbad, 
California, USA. 
10 Recombinant fragment (Human) GDF5 protein 
(Catalogue No: AB55329) 
 
Abcam, UK 
11 Recombinant Mouse GDF5, Carrier free  
(Catalogue No: 853-G5-050/CF) 
 
R&D Systems, UK 
12 TrypLE 
(Catalogue No: 12604-013) 
 
Invitrogen, Carlsbad, 
California, USA. 
13 Accutase, cell detachment solution 
(Catalogue No: L03-AT104) 
 
ICT,USA 
14 Phosphate-Buffered Saline (PBS) 7.2 (1X) 
(Catalogue No: 20012-027) 
 
Invitrogen, Carlsbad, 
California, USA. 
15 Phosphate-Buffered Saline (PBS) 7.2 (10X)  
(Catalogue No: 70013-032) 
 
Invitrogen, Carlsbad, 
California, USA. 
 
2.1.3 Immunostaining Reagents 
Both direct and indirect staining methods were used for immunofluorescence 
staining, in flow cytometry analysis as well as immunohisto- and immunocyto- staining. 
The reagents used for immune staining are listed in Table 2.3. 
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Table 2.3 Reagents used for immunofluorescence staining for flow cytometry analysis 
(A) and for fluorescence imaging (B).  
(A) 
 
Antigens Clone 
$o. 
Fluorochrome 
conjugate 
Catalogue 
$o. 
Manufacturer Species 
specificity 
Integrin beta 1 
(CD29) 
P4G11 Non-conjugated Ab78502 Abcam, UK Rabbit 
only 
 
CD29 MAR4 APC 559883 BD Biosciences, 
US 
Human 
only 
 
H-CAM 
(CD44) 
W4/86 Non-conjugated MCA806
G 
SeroTec, US Rabbit 
only 
 
CD44 G44-26 
(C26) 
APC 559942 BD Biosciences, 
US 
Human 
only 
 
5'-nucleotidase 
cytosolic II 
(CD73) 
 
eBioTY
/11.8 
PE-CyTM 7 25-0731 eBioscience, US, 
California) 
Rabbit 
only 
CD73 AD2 
 
 
PE-CyTM7 561258 BD Biosciences, 
US 
Human 
only 
 
CD73 AD2 FITC 561254 BD Biosciences, 
US 
Human 
only 
 
TAPA-1 
(CD81) 
JS-81 APC 555676 BD Biosciences, 
US 
Rabbit 
and 
Human 
 
Thy-1 
membrane 
glycoprotein 
(CD90) 
 
5E10 PE-CyTM 7 561558 BD Biosciences, 
US 
Rabbit 
and 
Human 
Hematopoietic 
precursor 
antigen (CD34) 
 
ICO115 PerCP-Cy5.5 Sc-7324 
PCPC5 
Santa Cruz 
Biotechnology, 
California 
Rabbit 
only 
CD34 My10 PE 348057 BD Biosciences, 
US 
Human 
only 
 
CD34 My10 PerCP-Cy5.5 347203 BD Biosciences, 
US 
Human 
only 
 
Leukocyte 
common 
antigen (CD45) 
 
L12/20
1 
Non-conjugated 
 
MCA808
GA 
Gentaur 
Molecular 
Products, 
Belgium 
Rabbit 
only 
CD45 2D1 APC-H7 641399 BD Biosciences, 
US 
Human 
only 
 
c-kit (CD117) YB5.B8 PE 555714 BD Biosciences, 
US 
Rabbit 
and 
Human 
 
HLA-DR TU36 FITC 555560 BD Biosciences, 
US 
Rabbit 
and 
Human 
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Table 2.3 continued 
 (B)  
$o Antibody Dilution Catalogue 
$o. 
Manufacturer 
1 Type-I collagen mouse mAb 1:200 GTX2630
8 
GeneTex, Inc, 
Irvine, CA 
 
2 Type-II collagen mouse mAb 1:200 CP18 Calbiochem, 
Darmstadt, 
Germany 
 
3 Type-III collagen mouse mAb 1:200 CP19 Calbiochem, 
Darmstadt, 
Germany 
 
4 Nucleostamin (9D5.3) mouse 
mAb 
 
1:200 ab78129 Abcam, UK 
5 Tenascin C (EB2) mouse mAb 1:200 ab88280 Abcam, UK 
 
6 Scleraxis (D-14) goat 
polyclonal antibody 
1:200 sc-87425 Santa Cruz 
Biotechnology, 
California 
 
7 Tenomodulin (C-20) goat 
polyclonal antibody 
1:200 sc-49324 Santa Cruz 
Biotechnology, 
California 
 
8 Fluorescein isothiocyanate 
(FITC)-conjugated rat anti-
mouse IgG (A85-1) 
 
1:200 553443 BD Biosciences, 
US 
9 Texas red-conjugated donkey 
anti-goat IgG 
1:200 sc-2783 Santa Cruz 
Biotechnology, 
California 
 
10 Alexa Fluor® 546 phalloidin 1:40 A22283 Invitrogen, 
Carlsbad, 
California, USA 
 
11 Hoechst 33342, 
trihydrochloride, trihydrate 
(10 mg/ml) 
5 µg/ml H3570 Invitrogen, 
Carlsbad, 
California, USA 
 
12 FluoroGel mounting medium - GTX2821
4 
GeneTex, Inc, 
Irvine, CA 
 
2.1.4 Surgical Procedures 
The consumables used for surgical procedures and animal (rabbit) handling, i.e. 
surgical scrubbing for bone or tendon harvesting, aseptic and anesthetic procedure in 
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defect creation and tendon repair. The scrubbing solutions and anesthetics used are as 
listed in Table 2.4. 
 
Table 2.4 Consumables and drugs for surgical procedure.  
$o. Sterilize/Anesthetics Solutions 
 
Manufacturer, Country 
1 Povidon iodine topical solution USP 
(10% w/v) 
Catalogue No: MAL070101352x 
 
Unidon Solution, Mumbai, 
India. 
2 Ketamine (100 mg/ml; 300 mg/kg b.w.) 
 
Ilium, Australia. 
3 Xylazil-20 (20 mg/ml; 3 mg/kg b.w.) 
 
Ilium, Australia. 
4 Ophthalmologic ointment (Eye ointment) 
10mg/g chloramphenicol, 5000 IU/g 
polymyxin B sulphate 
 
Ilium opticin, Australia. 
5 Lignocaine hydrochloride (20 mg/ml) 
 
Ilium, Australia. 
6 Premilene® 3-0 non-absorbable 
polypropylene monofilament suture  
 
B. Braun, Germany. 
7 Ethicon  4-0 coated Vicryl undyed braided 
absorbable suture  
 
Johnson & Johnson 
International, Brussels, 
Belgium. 
 
8 Meloxicam injection (5 mg/ml; 0.3 mg per 
kg b.w.)  
 
Meloxicash, India. 
9 Kombitrim 240 (sulfamethoxazole 
200 mg/ml + trimethoprim 40 mg/ml; 
30 mg per kg b.w.) 
 
Kela, Belgium. 
10 Pentobarbital sodium (Nebutal
 ®
 Sodium 
Solution; 50 mg/ml) 
 
Boehringer, Ingelheim, 
Germany. 
 
2.1.5 Gene Specific Primers 
Primers used for RT-PCR and qRT-PCR in this study were synthesized by 1st 
Base, Malaysia as listed in Table 2.5. Gene specific primers for rabbit and human genes 
were designed with Primer Premier 5 (Premier Biosoft, Palo Alto CA) or adapted from 
previous study as listed in Table 2.5. The primers for CD29, CD166, CD34 and CD45 
were only used for rabbit samples in reverse transcription-polymerase chain reaction 
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(RT-PCR) analysis, whereas, for Glyceraldehyde-3-phosphate dehydrogenase (Gapdh), 
type-I collagen (Col-I) and scleraxis (Scx), the primers were used in both human and 
rabbit samples in quantitative RT-PCR (qRT-PCR) analysis. The nucleostemin (st), 
type-III collagen (Col-III) and decorin (Dcn) were used for qRT-PCR in human samples 
only. 
 
Table 2.5 Primers used for RT-PCR and qRT-PCR in this study. 
$o Gene name/ 
Sample  
Primer sequence  Amplicon 
size (bp) 
GenBank 
Accession 
$o 
Primer 
design 
software or 
Reference 
source 
1 CD29 Forward:  
5'-CAA GAA GGA ATG CCT 
ACG TC -3' 
Reverse: 
5'-CAA TGC CAC CAA GTT TCC 
CAT-3' 
 
720 FCU2735
1 
Primer 
Premier 5 
2 CD166 Forward:  
5'-GCT CCC CAG TAT TTA TTG 
CCT TC-3' 
Reverse: 
5'-GTA GCA CCT TTC CAT TCC 
TGT A-3' 
 
345 Y13243 Primer 
Premier 5 
3 CD45 Forward: 
5'-
AGGTAGTAGATGTTTTCCAAG
TAGTGA-3' 
Reverse: 
5'-
ACTTGTCCATTCTGGGCAGGG
TAG-3' 
 
130 XM_0027
17662 
Primer 
Premier 5 
4 CD34 Forward: 
5'-
AGAACTTTCCAGCATGTTCCA
GTTTATG-3' 
Reverse: 
5'-
GGCTTGCCACATCTTGCTCGG
TGA-3' 
 
95 XM_0027
17543 
Primer 
Premier 5 
5 Glyceraldehyd
e-3-phosphate 
dehydrogenase 
(Gapdh) 
Forward: 
5'-AAC ATC ATC CCT GCC TC 
TAC TG -3' 
Reverse: 
5'-CTC CGA CGC CTG CTT CAC 
-3' 
 
196 NM_0020
46  
Kuo and 
Tuan 2008 
6 Type-I 
Collagen 
(Col-I) 
Forward: 
5'- CTG ACT GGA AGA GCG 
GAG AG -3' 
Reverse: 
5'- TCT GGG CAA TGC TGG 
GCT GTG TGG G-3' 
 
129 AY63366
3 
Primer 
Premier 5 
7 Scleraxis (Scx) 5'-CAG CGG CAC ACG GCG 
AAC -3' 
5'-CGT TGC CCA GGT GCG 
AGA TG -3' 
 
165 BK000280 Kuo and 
Tuan 2008 
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Table 2.5, continued 
 
8 Nucleostemin 
(st) 
5'-ATG ACC TGC CAT AAG 
CGG TAT-3' 
5'-AAG GGA GCA CTG TTT 
GGA ACT-3' 
 
131 AK31548
4 
Primer 
Premier 5 
9 Type-III 
Collagen (Col-
III) 
5'-CAG CGG TTC TCC AGG 
CAA GG-3' 
5'-CTC CAG TGA TCC CAG CAA 
TCC C-3' 
 
179 NM_0000
90 
 
Kuo and 
Tuan 2008 
10 Decorin (Dcn) 5'-CTC TGC TGT TGA CAA TGG 
CTC TCT-3' 
5'-TGG ATG GCT GTA TCT CCC 
AGT ACT-3' 
257 NM_1335
05, 
NM_1335
04, 
NM_0019
20, 
NM_1335
03  
 
Kuo and 
Tuan 2008 
11 Tenascin C 
(Tnc) 
Forward: 
5'-GGG TCC TCA AGA AAG 
TCA TCC G-3' 
Reverse: 
5'-CTG ACT CCA GAT CCA CCG 
AAC-3' 
 
62 NM 
002160 
Primer 
Premier 5 
12 Peroxisome 
proliferator-
activated 
receptor-
gamma 
(Ppar-γ) 
 
Forward: 
5'-AGCAAAGAAGTCGCCATCC-
3' 
Reverse: 
5'-
CGTTCAAGTCAAGGCTCACA-
3' 
118 NM_0010
82148 
Primer 
Premier 5 
13 Runt-related 
transcription 
factor 2 
(Runx2) 
Forward: 
5'-
TCAGGCATGTCCCTCGGTAT-3' 
Reverse: 
5'-
TGGCAGGTAGGTATGGTAGTG
G-3' 
 
54 AY59893
4 
Primer 
Premier 5 
14 SRY (sex 
determining 
region Y)-box 
9 (Sox9) 
Forward: 
5'-
AGAGCGAAGAGGACAAGTTC
CCCGT-3' 
Reverse: 
5'-
ATGGGCACCAGCGTCCAGTCG
TAGC-3' 
 
85 XM_0027
19499 
Primer 
Premier 5 
 
2.1.6 Commercial Kits 
2.1.6.1 Differentiation Assay 
StemPro® Osteogenesis Differentiation Kit (Invitrogen, Carlsbad, California, 
USA) was used for osteogenic differentiation of mesenchymal stem cells in in vitro cell 
culture environment. 
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StemPro® Adipogenesis Differentiation Kit (Invitrogen, Carlsbad, California, 
USA) was used for adipogenic differentiation of mesenchymal stem cells in in vitro cell 
culture environment. 
 
2.1.6.2 Colorimetric Assay 
The Sircol™ Soluble Collagen Assay (Biocolor, Ireland) was used to determine 
the acid-soluble collagens released into culture medium by mammalian cells during in 
vitro culture. 
 
2.1.6.3 Histology Staining 
The Von Kossa special stain kit, method for calcium (Bio-Optica, Milano, Italy) 
was used for staining of calcium deposition in monolayer cultured cells in chamber 
slides. 
The Van Gieson Trichrome staining kit (Bio-Optica, Milano, Italy) was used for 
connective tissue and collagen fibers staining in histological sections and monolayer 
cells seeded in chamber slides. 
 
2.1.6.4 Total R$A Purification and Quality Assessment 
The AllPrep DNA/RNA/Protein Mini Kit (Qiagen, USA) was used to purify 
total RNA. This kit allowed an enrichment for mRNA and most RNA <200 nucleotides 
are selectively excluded. The purified RNA samples were ready to use for RT-PCR, 
quantitative qRT-PCR and microarray. 
The Qiagen® RNase-Free DNase Set (Qiagen, USA) was used with the AllPrep 
DNA/RNA/Protein Mini Kit for on-column digestion of DNA during RNA purification. 
The Agilent RNA 6000 Nano kit (Agilent Technologies, Germany) was used to 
determine the total RNA integrity and quality with the Agilent 2100 expert bioanalyzer. 
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2.1.6.5 Polymerase Chain Reaction (PCR) 
The Superscript
TM
 III One-Step RT-PCR System with Platinum
R
 Taq DNA 
Polymerase kit (Invitrogen, Carlsbad, California, USA) was used for one step reverse 
transcription-PCR. 
The Transcriptor High Fidelity cDNA Synthesis kit (Roche Diagnostics GmbH, 
Mannheim, Germany) was used to synthesize cDNA of high accuracy which suitable for 
used in quantitative PCR (qRT-PCR). 
The iQ™ Sybr® Green Supermix (Bio-Rad, Hercules, CA, USA) was used for 
dye-based qRT-PCR with Bio-Rad CFX96™ real-time PCR System. 
 
2.1.6.6 Microarray Gene Expression Analysis 
The Applaus™ WT-Amp ST System (NuGEN Technologies, Inc, San Carlos, 
CA, USA) was used to prepare amplified cDNA sample for global gene expression 
analysis on Affymetrix® Gene Chip® Gene 1.0 ST Arrays. 
The GeneChip® Human Gene 1.0 ST Array (Affymetrix Inc, Santa Clara, CA, 
USA) was used for whole-genome gene level expression studies of known genes. This 
GeneChip array comprised more than 750,000 unique 25-mer oligonucleotide features 
constituting over 28,000 gene-level probe sets. 
The MinElute Reaction Cleanup Kit was used for purified the cDNA samples 
amplified with Applaus™ WT-Amp ST System, prior to in vitro cDNA fragmentation 
and transcription with biotinylated nucleotide, in preparation for hybridization on 
Affymetrix GeneChip® Human Gene 1.0 ST Array. 
The Encore™ Biotin Module (NuGEN Technologies, Inc, San Carlos, CA, 
USA) was used to fragmentize and label the purified cDNA samples in preparation of 
targets for hybridization on Affymetrix GeneChip® Human Gene 1.0 ST Array. The 
GeneChip® Hybridization Wash and Stain Kit was used for hybridization with 
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GeneChip® Hybridization Oven 640, automated washing and staining of GeneChip® 
Human Gene 1.0 ST Array with the Fluidics Staition 450 and scanning probe arrays 
using the Affymetrix GeneChip® Scanner 3000 7G.  
 
2.1.6.7 Validation of Microarray Data 
QuantiGene® Plex 2.0 Assay (Plex set 11904 Human) kit (Affymetrix, Santa 
Clara, CA) was used for confirmation of the microarray analysis. This assay was used to 
determine the gene expression levels in total RNA samples without RNA amplification 
step. Thus, it provided an independent method of measurement relative to the 
quantitative PCR and microarray platforms. It used three sets of pooled oligonucleotides 
that function to capture, provide binding sites for signal amplification molecules, and 
stabilize the mRNA of interest.  
 
2.2 Biological Samples 
2.2.1 Human Samples Procurement 
Ethics approval to conduct this study was granted by the University of Malaya 
Medical Centre (UMMC) Ethics Committee (Reference number: 602.22; Appendix 
A1). Human bone marrow was harvested from adult donors (Appendix A2) undergoing 
intramedullary nailing in UMMC. The bone marrow samples were collected in the 
blood collection (EDTA) tubes and transported to tissue culture laboratory for isolation 
and culture. 
Adult human hamstring tendons free of pathology were obtained from donors 
who underwent ligamentous reconstruction of the knees and arthroplasty of the knee(s) 
(Appendix A2). Written informed consent was obtained from each donor. The 
hamstring tendons that were obtained were kept in sample bottle with sterile normal 
saline before transported to laboratory for further processing. 
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2.2.2 Rabbit Samples Procurement 
Ethics approval to conduct the in vitro and in vivo experiments in this study was 
granted by the Animal Care and Use Committee (ACUC), Faculty of Medicine, 
University of Malaya (Reference number: PM/24/06/2008/TKZ(b)(R); Appendix B).  
 
2.2.2.1 In vitro Study 
For primary culture purpose, the New Zealand white rabbits (at least 4 months 
old) were euthanized by an overdose of pentobarbital sodium (Nebutal
®
 Sodium 
Solution) (Boehringer, Ingelheim, Germany). All the long bones (tibia, femur and 
humerus bones) were harvested from the rabbit under aseptic condition. All the 
harvested bones were kept in phosphate buffered saline (PBS, pH 7.2) supplemented 
with penicillin-streptomycin 1% (v/v Invitrogen-Gibco) before transferred to tissue 
culture laboratory for further processing. Figure 2.1 depicted the surgical tools used for 
rabbit bone and tendon harvesting. 
 
Figure 2.1  Surgical tools used in aseptic rabbit bone and tendon procurement. 
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2.2.2.2 In vivo Transplantation Study 
For in vivo transplantation study, eighteen healthy adult New Zealand white 
rabbits (2.87±0.53 kg and age of 6-12 months) were randomly assigned into 6 groups 
(n=3). The rabbits were anesthetized by intramuscular injection of ketamine (100 
mg/ml; 300 mg/kg body weight; Ilium, Australia) and xylazil-20 (20 mg/ml; 3 mg/kg 
body weight; Ilium, Australia). The rabbit eyes were protected by application of 
ophthalmologic ointment (Ilium opticin, Australia) to prevent damage or dryness of the 
cornea during induction phase of anesthesia and the surgery. The surgical area was 
disinfected with povidon iodine topical solution 10% w/v (Unidon Solution, India) and 
3 ml of 20 mg/ml lignocaine hydrochloride (Ilium, Australia) was injected 
subcutaneously for local anesthetic effect. Surgical defect creation and repair were 
conducted with assistance from a medical officer. Figure 2.2 depicted the surgical tools 
used for rabbit in vivo transplantation surgery. 
 
Figure 2.2  Surgical tools used for rabbit transplantation study.  
The microsurgery set was used for tendon defect creation. 
 
2.3 General Laboratory Equipment 
The laboratory equipment used for the experiments conducted in this study was 
as listed in Table 2.6. 
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Table 2.6  List of general and specialized equipment used for cell culture, molecular   
biology analysis and cell imaging analysis. 
 
$o Equipment  Model Brand 
 
1 CO2 incubator CCL-170B-8 
 
 
Esco, Singapore 
2 CO2 incubator Galaxy 170R New Brunswick, 
Enfield, CT, USA 
 
3 Refrigerated 
centrifuge 
5810R Eppendorf, Hauppauge, 
NY, USA 
 
4 Orbital mixing 
chilling/Heating dry 
bath 
 
Echotherm™ 
SC20 
Torrey Pines Scientific 
Inc, Carlsbad, CA. 
5 Vortex mixer 
 
VTX-3000L Uzusio, Japan 
6 Inverted phase 
contrast microscope 
 
CKX41 Olympus, Tokyo, Japan 
7 Water bath 
 
Precisterm Selecta®, Spain 
8 Laser confocal 
microscope 
TCS SP5 II Leica Microsystems, 
Mannheim, Germany 
 
    
9 Class II biosafety 
cabinet 
Airstream (AB2-
4S1) 
Esco, Singapore 
    
10 Automated 
microfluidic 
electrophoresis 
system 
 
Experion
TM
 Bio-Rad, Hercules, CA, 
USA 
 
11 Bioanalyzer Agilent 2100 Agilent Technologies, 
Germany 
 
12 Nanodrop UV-Vis 
Spectrophotometer 
 
NanoDrop™ 
2000c  
Thermo Scientific, 
Wilmington, DE 
13 CFX96 Real time 
PCR system 
 
C1000™  Bio-Rad, Hercules, CA, 
USA 
 
14 Genechip® 
hybridization 
incubator 
 
GeneChip® 
Hybridization 
Oven 640 
 
Affymetrix Inc, UK 
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Table 2.6, continued   
    
15 Genechip® 
automated fluidic 
system 
 
Fluidics Station 
450 
Affymetrix Inc, UK 
16 Genechip® scanner  GeneChip® 
Scanner 3000 7G 
Affymetrix Inc, UK 
    
17 Microtiter plate 
luminometer 
Luminex Bio-Rad, Hercules, CA, 
USA 
 
18 Fume cabinet DFH4000 Erla Technologies, 
Malaysia  
 
 
2.4 Standard Methods  
2.4.1 Tenocyte Primary Culture 
2.4.1.1 Human Hamstring Tendon-Derived Tenocyte (hTeno) Primary Culture 
Human hamstring tendon specimens were processed using the methods modified 
from Zhang and Wang (2010a). Briefly, the tendons were minced into approximately 
1 mm
3
 in size
 
under a sterile condition. The explants were then transferred into a 15 mL 
falcon tube with 0.4 mg/mL type I collagenase (200 U/ml solution) in PBS (pH 7.2), 
and incubated at 37
o
C in a humidified atmosphere of 5% CO2 for 2 h to allow for the 
enzymatic digestion process to occur. The specimens were subsequently centrifuged at 
1800 rpm at 15
o
C for 5 mins. The supernatant was then removed and the pellet was 
washed twice with 10 mL PBS. Following that, the digested explants were cultured in 
T75 tissue culture flasks (Nunc
TM
, USA) with DMEM-high glucose (4.5 g/L glucose) 
(Invitrogen-Gibco, USA), supplemented with 10% fetal bovine serum (FBS) 
(Invitrogen-Gibco, USA), 100 unit/mL penicillin-streptomycin and 200 mM 
GlutaMAX™-I (Invitrogen-Gibco, USA). Cultures were incubated at 37
o
C in a 
humidified atmosphere of 5% CO2 and supplemented with fresh culture medium at 3-
day intervals. Forty eight hours after culturing, the digested tissues were discarded, and 
the outgrown cells were maintained at 80-90% of confluency for subculture using 
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trypsin digestion. These primary native human tenocyte (hTenos) cultures (P2 or P3) 
were used as positive controls in the subsequent total collagen and gene expression 
experiments. The cells isolated appeared to have fibroblastic morphology (Figure 2.3), 
similar to that reported by Zhang and Wang (2010a) in rabbit tenocyte culture. 
   
Figure 2.3  Human tenocyte primary culture.    
A. Cells were appeared in fibroblastic spindle shape. Low magnification 
image (4x). 
B. Cells appeared to be stretched with long and thin processes, these 
cells tended to group in close contact, parallel arrangement and grow 
in high-density colonies. High magnification image (20x). 
 
2.4.1.2 Rabbit Achilles Tendon-Derived Tenocyte (rbTeno) Primary Culture 
Rabbit Achilles tendons were processed with the same protocol used in human 
hamstring tendon-derived tenocyte (hTeno) isolation and culture (Section 2.4.1.1). 
Rabbit tenocytes isolated appeared to have fibroblastic morphology (Figure 2.4), similar 
to that reported by Zhang and Wang (2010a) in rabbit tenocyte culture. 
   
Figure 2.4  Rabbit tenocyte primary culture. 
 
A B 
A B 
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Figure 2.4, continued 
 
A. Cells were appeared in fibroblastic spindle shape.  Low 
magnification image (4x). 
B. Cells appeared to have similar morphology compared to that of 
human tenocyte primary culture. High magnification image (20x). 
 
2.4.2 Measurement of Cell Length and Width 
Photographs were taken at representative areas of culture plates. The length and 
the maximum widths (cell body width) perpendicular to the long axes of individual cells 
were measured using ImageJ 1.46r software (National Institute of Mental Health, 
Maryland, USA). At least 8 representative cells were measured from each independent 
experiment. Data were presented as mean ± standard error of mean. The statistical 
analysis was performed using SPSS Statistic software (version 19). Student’s t-test (2 
sided, unpaired) was carried out to compare the differences in mean values and 
p-value < 0.05 was taken as significant.  
 
2.4.3 Trilineages Differentiation Assay 
MSC primary cultures (at P2, N=3) were seeded in the cell culture vessel at cell 
density of 5x10
3
 cells/cm
2
. For histological staining, cells were seeded onto chamber 
slides, whereas for gene expression analysis, cells were seeded in T-25 culture flask. 
MSC cultures were incubated in MSC growth medium for three days at 37 
o
C in a 
humidified CO2 incubator. The MSC growth medium was then replaced with pre-
warmed StemPro® Osteogenesis Differentiation medium (Invitrogen, Carlsbad, 
California, USA) or StemPro® Adipogenesis Differentiation medium (Invitrogen, 
Carlsbad, California, USA) or chondrogenic medium (Appendix C) and refed at every 3 
days interval. After 28 days, cells seeded in chamber slides were fixed with appropriete 
fixative and proceeded to specific histological staining (Section 2.4.9).  
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2.4.4 Cell Proliferation Assay 
AlamarBlue® assay was conducted to determine the cell proliferation in MSCs 
based on the colorimetric quantitative analytical principle. Two days after the cells were 
supplemented with various concentration levels of GDF5, 25 µl of alamarBlue® reagent 
(Invitrogen-Gibco, USA) was added into the medium. Culture plates were protected 
from light with aluminium foil. Absorbance readings at 570 nm and 600 nm were 
obtained using a spectrophotometer (Epoch, Biotek, USA) at various time points i.e. 0, 
2, 4, 6, 12 and 24, 36, 48 and 60 h. Untreated hMSCs cultured in MSC growth medium 
were used as controls. Three independent experiments were performed, each in 
octuplicates in the 96-well plates.  
 
2.4.5 Total Soluble Collagen Assay 
Total soluble collagen in the culture medium was quantified with colorimetric 
Sircol
TM
 soluble collagen assay (Biocolor, Ireland). Briefly, the cell culture medium 
was mixed with Sircol dye reagent with vigorous agitation in a 1.5 mL microcentrifuge 
tube for 30 mins. The mixture was then centrifuged for 10 mins at 10,000xg to collect 
the collagen-dye complex at the bottom of the centrifuge tubes. The unbound dye 
solutions were later removed by draining the tubes. Subsequently, 1 mL of the alkaline 
reagent was added to each microcentrifuge tube. As the unbound dye dissolved, the 
absorbance of the samples was measured at 540 nm. The collagen content in the 
medium was calculated based on the standard curve plot, with type-I collagen supplied 
with the kit as the reference sample. In both the dose and time response experiments, 
three independent experiments, each in triplicates were performed.  
Statistical analysis was analyzed with SPSS (ver. 17) software. Comparisons of 
mean values between the different concentrations and various time points were 
conducted using one-way analysis of variance (ANOVA) statistical test.  Least 
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significant differences (LSD) analysis with Bonferroni adjustment for multiple pairwise 
comparisons of the mean total collagen differences was conducted. Statistical 
significance was accepted when p value was less than 0.05 (p<0.05). 
 
2.4.6 Sample Preparation for Transmission Electron Microscopy Imaging 
For electron microscopy imaging, the medium was discarded from the culture 
flask containing rbMSC (or hMSC) at 70-80% confluence. The cells were rinsed twice 
with PBS (pH 7.2) (Invitrogen-Gibco, USA) before being trypsinized and scraped from 
flask with a cell scraper, centrifuged at 800 xg for 10 mins to form a cell pellet at the 
bottom of centrifuge tube. The cell pellet was then fixed in 4% glutaraldehyde (Sigma-
Aldrich, Germany) overnight before being further processed. The pellet was washed 
three times in 0.1 M cacodylate buffer (pH7.4) (Merck AG, Darmstadt, Germany), prior 
to, and post-secondary fixation for 2 h at room temperature in a mixture of osmium 
tetraoxide : cacodylate buffer (1:1). The pellet was kept overnight in 0.1 M cacodylate 
buffer (pH7.4 (Merck AG, Darmstadt, Germany)). The next day, the pellet was washed 
with uranyl acetate for 10 mins, followed by three washes with double distilled water. 
Then, the pellet was dehydrated through a graded ethanol series (35, 50, 70 and 95%) 
for 10 mins each; 100% for 15 mins, three times; propylene oxide and epoxy resin 
mixture (1:0 for 15 mins twice; 1:1 for 1 h and 1:3 for 2 h) and in fresh epoxy resin, 
overnight, on the rotary mixer (Ted Pella, Redding, California, USA), at 1 rpm. The 
specimen was then embedded in epoxy resin for semithin and ultrathin sectioning with 
ultramicrotome (Reichert Ultracuts, Leica Microsystems, Vienna, Austria). Images were 
obtained with a transmission electron microscope (Leo Libra 120, Carl Zeiss SMT AG, 
Oberkochen, Germany). Electron micrographs were prepared by the Electron 
Microscope Unit in University of Malaya.  
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2.4.7 Gene Expression Analysis  
2.4.7.1 Total R$A Isolation 
Total RNA was extracted from 1X10
6
 cells of 70-80% confluent rbMSC primary 
culture (P1-P3) using AllPrep DNA/RNA/Protein Mini kit kit according to 
manufacturer’s instructions and treated with RNase-free DNase I (Qiagen GmbH, 
Hilden, Germany). Briefly, the cell harvested for total RNA extraction were lysed with 
buffer RLT before loaded into the Allprep DNA spin column. The flow through 
collected in the collection tube was mixed with 100% ethanol before loaded into the 
RNeasy spin column. After one wash with buffer RW1, the sample was treated with 
on-column DNase I (Qiagen GmbH, Hilden, Germany) digestion. After washing steps 
with buffer RW1 (once) followed by buffer RPE (twice) the total RNA was eluted with 
30 µl of nuclease-free water. Total RNA samples were stored at -80
o
C until further 
analysed with RT-PCR, qRT-PCR or microarray. The concentration of total RNA was 
determined by NanoDrop™ 2000c UV-Vis Spectrophotometer (Thermo Scientific, 
Wilmington, DE). The integrity of total RNA samples used for microarray analysis was 
determined by Agilent 2100 bioanalyzer and Agilent RNA 6000 Nano kit (Agilent 
Technologies, Germany). 
 
2.4.7.2 One Step RT-PCR Analysis  
A. RT-PCR Analysis 
The RT-PCR analysis was carried out using Superscript
TM
 III One-Step RT-PCR 
System with Platinum
R
 Taq DNA Polymerase kit (Invitrogen, Carlsbad, California, 
USA). The RT-PCR reactions were prepared according to the manufacturer’s 
instructions (with some modifications) in a final volume of 25 µl with 12.5 µl 2X 
reaction mix, 1 µl (or 1 µg) of total RNA, 10 µM of each primers, 1 µl of Superscript
TM
 
III RT/Platinum
R
 Taq Mix. The RT step involved incubation at 42
o
C for 60 mins. The 
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amplification protocol was as follows: an initial denaturation of 94
o
C for 2 mins 
followed by 35 cycles of 94
o
C for 15 s, 58
o
C for 30 s and 72
o
C for 30 s. Negative 
control tubes for each gene that contained water instead of template RNA or cDNA 
were also run under the same conditions. Gapdh was used as internal control and RNA 
from mononuclear cells was used as positive control.  
 
B. PCR Amplicon Analysis 
To confirm the absence of primer-dimers and other spurious products, the PCR 
products were evaluated using an Experion
TM
 automated microfluidic electrophoresis 
system (BioRad) as described in the manufacturer’s protocol.  This provides high 
resolution banding patterns of the separated DNA molecules as well as the quantitative 
output of their relative abundance. Briefly, a small aliquot (~1 µl) of PCR product or 
DNA ladder was loaded into the sample well or ladder well on the DNA 1K chip (Bio-
Rad, Hercules, CA) and analysed with the Experion
TM
 automated electrophoresis 
system (Bio-Rad, Hercules, CA, USA). An electropherogram and a virtual gel were 
generated by the Experion software analysis tool when the run was completed for each 
sample, and the sizing of the PCR product was performed automatically based on the 
DNA standard electropherogram.  
 
2.4.7.3 Two Steps qRT-PCR 
A. Reverse Transcription of Total RA 
In this study, 1 µg of total RNA was reverse-transcribed into cDNA with the 
transcriptor high fidelity cDNA synthesis kit (Roche Diagnostics GmbH; Mannheim, 
Germany). The reverse-transcription (RT) reaction was conducted based on the 
manufacturer’s protocol with the oligo-dT primer. RT was performed with an initial 
denaturation of 11.4 µl primer-template mixture (which consist of 1µg of total RNA, 
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2.5 µM anchored-oligo(dT)18 primer and PCR-grade water) at 65
o
C for 10 min. Then, 
the reaction mixture was immediately chilled on ice, before the remaining RT mixture 
(consist of 4 µl of RT buffer, 0.5 µl of 20U protector RNase inhibitor, 2 µl of 
deoxynucleotide mix, 1 µl of DTT and 1.1 µl of high fidelity reverse transcriptase) was 
added into it. The RT reaction was completed by incubation for 30 min at 55
o
C. The RT 
reaction was inactived by incubation at 85
o
C for 5 min. The synthesized cDNA was 
stored at -20
o
C until further analysed in qRT-PCR analysis. 
 
B. qRT-PCR Analysis 
qRT-PCR was performed with a Bio-Rad CFX96™ Real-time detection system 
(Bio-Rad Laboratories, Inc., Hercules, CA) and in a final volume of 20 µl of reaction 
mixture which consist 10 uL iQ
TM
 SYBR® Green Supermix (Bio-Rad Laboratories, 
Inc., Hercules, CA), 0.6 µL cDNA samples, and 0.2 µM of each primer (forward and 
reverse primers; Table 2.4). The optimum annealing temperature for each pair of 
primers was determined empirically (Appendix D).  The amplification protocol was as 
follows: an initial denaturation and activation step at 95
o
C for 30 s followed by 40 
cycles of 95
o
C for 15 s and 61
o
C for 45 s. A melting curve program was carried out 
routinely to confirm the presence of a single product (55-95
o
C with a heating rate of 
0.5
o
C per second and a continuous fluorescence measurement). The annealing 
temperature at 61
o
C was derived empirically with temperature gradients. To estimate 
amplification efficiency, a standard curve was generated for each target molecule via 5-
fold serial dilution of a cDNA pool containing the target gene sequences. Data was 
analysed with the CFX manager software. A relative quantification method (with 
corrected PCR efficiency (Pfaffl, 2001)) was performed. All the data was normalized to 
GAPDH, which was used as the reference gene, after correcting for differences in 
amplification efficiency (as recommended in the CFX manager package). Data was 
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presented as log10-fold (or log2-fold change (±S.D.) of relative quantification of target 
mRNA relative to control samples (untreated hMSCs). Student’s t-tests were employed 
to determine the differences between the untreated and GDF5 treated samples. For all 
comparisons, the statistical significance was accepted at 95% confidence interval 
(p<0.05). 
 
2.4.7.4 Microarray Sample Preparation and Analysis 
A. Total RA Integrity Assessment  
Total RNA quality and integrity was assessed with Agilent 2100 bioanalyzer and 
Agilent RNA 6000 Nano kit (Agilent Technologies, Germany) according to protocols 
suggested by manufacture. Briefly, 9 µL gel-dye mix was loaded into the assigned well 
in the RNA Nano chip. The chip was subsequently pressurized for 30 sec. Then, another 
two assigned wells were filled with the gel-dye mix, while the remaining wells were 
loaded with 6 µL of each RNA Nano marker. 1 µL of denatured RNA ladder was loaded 
into the ladder well and 1 µL of denatured total RNA sample was loaded into each 
sample well. The chip was vortex at 2400 rpm for 60 s and inserted into the receptacle 
in the Agilent 2100 bioanalyzer. To prevent denaturation of RNA samples, the electrode 
was decontaminated with RNase away and RNase-free water prior to chip loading. RNA 
6000 Nano assay was executed via Agilent 2100 expert software. During the run, a 
current was sequentially applied to each sample to separate the RNA samples 
sequentially. RNA is detected by fluorescence of the intercalating dye in the gel-dye 
mix. An electropherogram was generated at the end of each sample run. A successful 
run was observed with one marker peak, two ribosomal (18S, 28S) peaks, which 
denoted a successful sample preparation. The total RNA concentration, ratio of 
ribosomal subunit (28S/18S) and the RNA Integrity Number (RIN) was automatically 
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generated by the 2100 expert software based on the electropherogram. Only samples 
with RIN value ≥ 7.0 were proceeded for microarray analysis (Appendix E1). 
 
B. Target Preparation  
Sample preparation protocols were conducted as described in NuGEN Ovation 
manual and Affymetrix GeneChip Expression Analysis Technical Manual. Briefly, an 
aliquot of 200 ng of total RNA (in 5 µL of nuclease free water) was converted to first-
strand cDNA using reverse transcriptase primed by a poly-(T) oligomer that 
incorporated a synthetic RNA sequence. Second-strand cDNA synthesis was followed 
by ribo-SPIA (Single Primer Isothermal Amplification, NuGEN Technologies Inc. San 
Cario, CA) for linear amplification of each transcript, and the resulting cDNA was 
purified. As assessed by Nanodrop UV-Vis spectrophotometer, the cDNA yields in this 
experiment ranged from 0.053 to 1.250 µg (Appendix E2). A total of 2.5 µg of purified 
cDNA (per sample in 12.5 µL) was fragmented and biotin labelled. Then, the 
biotinylated cDNA samples were added to Affymetrix hybridization cocktails and 
heated at 99
o
C for 2 min and hybridized for 20 h at 60 rpm rotation and 45
o
C to Human 
GeneChip (Affymetrix Inc, Santa Clara, CA) in GeneChip® Hybridization Oven 640 
(Affymetrix Inc, Santa Clara, CA). Microarrays were washed at low (6X SSPE) and 
high (100 mM MES, 0.1 M NaCl) stringency and stained with streptavidin-
phycoerythrin. Fluorescence was amplified by adding biotinylated anti-streptavidin and 
an additional aliquot of streptavidin-phycoerythrin stain. All the washing and staining 
steps were conducted with Fluidics Station 450 (Affymetrix Inc, Santa Clara, CA).  
Fluorescence signals were collected after excitation at 570 nm by the Affymetrix Gene 
Chip Scanner 3000 7G (Affymetrix Inc, Santa Clara, CA). The captured microarray 
image files were analysed via Affymetrix GeneChip® Command Console 3.2.3 (v.5, 
Affymetrix Inc., Santa Clara, CA) to get the CEL intensity files. The CEL files were 
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processed with data preprocessing bioinformatics software and gene expression was 
assessed after normalization.  
 
C. Bioinformatics Analysis  
Various bioinformatics analysis software/programs were used in microarray data 
analysis. The software/programs used in this study are as listed in Table 2.7.  
 
Table 2.7 The software/programs used for bioinformatics analysis of microarray data. 
$o. Software/Programe Reference Application 
 
1. Affymetrix GCOS www.affymetrix.com Preprocessing of 
microarray image 
files. 
2. Affymetrix Power 
Tools and DABG 
detection calls 
www.affymetrix.com Preprocessing and 
filtering. 
3. Linear Models for 
Microarray Data 
(Limma) software 
package for R 
programming 
http://www.bioconductor.org Differential 
expression 
analysis. 
4. GeneGo Metacore™ 
Pathway Analysis 
http://www.genego.com/metacore.php Signaling 
pathway analysis 
 
 
2.4.7.5 QuantiGene® Plex 2.0 Assay 
QuantiGene® Plex 2.0 Assay (Affymetrix, Santa Clara, CA) was used for 
confirmation of the microarray analysis. The assays of 15 genes (12 target and three 
housekeeping genes, detailed in Appendix F) were performed according to the 
manufacturer’s protocol for (A) control hMSCs, (B) day 4 GDF5-induced hMSCs, (C) 
day 10 GDF5-induced hMSCs and (D) tenocytes.  Briefly, 20 µL of starting total RNA 
(200 ng) from each sample was mixed with 33.3 µL of Lysis mixture, 1 µL of Capture 
Beads and 5 µL of target gene-specific probe set (2.0 probe set), and 2 µL of blocking 
reagent and 38.7 µL nuclease-free water. Each sample mixture was then dispensed into 
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an individual well of Capture plate (Affymetrix, Santa Clara, CA). The Capture Plate 
was sealed with a foil tape and incubated at 53 
o
C for 20 h. The hybridization plate was 
spin-down briefly to collect all the evaporated solution to the bottom of the 
hybridization plate. Then, the sample mixtures in the hybridization plate were 
completely transferred to the magnetic separation plate. The magnetic separation plate 
was then placed on a hand-held magnetic plate washer before the hybridization mixture 
was removed, and followed by three washing steps with 250 µL of wash buffer. After 
the last wash, the residual wash buffer was removed by blotting the magnetic separation 
plate on the folded tissue. Signals for the bound target mRNA were developed by 
successive incubation in three working solutions: 2.0 pre-amplifier, 2.0 amplifier and 
biotinylated label probes and SAPE. Two washes was performed between the 
incubations to remove unbound reagents. The plate was covered with aluminium foil 
during SAPE incubation to prevent photo bleaching. At the end of last washing step, 
130 µL of SAPE buffer was added to each well and the plate was protected with foil 
plate seal and aluminium foil at each washing step.  
Luminescence from each well was measured using a microtiter plate 
luminometer (Bio-Rad, Hercules, CA, USA). The signals were captured with the 
instrument after a calibration was performed. Prior to the measurement, each bead type 
was identified in the luminometer software in order to specify to which transcripts the 
beads corresponded. 
For all samples, background signals were determined in the absence of RNA 
samples and subtracted from signals obtained in the presence of RNA samples. The 
presence and absence call was determined by limit of detection (LOD) of the assay, 
where LOD = background + 3 x standard deviation of background. The expression 
value of each sample was calculated by normalizing the average background-subtracted 
signal of each sample to the geomean of the selected housekeeping genes (which consist 
  
67 
 
of TATA box binding protein (Tbp), hypoxanthine phophoribosyltransferase 1 (Hprt1) 
and phosphoglycerate kinase 1 (Pgk1) that represented low, medium and high abundant 
housekeeping genes, respectively) prior to the calculation of gene expression fold 
change. The gene expression fold change value, for instance fold change in sample X 
versus sample Y, was calculated with formula log2 fold changes = log2(expression value 
of X/expression value of Y). A gene is considered for fold change analysis if the signal 
in both sample X and sample Y passes the LOD. 
 
2.4.8 Immunofluorescence Staining  
2.4.8.1 Flow Cytometry Immunophenotyping 
A. Sample Preparation 
The hMSCs or rbMSCs were harvested with accutase™ (Innovative Cell 
Technologies, Inc, California, USA) and resuspended in phosphate buffered saline 
(PBS, pH 7.2) at a final concentration of 1x10
7
/mL. An aliquote of 100 µL was 
distributed into each round-bottomed tubes for phenotypic characterization using 
fluorescence-activated cell sorting (FACS; BD FACS Cantor II, BD Biosciences, US). 
Cell suspension was incubated with the optimum dilution of fluorochrome-conjugated 
or unconjugated primary antibody (Table 2.3) at 4 
o
C for 30 min.  
The MSC positive antigens included to the phenotyping profile were: CD29, 
CD44, CD73, CD81, and CD90.1. To discriminate MSCs from hematopoietic stem and 
progenitor cells, isolates were stained for CD34, CD45, CD117 and HLA-DR. All 
mAbs were immunoglobulin G1 (IgG1) isotype except for HLA-DR, which is 
immunoglobulin G2b (IgG2b). After 30-mins of incubation, cells were washed using 
2 mL of PBS and resuspended in the stabilizing fixative (BD Pharmingen™, USA) to 
protect the tandem dyes such as PE-Cy7- or AP-Cy7. Non-specific fluorescence 
emission was detected by incubating cells with fluorescence conjugated isotype control. 
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At least 10,000 events were captured by the system. Flow cytometry data were analyzed 
using CELLQUEST software (Becton Dickinson). Gating was done to exclude cell 
debris and unwanted aggregates (FSC/SSC dotplot). Non-specific isotype-control (IgG1 
or IgG2a) were used to determine the background fluorescence emission, if any. 
 
B. Unlabeled Spectral Overlap Determination (Compensation Setup with BD 
CompBeads) 
All PMT voltages were adjusted with the unstained control tube before recording 
the single-stained control tubes (with anti-mouse Ig Kappa CompBeads; BD 
Pharmingen™, USA; Appendix G1). Then the pre-set photomultiplier tube (PMT) 
voltages were used to record each of the single-stained BD CompBead Tube. All the 
voltages for colour detector were kept constant for the remaining compensation tubes, 
only scatter was adjusted when needed. The auto-compensation feature in the BD 
FACSDiva was used to calculate the overlapping spectral. Briefly, a region on the dot 
plot was adjusted to encompass the appropriate population for one of the single stained 
controls and the gate was copied and applied to all the other control tubes. Subsequently, 
a gate was created around each of the negative and positive populations on the 
histogram of each single-stained control (Appendix G2). The Auto-Interval tool was 
used to quickly create an Interval gate around each population. The gate on the negative 
population was adjusted to go past the left axis of the histogram to include all events, as 
recommended by the manufacturer, BD Biosciences. After all histogram have been 
gated, the spectral overlaps were calculated automatically and stored for future use as 
compensation setup. The spectral overlap values from this compensation setup were 
used for all the following experiments as the instrument setting. The compensation was 
automatically calculated for each tube in the experiments based on the corresponding 
single-stained control in the saved setup. Based on the predetermined unlabeled spectral 
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overlap setup, the Spectral overlap values were calculated from the single-stained 
controls (recorded earlier) and applied to the particular tubes in the linked experiment. 
This system description was used in all the downstream experiments for multicolour 
stained samples compensation. 
 
2.4.8.2 Fluorescence Imaging 
For fluorescence imaging, cells seeded on cover slips or tissue sections (8 µm 
thick) mounted on the silanized slides (Dako, Denmark) were fixed with ice cold 
acetone for five min. Then, the specimens were rinsed twice with stain buffer (BD 
Pharmingen™, USA) before hybridized with primary antibodies (unconjugated mouse 
monoclonal or goat polyclonal antibodies; Table 2.3) at 4 
o
C, overnight in a humid 
chamber. After overnight hybridization, the specimens were washed twice with stain 
buffer before proceed to staining with fluorescence-conjugated-secondary antibodies 
(fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG and Texas Red-
conjugated anti-goat IgG) and counterstained with nucleus stain (either with or without 
phalloidin-Alexa Fluor® 546 stain), for 30 min at room temperature. Then, the 
specimens were washed twice with stain buffer before mounted with fluoroGel 
mounting medium (GeneTex, Inc, Irvine, CA). Fluorescence images were examined and 
captured either using Nikon-Eclipse-Ti-U microscope with NIS-Element AR software 
(Nikon, Japan) or laser confocal microscope (Leica TCS SPII confocal laser scanning 
system; Leica Microsystem, GmbH, Germany) with LAS AF Lite software (Leica 
Microsystems, Mannheim, Germany). For stained specimens observed under the 
confocal microscope, fluorescence images were captured with sequential scanning to 
avoid fluorescence signal cross-talk; and line averaging (8 lines) was used to enhance 
the quality of the image.   
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2.4.9 Histological Staining 
2.4.9.1 Hematoxylin and Eosin Stain 
Hematoxylin and eosin (H&E) staining method was used in this study for 
morphological evaluation. Tissue sections of 8 µm from cryosectioning were mounted 
on to the glass slides and fixed with 70% ethanol. For monolayer culture cells in 
chamber slides, cells were fixed with 4% formaldehyde (System®, Italy). The slides 
were stained with hematoxylin and eosin stain in a fume hood. After ethanol or 
formaldehyde  fixation, the slides were stained with Mayer’s hematoxylin (Dako, 
Denmark) for 5 min, and immediately washed in running tap water for 5 min or less, 
and continued to differentiate in 1% acid alcohol for 5 s. The slides were then washed 
again in tap water for 5 min or less, followed by counterstaining in 1% eosin (Appendix 
H) for 10 min. Then, the slides were washed again in tap water for 5 min before 
dehydrated through ascending ethanol (85%, 90%, 100%), cleared in xylene and 
mounted in DPX mounting medium (Fluka, Germany).    
 
2.4.9.2 Van Gieson Trichrome Stain 
Van Gieson trichrome staining kit (Bio-Optica, Milano, Italy) was used in this 
study to stain the connective tissue. This staining kit consist of Weigert’s iron 
haematoxylin for nuclei, picric acid for cytoplasm and fuchsin for collagen. Similar to 
H&E staining, the slides were brought to distilled water after being fixed with ethanol. 
Then, five drops of reagent A and reagent B were put on the tissue section and 
incubated at room temperature for 10 min. Subsequently, the tissue section was blue in 
running tap water for 10 min, followed by adding 10 drops of reagent C on to the tissue 
section. The reagent C was left to react on the tissue section for 10 min. Then, the tissue 
sections were washed rapidly (3 second) in distilled water and dehydrated through 
ascending ethanols. The tissue sections were stopped for one minute in the final 
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absolute ethanol. The stained slides were then cleared in xylene and mounted with DPX 
mounting medium (Fluka, Germany). The collagen fibers appeared purplish red, while 
the nuclei appeared black, cytoplasm, smooth and striated muscle and erythrocytes 
appeared yellow. 
 
2.4.9.3 Von Kossa Stain 
Von Kossa special stain kit, method for calcium (Bio-Optica, Milano, Italy) was 
used to demonstrate calcium depositions in cell culture. Similar to H&E staining, the 
slides were brought to distilled water after being fixed with ethanol or formaldehyde. 
Then, 10 drops of reagent A were put on the tissue section and left to react at room 
temperature for 10 min. After that, the slides were rinsed well in distilled water before 
10 drops of reagent B were put to the slides and left to react in dark for one hour. After 
that, the slides were rinsed well again in distilled water, followed by adding 5 drops of 
distilled water and 10 drops of reagent C, and left to react for 5 min (or until the silver 
salt turned black). Then, the slides were rinsed again in distilled water. Subsequently, 10 
drops of reagent D were added to the slides and left to react for 5 min before rinsed in 
distilled water, followed by addition of 10 drops of reagent E to react for another 5 min. 
Lastly, the slides were rinsed again with distilled water, dehydrated through ascending 
ethanol, cleared in xylene and mounted with DPX mounting medium (Fluka, Germany). 
The deposited calcium appeared black and nuclei appeared red. 
 
2.4.9.4 Oil-red-O Stain 
Cells cultured in monolayer on the slides were fixed with 10% buffered formalin 
for 10 min. After fixation, the slides were gently rinsed with distilled water. Then, 2 ml 
of 60% isopropanol was added to the slides and incubated at room temperature for 5 
min. After that, the isopropanol was replaced with 2 ml of oil-red-O working solution 
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(Appendix H) and incubated for another 5 min at room temperature. Then, the oil-red-O 
solution was removed and the slides were rinsed with room temperature tap water until 
the water rinsed off was clear. Finally, 2 ml of tap water was added to each slides and 
the stained slides were viewed on a phase contrast microscope. The lipids appeared red 
and the nuclei are blue.   
 
2.4.9.5 Safranin O Stain 
Safranin O staining reagents/solutions were prepared as stated in Appendix H. 
Cells cultured in monolayer on the slides were fixed with 10% buffered formalin for 10 
min and gently rinsed with distilled water. The slides were stained with modified 
Weigert’s iron hematoxylin for 5 min followed by gentle wash in distilled water until 
the excess dye stop leaching out from the stained sample. Then, the slides were 
differentiated in 1% acid-alcohol for 2 s followed by three gentle rinses in distilled 
water. Subsequently, the slides were stained for 1 min in 0.02% fast green, 30 s in 1% 
acetic acid and 10 min in 1% safranin O. Then, the slides were rinsed briefly in 95% 
ethanol, dehydrated in ascending ethanol (95% 100% and 100%), cleared in 3 changes 
of xylene and lastly mounted with DPX mounting medium (Fluka, Germany). The 
proteoglycan appeared orange to red while the nuclei stained black and cytoplasm 
stained bluish green.  
 
2.4.10 Atomic Force Microscopy Live Cell Imaging 
2.4.10.1 Sample Preparation 
Cells were seeded onto glass cover slip. To increase the stability of cell 
membrane and to prevent the lateral mobility of receptors, cells were incubated with 
mild concentration of glutaraldehyde (0.5% v/v) for 2 h at 37
o
C prior to imaging. The 
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cover slip was attached to a closed cell incubation sample plate (Figure 2.5) for imaging 
in a fluidic environment. 
 
 
Figure 2.5   Closed cell incubation sample plate for atomic force microscopy imaging. 
The closed cell incubation sample plate was used to incubate the cells 
during the entire imaging process. 
 
 
2.4.10.2   Image Acquisition 
Atomic force microscopy imaging was conducted with an atomic force scanner 
(AFM5500, Agilent Technologies, Germany) mounted in an acoustic chamber 
(vibration free environment) to reduce the noise or turbulence from the surrounding 
environment. Cantilever used were sharpened microlever (Bruker, Italy) with silicon 
nitride probe (spring constant 0.0005 to 0.02; nominal value=0.01) for soft sample such 
as cells. Atomic force images were acquired in AC mode for liquid imaging with 
harmonic frequency (tip resonance frequency) at ~3-5 V amplitude. All images were 
taken in cell culture medium at 37 
o
C, with low scanning speed at ~0.3 Hz (or <0.5) and 
with at least 512X512 points/line resolution. Each sample was scanned for at least three 
times, and the best representative image was shown. During the entire experiment 
process, the cells were tightly adhered to the substrate (cover slip). 
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2.5 METHODS DEVELOPME$T 
2.5.1 Isolation and Culturing of Primary Mesenchymal Stem Cells 
2.5.1.1 Human Bone Marrow-Derived MSC (hMSC) Primary Culture 
Human MSCs (hMSC) were isolated from bone marrow samples and expanded 
in vitro following methods that had been previously established (Tan et al., 2011). 
Briefly, a volume of 2 mL of bone marrow was diluted with 2 mL of phosphate buffered 
saline (PBS, pH 7.2) and layered onto 3 mL of Ficoll-Paque Premium (GE Healthcare, 
Sweden) before undergoing gradient centrifugation at 2200 rpm for 30 mins (Eppendorf 
5810R). 
The mononuclear layer (second from top layer) was then collected and washed 
twice with Dulbecco’s modified Eagle’s medium-low glucose (DMEM-LG; Invitrogen-
Gibco, USA) supplemented with antibiotic/antimycotic 1% (v/v) (Invitrogen-Gibco, 
USA). The isolated mononuclear cells were cultured in growth medium (DMEM-LG 
supplemented with 10% fetal bovine serum (FBS), antibiotic/antimycotic 1% (v/v) and 
GlutaMAX™-I (Invitrogen-Gibco, USA), and transferred into T75 tissue culture flasks 
(Nunc
TM
, USA). The medium was changed at day five to remove non-adherent cells, 
and the subsequent medium change was conducted at three-day intervals. 
 
2.5.1.2 Rabbit Bone Marrow-Derived MSC (rbMSC) Primary Culture 
 Rabbit bone marrow was harvested from New Zealand white rabbits with the 
protocol approved by the Animal Care and Use Committee, Faculty of Medicine, 
University of Malaya. Three adult New Zealand white rabbits (at least 4 months old) 
were euthanized by an overdose of pentobarbital sodium (Nebutal
 ®
 Sodium Solution) 
(Boehringer, Ingelheim, Germany). Rabbit bone marrow was isolated from the tibia and 
femur and resuspended in 2 mL of phosphate buffered saline (PBS, pH 7.2; Invitrogen-
Gibco, USA). The bone marrow suspension was layered on 3 mL Ficoll-Paque™ 
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Premium (density: 1.077 g/mL; GE Healthcare, Sweden) for gradient centrifugation at 
2200 rpm for 30 min in a 15 mL centrifuge tube. The same protocols used in hMSCs 
isolation (Section 2.5.1.1) were applied in the subsequent isolation steps. 
 
2.5.2 Determination and Comparison of hMSC and rbMSC Characteristics 
2.5.2.1 Cell Morphology and Size 
The isolated hMSC and rbMSC were observed under phase contrast microscope 
and the morphological appearances between these two cell types were compared. Both 
cell types appeared to have heterogeneous fibroblastic appearance and formed distinct 
colonies on flask surfaces (Figure 2.6). The cells demonstrated increased proliferation, 
gradually and uniformly maintaining a homogeneous fibroblastic morphology. Both 
hMSCs and rbMSCs were mainly of spindle-shaped appearance and elongated 
morphology with two processes that extended in opposite directions from a small cell 
body. In the subsequent passages i.e. P1 to P3, cultures with low proliferative 
(prolonged passage time), large polygonal and flattened cells with short or no processes 
(Figure 2.6 H and K) were discarded. These cells were discarded because these cellular 
morphology has been reported as (i) senescent MSC (Cheng et al., 2003; Fu et al., 2012; 
Schellenberg et al., 2011), and (ii) associated with low proliferative rate and were less 
potential or characterized as “mature” (Colter et al., 2000; Colter et al., 2001; Neuhuber 
et al., 2008; Sekiya et al., 2002) and (iii) associated with different stages of cell 
differentiation rather than the existence of distinct cell types or subtypes (Docheva et 
al., 2008; Sekiya, et al., 2002; Smith et al., 2004). This further alludes to the importance 
of culturing the subset of hMSCs or rbMSCs that is more homogeneous, proliferative 
and exhibit fibroblastic spindle-shaped for the downstream applications. Although 
similar in their morphological appearance, the rbMSCs cell length (202.66 ±8.40 µm) 
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and width (13.09±0.91 µm) were significantly longer and wider than hMSCs 
(152.04±43.35 µm in length; 9.82±0.66 µm in width) (p<0.01; Figure 2.6 M & 1N). 
 
Figure 2.6  Morphology of primary culture of human and rabbit bone-marrow derived 
mesenchymal stem cells (hMSC and rbMSC respectively). 
Representative images from three independently performed experiments 
were shown (A to L); images were captured under phase contrast 
microscope at 4x objective (images of 40 x objectives were shown on the 
left upper corner of each image). Cell lengths and widths of eight 
representative cells from each individual experiment (n=3) were measured 
and data are presented as mean ± standard error of the mean (M and N). 
Cells were in fibroblast-like spindle-shaped at day 4, 7, 10 and 24 in rbMSC 
cultures (A, B, C and G respectively) and in hMSCs cultures (D, E, F and J 
respectively). Some non-fibroblastic flat cells were observed in rbMSC (H) 
cultures and hMSC cultures (K) upon subculturing (P1 onwards). Majority 
of the cells remained fibroblastic spindle shaped in rbMSCs (I) and hMSCs 
(L) upon subculturing from P1 to P3. The rbMSCs possessed significantly 
higher cell length (M) and cell width (N) compared to hMSC (p<0.05). 
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2.5.2.2 Ultrastructural Characteristics 
Both hMSCs and rbMSCs were harvested and processed for transmission 
electron microscopy imaging (Figure 2.7).  
 
Figure 2.7 Transmission electron microscopy analysis of the ultrastructure of rbMSCs 
and hMSCs.   
Representative images of rbMSCs and hMSCs ultrastructure were shown. 
Both rbMSCs and hMSCs showed similar ultrastructure features. An 
eccentric and irregular-shaped nucleus (N), usually with multiple nucleoli 
(n), with various mitochondrial profiles (m); and small vacuoles (v) in 
rbMSCs (A and B) and hMSC (D and E). Chromatin formed a thin and 
dense layer inside the perinuclear cisternae (c) and the plasma membrane 
formed many thin pseudopodia (p). Mitochondrial showed both rounded and 
elongated profile with thick cristae in both rbMSCs (C) and hMSCs (F).  
 
The rbMSCs displayed phenotypic appearances that were indistinguishable to 
hMSCs (Figure 2.7). They were relatively uniform in their ultrastructural 
characteristics. Generally, both hMSCs and rbMSCs possessed a large, eccentric, 
irregular-shaped nucleus and a rich inner cytoplasmic zone (Figure 2.7 A, B, D and E). 
The nucleus showed multiple nucleoli and the chromatin formed a thin and dense layer 
inside the perinuclear cisternae. The periphery of the plasma membrane displayed many 
small pseudopodia in both hMSCs and rbMSCs (Figure 2.7 A and D). In addition, 
within the rich cytoplasm region (Figure 2.7 A and B), a small amount of Golgi rough 
endoplasmic reticulum as well as a modest number of mitochondrial with different 
profiles (rounded and elongated profile with thick cristae) were present. There was 
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neither fat globule in the cells nor ultrastuctural disruption, denoting that no cell was at 
the senescence stage of development. 
 
2.5.2.3 Surface Markers Expression 
A. rbMSC Surface Markers Expression 
Due to the limited availability of mAb for rbMSC characterization, initially, 
rbMSC could only be analysed for CD44 (with immunofluorescence staining) as well as 
CD29, CD166, CD34 and CD45 (with RT-PCR analysis using our custom designed 
primers based on the available sequences obtained from other species). 
Immunofluorescence staining to detect CD44 surface markers was positive for rbMSCs 
(Figure 2.8 A). RT-PCR analysis demonstrated a positive expression for CD29 and 
CD166 in rbMSCs (Figure 2.8 B), but was negative for other surface markers (CD45 
and CD34) (Figure 2.8 B). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was 
used as the house-keeping gene.  
                                                             
Figure 2.8   Surface marker analysis for rbMSCs.  
(A) Immunofluorescence staining image for positive expression of CD44 
(in red, anti-mouse IgG allophycocyanin conjugated Goat F (ab’)2) 
counterstained with nucleus stain (in blue) in both rbMSC and hMSC.  
(B) RT-PCR analysis for CD166 (lane 1), CD29 (lane 2), CD45 (lane 4), 
CD34 (lane 5) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH, in lane 3). Lane L indicates the DNA ladder. Presence of 
amplicon in lane 1, 2 and 3 indicated positive expression of the 
corresponding genes and absence of amplicon in lane 4 and 5 denoted 
that these genes were not expressed. 
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B. Flow Cytometry Immunophenotyping of hMSC and rbMSC  
With the increase availability of the mAb for rbMSC, flow cytometry analysis 
was conducted for immunophenotyping of rbMSC for a better comparison with that of 
hMSCs. The cultured hMSC donor cells fulfilled all MSC criteria set by ISCT (Table 
2.8; Appendix I1), including CD105, CD14 and CD19 (only tested in hMSCs due to 
mAb availability; Appendix I2). The cultured rbMSCs expressed multiple markers of 
MSCs. The cultured rbMSCs revealed positive for CD29, CD44, CD73, CD81 and 
CD90, but was negative (or dim positive) for CD34, CD45, CD117 and HLA-DR 
(Table 2.8 A; Appendix I1). In the multi-colour analysis, at least 70% of rbMSCs 
expressed double positive, double negative or co-expressed positive and negative 
markers as compared to 90% of that in hMSCs. The results of these analyses are 
summarized in Table 2.8 B.  
 
Table 2.8  Summary of flow cytometry analysis for (A) single marker and (B) co-
expression of two markers.  
 
(A) 
Cell 
type 
CD29+ 
(%) 
CD44+ 
(%) 
CD73+*  
(%) 
CD81+ 
(%) 
CD90+* 
(%) 
CD34-*  
(%) 
CD45-* 
(%) 
CD117+ 
(%) 
HLA-
DR-* 
(%) 
rbMSC 85.0 81.6 96.4 96.9 96.9 7.1 18.0 17.4 4.3 
hMSC 100.0 99.6 98.6 99.9 100.0 0.2 0.1 1.4 0.2 
 
 
(B)  
Antigens rbMSC (%) hMSC (%) 
CD29
+
 and CD34
-
*
 
78.4 99.8 
CD44
+
 and CD73
+
* 70.9 93.7 
CD44
+
 and CD34
-
* 82.1 98.4 
CD90
+
* and CD73
+
* 70.1 96.4 
CD90
+
* and CD81
+
 89.8 100.0 
CD90
+
* and CD34
-
* 89.8 97.3 
CD90
+
* and CD45
-
* 81.6 92.0 
CD90
+
* and CD117
-
 79.6 99.0 
CD73
+
* and CD81
+
 75.0 99.5 
CD73
+
* and *CD34
-
* 83.2 97.7 
CD73
+
* and *CD117
-
 71.2 98.6 
CD81
+
 and CD34
-
* 91.8 98.0 
  
80 
 
   
   
CD81
+
 and CD117
-
 76.9 98.6 
CD81
+
 and HLA-DR
-
* 76.3 99.4 
CD34
-
* and CD45
-
* 76.2 91.0 
CD34
-
* and CD117
-
 77.3 97.0 
CD45
-
* and HLA-DR
-
* 72.0 97.7 
*CD markers that are prerequisite by ISCT criteria. 
 
 
2.5.2.4 Cell Proliferation 
 AlamarBlue® assay was used to determine the cell proliferation rate of hMSC 
and rbMSC. Both hMSC and rbMSC showed typical “S shaped curve” as seen in many 
cell cultures (Figure 2.9). No significant differences were observed in the alamarBlue® 
reduction in both hMSCs and rbMSCs during the “lag phase” of cell proliferation. As 
the cells enter into their exponential “log phase”, although rbMSCs showed a lower cell 
proliferation than hMSCs, both rbMSCs and hMSCs reached a plateau phase at 72 h. 
The population doubling time of rbMSCs and hMSCs were 6.4±1.3 and 7.6±1.7 hours 
respectively. However, there were no significant differences between the two (p>0.05). 
 
Figure 2.9   AlamarBlue® cell proliferation assay of hMSC and rbMSC cultures.  
No significant difference in cell proliferation rates at the lag phase and 
plateau phase between hMSC and rbMSC. 
 
 
 
 
Table 2.8 continued 
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2.5.2.5 Trilineage Differentiation Analysis 
Trilineage differentiation assay was conducted in both hMSC and rbMSC to 
determine their multilineage differentiation (osteogenic, adipogenic and chondrogenic 
differentiation) capability. The differentiation potential was determined with 
histological staining and gene expression quantification analysis. 
 
A.  Histological Staining 
In the osteogenic differentiation assay, the presence of calcium oxalates was 
clearly observed from the Von Kossa staining on the differentiated rbMSCs, which was 
not present in the undifferentiated cells (Figure 2.10 A). Adipogenesis of rbMSCs was 
detected by staining intracellular lipid droplets using oil-red-O (Figure 2.10 B) in the 
adipogenic-induced rbMSCs cultures. The use of safranin-O aided the detection of 
proteoglycan deposition in chondrogenic-induced rbMSCs, however, this was negative 
in the control group (Figure 2.10 C). These observations suggest that rbMSCs have the 
potential to undergo the tri-lineage i.e. osteogenic, chondrogenic and adipogenic, 
differentiation required to fulfil the characteristics of MSCs.  
As compared to cultured hMSCs, hMSCs demonstrated a greater propensity to 
differentiate into the osteogenic and adipogenic lineages than rbMSCs based on the 
qualitative (histological staining) results where more prominent deposition of calcium 
oxalate crystals and more mature adipocytes (more lipid vacuoles present) were 
observed in induced hMSCs compared to that of rbMSCs under the same culture 
conditions. 
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Figure 2.10 Tri-lineage differentiations of primary hMSCs and rbMSCs.  
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Figure 2.10 continued 
 
(A) Osteogenic differentiation of rbMSC and hMSC (as positive control) for 
28 days. rbMSC and hMSC were cultured in standard MSC growth 
medium (control cultures) or osteogenic induction medium. Lower 
images: Intracellular deposition of calcium oxalate crystals (black 
colour signifies) in osteogenic-rbMSCs as revealed by Von Kossa 
staining (right). No accumulation of calcium oxalate crystals was 
observed in uninduced control rbMSC culture stained with Von Kossa 
staining for comparison (left). Upper images: Positive control of 
adipogenic differentiation in hMSCs (right) and non-induced control 
hMSC (left) stained with oil-red-O staining. Magnifications were 
denoted at the upper left corner of the images.  
(B) Adipogenic differentiation assay of rbMSC and hMSC (as positive 
control) for 28 days. rbMSC and hMSC were cultured in standard MSC 
growth medium (control cultures) or adipogenic induction medium. 
Lower images: Presence of intracellular accumulated lipid droplets (red 
colour in the image) in adipogenic-rbMSCs as revealed by oil-red-O 
staining (right). No accumulation of lipid droplets was observed in non-
induced control rbMSC culture stained with oil-red-O staining for 
comparison (left). Upper images: Positive control of adipogenic 
differentiation in hMSCs (right) and uninduced control hMSC (left) 
stained with oil-red-O staining. Magnifications were denoted at the 
upper left corner of the images. 
(C) Chondrogenic differentiation assay of rbMSC and hMSC (as positive 
control) for 28 days. rbMSC and hMSC were cultured in standard MSC 
growth medium (control cultures) or chondrogenic induction medium. 
Lower images: Presence of glycosaminoglycans or highly sulfated 
proteoglycans (pinkish colour in the image) in chondrogenic-rbMSCs 
as revealed by safranin-O staining (right). No accumulation of 
glycosaminoglycans was observed in non-induced rbMSC culture 
stained with safranin-O for comparison (left). Upper images: Positive 
control of chondrogenic differentiation in hMSCs (right) and non-
induced control hMSC (left) stained with safranin-O. Magnifications 
were denoted at the upper left corner of the images. 
 
B.  Gene Expression Quantification Analysis 
rbMSCs expressed significantly higher Runx2 (osteogenic marker) and Sox9 
(chondrogenic marker) expression on both day 7 and day 28 as compared to that of 
hMSC (p<0.05) (Figure 2.11).  In adipogenic medium, both rbMSCs and hMSCs 
showed similarly elevated PPARγ (adipogenic marker) gene expression levels on day 28 
(p>0.05). An overall summary of comparison between hMSC and rbMSC chrateristics 
is showed in Table 2.9. 
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Figure 2.11 Gene expression analyses of the cultured hMSCs and rbMSCs in the temporal 
experiment of tri-lineage differentiation assay. 
The gene expression level for osteogenic (A), adipogenic (B) and 
chondrogenic (C) differentiation, at day 7 and day 28 were shown. The 
data reflected that the relative quantification of target mRNA normalized 
to control samples (untreated MSCs cultured in MSC growth medium). 
Data was presented as log2-fold change (with error bars signifying range of 
standard deviation). All the differentiation markers (Runx2, Pparγ and 
Sox9) were upregulated on day 28. However, spontaneous differentiation 
into osteogenic and chondrogenic lineages were observed in the rbMSCs 
with significant early up-regulation of the respective differentiation 
markers (Runx2 and Sox9) at day 7. 
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Table 2.9 A summary of rbMSCs and hMSCs characteristics. 
 
Characteristics rbMSC hMSC 
Plastic 
adherence 
Yes  
 
Yes 
Morphology  Fibroblastic spindle shaped with two processes that extended in 
opposite directions from the cell body and grow in high density 
colonies. 
Ultrastructural 
characteristic 
Cells possess a large eccentric and irregular-shaped nucleus with a 
prominent nucleolus. Chromatin formed a thin and dense layer inside 
the perinuclear cisternae. The rich inner cytoplasmic zone consists of 
a small amount of Golgi rough endoplasmic reticulum, mitochondria 
and polyribosome. The periphery of the plasma membrane displayed 
many small pseudopodia. 
Cell size (µm) 
      
Length: 202.66 ±8.4 
Width: 13.09±0.91 
Length: 152.04±43.35 
Width: 9.82±0.66 
 
Proliferation 
rate 
 
Population doubling: 6.4±1.3 h 
 
Population doubling: 7.6±1.7 h 
 
Phenotypic 
expression 
 
Highly expressed: 
CD29, CD44, CD73, CD81 and 
CD90. 
Low expression: 
CD117, CD45 
Negative expression: 
CD34 and HLA-DR 
 
Highly expressed: 
CD29, CD44, CD73, CD81 
and CD90. 
 
 
Negative expression: 
CD34, CD45, CD117 and 
HLA-DR 
Differentiation 
potential 
(histological 
observation) 
 
i. Osteogenic differentiation (Von Kossa staining): presence of 
intracellular deposition of calcium oxalate crystals. 
ii. Adipogenic differentiation (oil-red-O staining): presence of 
intracellular lipid droplets. 
iii. Chondrogenic differentiation (safranin-O staining): presence of 
apparent glycosaminoglycans or highly sulphated proteoglycans. 
Differentiation 
potential (gene 
expression): 
 
i. Upregulation of osteogenic 
marker (Runx2) at day 7 and 28, 
upon osteogenic differentiation 
induction. Higher Runx2 
expression was observed in 
rbMSCs compared to hMSCs. 
ii. Upregulation of adipogenic 
marker (Pparγ) at day 28, upon 
adipogenic differentiation 
induction. No significant 
difference in Pparγ expression 
between rbMSCs and hMSCs. 
iii. Upregulation of chondrogenic 
marker (Sox9) at day 7 and 28, 
upon chondrogenic 
differentiation induction. Higher 
Sox9 expression was observed 
in rbMSC compared to hMSCs. 
i. Upregulation of RUX2 at 
day 28, upon osteogenic 
differentiation induction. 
 
 
 
ii. Upregulation of PPARγ at 
day 28, upon adipogenic 
differentiation induction. 
 
 
 
iii. Upregulation of SOX9 at 
day 7 and 28, upon 
chondrogenic 
differentiation induction.  
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2.5.3 In vivo Transplantation  
2.5.3.1 Surgical Procedure For Tendon Defect Creation and Transplantation 
In brief, the surgical defect creation was conducted as follows: The surgical area 
was disinfected with povidon iodine topical solution 10% w/v (Unidon Solution, India) 
and 3 ml of 20 mg/ml lignocaine hydrochloride (Ilium, Australia) was injected 
subcutaneously for local anesthetic effect. A 3 cm incision was made on the shoulder 
and the infraspinatus tendon was exposed. The infraspinatus tendons were inspected to 
ensure there were no pre-existing gross lesion in the tendon or peritendinous tissues. An 
identical, full-thickness, window defect was dissected via ventral longitudinal incision 
in the central part of each infraspinatus tendon bilaterally. The proximal and distal ends 
of the window defect were marked with coloured (black or blue) Premilene® 3-0 non-
absorbable polypropylene monofilament sutures (B. Braun, Germany) to help identify 
the wound site at the time of sacrifice and dissection (Figure 2.12). A silicone sheet was 
used to maintain the defect. After three weeks, the silicon sheet was removed and the 
defects were repaired. Incision closure was completed with simple suture pattern with a 
Ethicon 4-0 coated Vicryl undyed braided absorbable suture (Johnson & Johnson 
International, Brussels, Belgium). 
Postoperative medication included Meloxicam injection (5 mg/ml; 0.3 mg per kg 
body weight; Meloxicash, India) and Kombitrim 240 (sulfamethoxazole 200 mg/ml + 
trimethoprim 40 mg/ml; 30 mg per kg body weight; Kela, Belgium) injection for three 
consecutive days in 24 h interval to minimize discomfort in the postoperative period. 
The activity of the animals was not restricted. The animals were fed an ordinary diet. 
Mobilization and walking pattern were noted daily.  After 6 weeks postoperatively, the 
rabbits were euthanized by an over dose of pentobarbital sodium (Nebutal
 ®
 Sodium 
Solution; Eutha-naze (TM), Kenya.) and the infraspinatus tendons of both shoulders 
were harvested for histology analysis. The specimens consisted of the entire 
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infraspinatus tendon beginning 1 cm proximal and ending 1 cm distal to the original 
defect. The defect in the infraspinatus tendon was identified by removing the 
peritendinous fibrous tissue and locating the marker sutures. All the specimens were 
snapped frozen and stored in -80 
o
C, before used for OCT embedding. All the tissues 
were sectioned in the frontal longitudinal sections (8 µm-thick), including scar tissue if 
present, in the no repair control or repaired defects. For gene expression analysis, 15 
ten-micron-cryo sections were collected in a 1.5 ml-Eppendorf® tube. Specimens were 
stored at -80
o
C before further processing for total RNA isolation.     
 
 
Figure 2.12  Defect creation and repair in rabbit infraspinatus tendon model.  
(A) A square, full thickness defect was surgically created by removing 
the central one-third of the infraspinatus tendon. The proximal and 
distal ends of the defect area were marked by polypropylene 
monofilament suture at each midpoint (arrow).  
(B) The defect was maintained by a silicone sheet (arrow).  
(C) At three weeks post defect creation, the silicone sheet was removed 
and a window defect was developed (arrow) in the middle of the 
infraspinatus tendon.  
(D) At time of recovery at six weeks post-surgical repair, the tendon 
defect was identify by locating the suture markers (arrow) inserted 
(during transplantation) at both ends of defect.  
(E) The summary of the workflow from defect creation to recovery of 
tendon specimens at 6 weeks post-surgical repair. 
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2.5.3.2 Histological Scoring 
Microscopically, the tendon defect area was identified by locating the marker 
suture (Figure 2.13). All the stained sections were scanned and analysed using 
Panoramic Viewer 1.14 (3DHistech, Hungary). Histological evaluations were 
performed with H&E and Van Gieson stained slides.  
The quality of tendon repair (as observed in H&E and VG stained sections) were 
scored based on Watkins (1985) and Soslowsky (1996) histological scores. These scores 
evaluated the cellularity, vascularity and collagen density in all treatment groups 
compared to the control group, at 6 weeks post-surgical repair. The parameters used for 
histological scoring were as stated in Table 2.10 and Table 2.11 (Soslowsky et al., 1996; 
Watkins et al., 1985). All data were expressed as mean±standard deviation and 
compared by non-parametric tests due to the small sample size used in this study. The 
Kruskal-Wallis test which is equivalent to the analysis of variance (ANOVA) analysis 
and Mann-Whitney U test which is equivalent to the Student’s t-test were conducted 
using SPSS software (SPSS). All p-values less than 0.05 were considered significant.  
 
Figure 2.13 The suture markers were used to locate the defect at the time of histological 
analysis.  
A suture marker inserted at both ends of the defect area (black arrows) 
during transplantation surgery, was used to identify the defect area in the 
hematoxylin and eosin stained tendon tissue sections (in frontal planed).  
(A)  The gross appearance of the infraspinatus tendon;  
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Figure 2.13, continued 
 
(B)  An overview of the infraspinatus tendon frontal section stained with 
haemaoxylin and eosin (Bar=2mm);  
(C)  The defect area observed at higher magnification to show the suture 
site (black arrows) at both ends of the defect. These sutures were used 
as the landmark to locate or to identify the defect site in the histology 
sections. (Bar=500µm). 
 
Table 2.10 Watkins score for histological evaluation of tendon repair (Watkins, et 
al., 1985). 
 
 
Category 
Histology 
characteristics 
Score 
+ (Immature) 
=1 
++  
=2 
+++ (Mature)  
= 3 
A Cellularity Marked Moderate Minimal 
B Proportion of cells 
resembling tenocytes 
<1/3 1/3-2/3 >2/3 
C Proportion of cells 
oriented parallel to 
longitudinal axis 
<1/3 1/3-2/3 >2/3 
D Vascularity Marked Moderate Minimal 
E Proportion of fibers of 
large diameter 
characteristics of 
mature tendon fibers 
<1/3 1/3-2/3 >2/3 
F Proportion of fibers 
oriented parallel to the 
longitudinal axis 
<1/3 1/3-2/3 >2/3 
G Wave formation Minimal Moderate  Marked 
 
 
Table 2.11 Soslowsky score for histological evaluation of tendon repair (Soslowsky, 
et al., 1996). 
 
 Category Histology 
Characteristic 
 
Score 
 
0 1 2 3 
A Collagen grade Normal 
collagen 
orientated 
tangentially. 
Mild changes 
with collagen 
fibers, < 25% 
disorganized. 
 
Moderate 
changes in 
collagen, 
> 50% 
disorganized. 
Marked 
changes in 
collagen, 
>50% 
disorganized. 
B Degree of 
angiogenesis 
Normal 
tendon tissue. 
Increase 
presence of 
capillaries. 
Moderate 
infiltration of 
tissue with 
vessels. 
 
 
C Cartilage 
formation 
No cartilage 
formation. 
Isolated hyaline 
cartilage 
nodules. 
Moderate 
cartilage 
formation of 
25% to 50%. 
Extensive 
cartilage 
formation, 
> 50% of the 
field 
involved. 
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CHAPTER 3 
RESULTS 1: EFFECT OF GDF5 O THE TEOGEIC DIFFERETIATIO 
POTETIAL OF HUMA AD RABBIT BOE MARROW-DERIVED 
MESECHYMAL STEM CELLS I VITRO 
 
 
 
 
 
 
Part of this chapter has been published in: 
Tan S.L., Ahmad R.E., Ahmad T.S., Merican A.M., Abbas A.A., Ng W.M., Kamarul T. 
(2012) Effect of growth differentiation factor 5 on the proliferation and tenogenic 
differentiation potential of human mesenchymal stem cells in vitro. Cells Tissues 
Organs 196: 325-338. 
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3.0 Results 1: Effect of GDF5 on the tenogenic differentiation potential of 
human and rabbit bone marrow-derived mesenchymal stem cells in vitro 
3.1 Introduction 
GDF5 is a pivotal factor in tendon neoformation, and this has been demonstrated 
in many previous studies as summarized in Table 1.7, both in in vitro or in vivo 
experiments. In the early development, the tendon progenitor (TP) marker Scx 
expression is dependent on the combined conditions of the expression pattern of 
transcription effectors and the distance that a particular source of growth factor is able 
to travel (Brent et al., 2005; Brent et al., 2003). An important scenario is that when the 
signal molecule diffuses out from a localized signaling center, and it concurrently 
creates a signal concentration gradient. Cells at different distances from the source are 
driven to behave in a variety of different ways; according to the signal concentration 
that they experience (Alberts et al., 1994). In the light of GDF5 is expressed in regions 
of future joints during the early stages of embryological development (Storm & 
Kingsley, 1999), GDF5 has been shown to be an important factor during early tendon 
healing (Chhabra et al., 2003). It is hypothesized that GDF5 has a tenogenic 
differentiation induction effect in TP cells, either in the early tendon development or in 
tendon healing process.   
Similar to other TGF-β superfamily members, GDF5 binds to the BMPR2 which 
in turn binds to intracellular Type I receptor (ALK2) (Nickel et al., 2005) and transmits 
its signal through the Smad/BMP signaling cascade. The binding of GDF5 to its 
receptor, forms an activated receptor complex. Smad8 is then phosphorylated by this 
activated receptor, which subsequently bind to Smad4. This is then followed by the 
translocation of the Smad8/Smad4 complex into the nucleus, which results in the 
regulation of selected transcription of targeted genes, which includes but not exclusively 
Scx (Bullough et al., 2008). Scx is a transcription factor, which will activate Col-I gene 
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expression in tenocytes thereby regulating this gene (Lejard et al., 2007). It has been 
speculated that the process of transcribing this gene will translate into increased COL- I 
production which is the most abundant protein in the tendon. Besides, other tendon 
candidate markers expression (i.e. tenascin C, decorin and tenomodulin) are also 
speculated to increase alongside with the COL-I expression. 
Previous studies in tenogenic effect of GDF5 has only demonstrated for 
immortalized cell lines (Farng et al., 2008) and rodent adipose tissue- derived MSCs 
(Park et al., 2010). To date, there are limited studies investigating the isolated effect of 
GDF5 on MSC proliferation and tenogenic differentiation in vitro. The effect of GDF5 
on harvested non-immortalized bone marrow-derived hMSCs, which represents the 
most commonly obtained source of MSCs (Hass et al., 2011), has not been previously 
described. A critical issue which has not been specifically addressed by previous studies 
is the establishment of the optimal concentration of GDF5 that can induce maximal 
phenotypic expression of the tenogenic hMSC in vitro. Therefore, this current study was 
conducted to determine the effect of GDF5 on the proliferation and tenogenic 
differentiation potential of hMSC in vitro. To explore this, a gradient concentration of 
GDF5 (0, 5, 25, 50, 100 and 500 ng/mL) was tested on the hMSCs considering that 
progenitor cells can differentiate into various types of mature cells, e.g., osteocytes, 
chondrocytes and tenocytes, in response to the amount of signal molecules received.  
In view of possible animal transplantation models being used in the later in vivo 
tendon repair experiments (Chapter Four), the effect of GDF5 in bone marrow derived 
rabbit MSCs (rbMSCs) from New Zealand white rabbit was also examined. This is of 
particular importance considering that an optimal concentration must be attained in 
order to induce the rbMSCs into the desired tenogenic lineage. This in turn may allow 
the in vivo tendon repair to be studied when those cells were transplanted into the rabbit 
tendon defect area. Thus, gradient concentrations of GDF5 were also tested in rbMSCs. 
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3.2 Experimental Design 
3.2.1 Cell Proliferation Experiment 
hMSC Primary cultures (at P2, n=3) were seeded in the standard 96-well culture 
plates at cell density of 10
4
 cells/mL and resuspended in 250 µl of culture medium. 
GDF5 at various concentration levels (either 0, 5, 25, 50, 100 or 500 ng/mL) were 
added to the cultures three days after seeding. Recombinant human GDF5 (Table 2.2) 
was used for hMSCs. Cells were incubated for an additional period of two days before 
alamarBlue® assay was commenced. Schematic diagram of experimental design for cell 
proliferation assay is showed in Figure 3.1. 
 
Figure 3.1  Experimental design for alamarBlue® cell proliferation assay for dose and 
time response experiments in human in vitro studies. 
 
 
3.2.2 Total Soluble Collagen Assay 
The MSC primary cultures (at P2, n=3) were seeded in standard 6-well culture 
plates at a density of 2 x 10
4
 cells per well, and supplemented with recombinant GDF5 
at various concentration levels (0, 5, 25, 50, 100 or 500 ng/mL). The tenocyte primary 
cultures (n=3) were seeded in similar density to that of MSCs and were used for 
comparison. These cells were not supplemented with GDF5. For dose-response analysis 
(in both hMSC and rbMSC), cell were observed under phase contrast microscope and 
total collagen expressions were measure at 96 h. The phase contrast micrographs were 
captured for hMSC and rbMSC cultures with or without GDF5 supplement. Based on 
the results obtained from dose-response experiment, only three concentrations, i.e. 0, 50 
and 100 ng/mL of GDF5, were selected for further analysis which determines the 
collagen and gene expression levels at different time points (day 4, 7 and 10). For time 
response experiments, total collagen assays were conducted at day 4, 7 and 10 in hMSC 
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culture supplemented with 0, 50 and 100 ng/mL of GDF5. Schematic diagram of 
experimental design for total collagen assay is showed in Figure 3.2. 
 
 
Figure 3.2  Experimental designs for total collagen assays for dose and time response 
experiments in human and rabbit in vitro studies. 
 
3.2.3 Gene Expression Analysis 
To determine the effect to GDF5 in inducing tenogenic candidate markers gene 
expression, hMSCs were cultured in medium supplemented with GDF5 at 0, 50 and 100 
ng/mL. After 4 days, the cells were harvested for total RNA extraction and the degree of 
cell differentiation was determined by quantitative RT-PCR (qRT-PCR). This was 
achieved by measuring Scx, Tnc, Col-I, Col-III, Dcn and st gene expressions. In 
addition, hMSCs were cultured in DMEM supplemented with 100 ng/mL GDF5 for 7 
days to determine the tenogenic lineage commitment in hMSCs post- GDF5 treatment. 
Cells were harvested at day 4 and 7 to evaluate the gene expression level of Scx, Tnc, 
Runx2 and Sox9. Schematic diagram of experimental design for gene expression 
analysis in hMSC is showed in Figure 3.3. 
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Figure 3.3  Experimental designs for gene expression analysis for dose and time response      
experiments in human in vitro studies. 
 
 
In gene expression experiments conducted on rbMSC, only Scx and Col-I gene 
expression levels were determined for rbMSCs treated with or without GDF5. This was 
due to the limited molecular biology information in rabbit model at the time when this 
experiment was conducted. Thus, only these two genes were evaluated in rbMSCs 
treated with 0, 50 and 100 ng/mL of GDF5. As an extension to the gene expression 
analysis of these two genes, the time response analysis were conducted to determine the 
mRNA expression levels of these genes in rbMSC treated with 100 ng/mL of GDF5 at 
day 0, 4, 10 and 27. Schematic diagram of experimental design for gene expression 
analysis in rbMSC is showed in Figure 3.4. 
 
Figure 3.4   Experimental designs for gene expression analysis for dose and time response 
experiments in rabbit in vitro studies. 
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3.2.4  Immunofluorescence Staining 
 For immunofluorescence staining, hMSC (or rbMSC) as well as human (or 
rabbit) tenocyte were seeded on cover slips. The hMSC (or rbMSC) were cultured with 
and without 100 ng/mL of GDF5 for 4 days before proceeding to immunofluorescence 
staining. Immunofluorescence staining was conducted for candidate tenogenic markers, 
i.e. COL-I, SCX, TNC and TNMD. Human (or rabbit) tenocytes were used as positive 
control and hMSC (or rbMSC) treated with GDF5 but do not stain with primary 
antibodies were used as negative control.  
In view of a limited number of genes analyzed in rbMSC, immunofluorescence 
staining for type-I collagen (COL-I) in rbMSCs cultured at different concentrations of 
GDF5 (0, 5, 25, 50, 100 and 500 ng/mL), and type-II and III collagen (COL-II and 
COL-III) in rbMSCs treated with 100 ng/mL of GDF5 were also conducted. 
 
3.3 Results 
3.3.1 hMSC Proliferation Under GDF5 Treatment 
The results of alamarBlue® assay showed a pattern of an increase in cell 
proliferation rate at low concentrations of GDF5 (5 ng/mL) and, in contrast, the cell 
proliferation rate appeared to be reduced at a high GDF5 concentration (500 ng/mL). 
However, the differences in the hMSC proliferation between the cultures treated with or 
without GDF5 were not significant (Figure 3.5), suggesting that GDF5 did not alter the 
proliferation rate of the tenogenic- hMSCs.  
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Figure 3.5  AlamarBlue® cell proliferation assay of the hMSCs cultures supplemented 
with different concentrations of GDF5.  
There was no significant difference in cell proliferation rates as reflected by 
the percentage of alamarBlue® reduction by hMSC (at P2, n=3) 
supplemented with varying levels of GDF5.  
 
3.3.2 Morphological Appearance of hMSC and rbMSC Under GDF5 Treatment 
Images of hMSCs and rbMSC in culture with and without GDF5 supplementation 
were captured with a phase contrast microscope (Figure 3.6 and Figure 3.7). There were 
no significant differences in the gross morphological appearance between these cells, 
irrespective of the GDF5 concentration levels used. The rbMSCs cultured with higher 
concentrations of GDF5 showed more elongated appearance and more extensive 
network of branching in their colonies-forming than those with lower concentrations of 
GDF5.  
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Figure 3.6  Morphological appearance of hMSC (at day 4) in culture medium 
supplemented with various concentrations of GDF5, i.e. (a) 0, (b) 5, (c) 25, (d) 
50, (e)100, and (f) 500 ng/mL; and (g) human tenocytes.  
There were no significant differences in gross appearance in the hMSC 
cultures with or without GDF5 supplementation. At 100 ng/mL of GDF5, 
cells appeared to be having similar unidirectional proliferation and 
fibroblastic morphology to that of the human tenocyte culture.  
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Figure 3.7  Morphological appearances of rbMSCs (at day 4) in culture medium 
supplemented with GDF5 at different concentrations, i.e. 0, 5, 25, 50, 100 and 
500 ng/mL.  
The concentrations of the GDF5 used were denoted at the left corner of each 
image at ng/mL. The rbMSCs showed more extensive network of branching 
with increase concentration of GDF5 supplemented (magnification at 10x 
objective). 
 
3.3.3 Total Soluble Collagen Assay 
Dose response analysis at 96 h following GDF5 supplementation revealed that 
total collagen was significantly increased at 100 ng/mL of GDF5 (p<0.05, Figure 3.8; 
Table 3.1A) in hMSC. Although rbMSC showed a significant increase at 500 ng/mL, 
(11.69±2.72 µg/mL; p<0.05; Table 3.1B), it also showed no significant difference 
compared to 100 ng/mL (Table 3.1B). Both hMSCs and rbMSCs showed no significant 
differences between 50 and 100 ng/mL in the total collagen expression. Based on the 
results obtained from this experiment, only three concentrations, i.e. 0, 50 and 
100 ng/mL of GDF5, were selected for time response experiments.  
In the subsequent time response experiment conducted in hMSCs, the results 
showed a significant increase in the total collagen expression in the culture medium 
from the hMSCs cultures supplemented with 100 ng/mL of GDF5 at day -4, -7 and -10, 
as compared to the untreated cultures (Figure 3.9). A significant increase in total 
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collagen expression was only observed at day -7 onwards in the hMSCs cultures treated 
with 50 ng/mL of GDF5. This finding demonstrates that 100 ng/mL of GDF5 is 
sufficient to induce a tenogenic response from hMSCs as early as day -4, but with the 
use of 50 ng/mL of GDF5, a longer period was required. 
 
Figure 3.8  Total collagen content analysis for hMSC and rbMSC cultured with different 
concentrations of GDF5.  
 Total collagen was significantly increased in hMSC (at P2, n=3) at 
>100 ng/mL of GDF5 supplementation (*p<0.05).  
 
 
Table 3.1  Statistical analysis of total collagen expression in hMSCs and rbMSCs 
cultured at different concentrations of GDF5. 
Summary of least significant differences (LSD) analysis with Bonferroni 
adjustment for multiple pairwise comparisons of the mean total collagen 
differences in the culture medium of hMSCs (A) and rbMSCs (B) 
supplemented with different amount of GDF5. The p-value was presented at 
95% confidence interval and significant value was denoted with an asterisk 
(* = p<0.05 and ** = p<0.01). 
 
A 
 
 
 
 p-Value 
Different concentration of GDF5 (ng/mL) 
5 25 50 100 500 
Different 
concentration 
of GDF5 
(ng/mL) 
0 0.515 0.978 0.157 0.008** 0.187 
5  0.520 0.426 0.035* 0.485 
25  0.153 0.007** 0.183 
50   0.178 0.921 
100  0.149 
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Table 3.1, continued 
 
B 
 
 
Figure 3.9  Total collagen content for time response analysis in hMSC at three 
concentration levels of GDF5, i.e. 0, 50 and 100 ng/mL of GDF5.  
 In comparison to hMSC without GDF5 treatment, the total collagen 
expression was significantly elevated (*p<0.05) in hMSCs (at P2, n=3) at 
100 ng/mL of GDF5 on day 4 onwards, whilst significant increased 
(*p<0.05) at 50 ng/mL was only observed at day 7 onwards.  
 
3.3.4 Gene Expression Analysis 
3.3.4.1 Relative Gene Expression Analysis of hMSC Tenogenic Differentiation at 
mRA Level 
A. Dose Response in GDF5-Induced mRA Expression 
 Gene expression analysis showed that there were significant differences in the 
relative gene expression levels for Col-I and Col-III, Dcn, Scx, Tnc and st of the 
hMSCs grown in 0, 50 and 100 ng/mL of GDF5 at 96 h (Figure 3.10). At 100 ng/mL of 
GDF5, candidate tenogenic- markers, Col-I, Scx and Tnc, were significantly up-
regulated (2.31±0.27, 2.30±1.81 and 3.55±0.27 fold increase, respectively; Figure 3.10). 
 Concentrations of GDF5 (ng/mL) 
5 25 50 100 500 
Concentratio
ns of GDF5 
(ng/mL) 
0 0.493 0.142 0.614 0.183 0.026* 
5  0.425 0.856 0.047* 0.004** 
25  0.329 0.006** 0.000** 
50   0.069 0.007** 
100  0.347 
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Figure 3.10  Relative gene expression analysis of candidate tenogenic markers in 
hMSCs cultured with GDF5 at different concentrations (0, 50 and 100 
ng/mL).  
There was a significant up-regulation of gene expression of candidate 
tenogenic marker genes type-I Collagen (Col-I), scleraxis (Scx), tenascin-
C (Tnc) and type-III collagen (Col-III) at 100 ng/mL of GDF5 (n=3; 
*p<0.05 and **p<0.01). (Data were presented as log10 fold change±S.D.) 
 
 Although the Col-III expressions were not significantly different in hMSCs 
cultured with GDF5 as compared to those without GDF5, the ratio of Col-I to Col-III 
appeared to be increased (Table 3.2). For DC expression, there was a 4.47±0.41 fold 
increase at 50 ng/mL and a 4.42±0.57 fold increase at 100 ng/mL at 96 h. No significant 
difference in st gene expression levels was observed in all groups, demonstrating that 
despite undergoing tenogenic differentiation, cells maintained their original MSC gene 
expression. 
 
Table 3.2  The ratios of type-I to type-III collagen (Col-I to Col-III) expression levels in 
hMSCs cultured at 0, 50 and 100 ng/mL of GDF5. 
The ratios were derived from the qPCR data. The results showed higher ratio of 
type-I to type-III collagen in hMSCs cultures with 100 ng/mL of GDF5 at 96 h.  
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B. GDF5-Induced Lineage Commitment in hMSC 
The results of lineage commitment experiment showed the candidate tenogenic 
marker genes Scx and Tnc were up-regulated (1.86±0.63 and 5.80±0.39 fold increase, 
respectively) on day 4 after the GDF5 treatment (Figure 3.11 A and B). However, on 
day 7, only Scx was persistently up-regulated (1.80±0.81 fold increase), whereas the 
expression of Tnc was reduced (0.65±0.08 fold decrease; p<0.01). The expression of 
non-tenogenic marker genes Runx2 and Sox9 was significantly down-regulated 
(2.83±1.64 and 1.12±0.08 fold increase, respectively; p<0.01) on day 7 (Figure 4.5 C 
and D). These findings suggested that hMSCs were undergoing tenogenic differentiation 
as early as day 4 following induction by GDF5 at 100 ng/mL.    
 
Figure 3.11 Relative gene expression analysis of cultured hMSCs in the temporal 
experiment at 100 ng/mL of GDF5. (A) Scleraxis (Scx), (B) tenascin-C (Tnc), 
(C) runt-related transcription factor 2 (Runx2) and (D) SRY (sex-
determining region Y)-box 9 (Sox9).  
The data reflect the relative quantification of target mRNA normalized to 
control samples (untreated hMSCs cultured in MSC growth medium). Data 
are presented in either log2- (in A, B and C) or log10- (in D only) scale, 
with error bars signifying the range of standard deviation. All the 
candidate tenogenic marker genes were up-regulated on day 4 (D4), but 
only Scx was persistently up-regulated on day 7 (D7). There was a 
significant increase in the expression of non-tenogenic marker genes (i.e. 
runt-related transcription factor 2 (Runx2), and SRY (sex-determining 
region Y)-box 9 (Sox9)) on day 4 of GDF5 treatment, which subsequently 
significantly down-regulated by day 7. (n=3; **p<0.01). 
A B 
C D 
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3.3.4.2 Relative Gene Expression Analysis of rbMSC Tenogenic Differentiation at 
mRA Level 
A. Dose Response in GDF5-Induced mRA Expression 
The Col-I gene was significantly (p<0.05) up-regulated in rbMSCs at a 
1.30±0.06 fold in 50 ng/mL cultures and a 1.29±0.21 fold in 100 ng/mL cultures. Col-I 
gene expression was significantly down-regulated at a 1.32±0.05 fold in rbMSCs 
without GDF5 supplementation. The Scx gene expression was significantly up-regulated 
(p<0.05) in rbMSCs cultured with GDF5 supplementation (a 6.18±0.48 fold for 
50 ng/mL and a 2.40±0.83 fold for 100 ng/mL supplemented culture; Figure 3.12).  
There were no significant changes in Scx gene expression in rbMSCs cultured at 
0 ng/mL of GDF5.   
 
Figure 3.12   Relative gene expression analysis of candidate tenogenic markers in rbMSCs 
cultured with GDF5 at different concentrations (0, 50 and 100 ng/mL).  
There was a significant up-regulation of gene expression of candidate 
tenogenic marker genes type-I Collagen (Col-I), and scleraxis (Scx), at 50 
and 100 ng/mL of GDF5 (n=3; *p<0.05). (Data were presented in 
mean±SEM.) 
 
 
B. Time Response in GDF5 Induced mRA Expression 
In the time response experiment, the Col-I expression was significantly (p<0.05) 
and persistently up-regulated on day 4 (8.76±0.71 fold) onward up to day 27 
(10.34±1.09 fold) when cultured with 100 ng/mL of GDF5 supplementation. However, 
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the Scx gene expression levels was significantly and persistently up-regulated at day 4 
(4.12±2.05 fold) onward up to day 10 (2.50±0.76 fold), and no significant changes on 
day 27 (0.69±0.63 fold; Figure 3.13).  
 
 
Figure 3.13  Relative gene expression analysis of Col-I and Scx in rbMSCs cultured with 
100 ng/mL GDF5 in time response experiments (day 0, 4, 10 and 27).  
Both genes were up-regulated at day 4 in both concentrations, 50 and 
100 ng/mL (n=3). However, only Col-I persistently expressed from day 4 
to day 27. Scx showed an increased on day 4 and only persistently up-
regulated up to day 10. A decrease was observed in Scx on day 27. (Data 
were presented in mean±SEM.) 
 
3.3.5 Expression of Tenogenic Markers at Protein Level with Fluorescence 
Imaging 
The results of immunofluorescence staining revealed that COL-I, TNMD, TNC 
and SCX protein expression were markedly increased in hMSCs (Figure 3.14) and 
rbMSCs (Figure 3.15) treated with 100 ng/mL of GDF5. These observations suggested 
that 100 ng/mL of GDF5 treatment able to induce hMSC and rbMSC to differentiate 
into tenogenic lineages. The COL-I appeared to stain around the nucleus of the rbMSCs 
with or without GDF5 supplement and regardless of the GDF5 concentrations (Figure 
3.16 A). In the rbMSCs treated with 100 ng/mL of GDF5, only COL-I and COL-III 
were detected, but not COL-II. Different staining pattern of COL-I and COL-III was 
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observed; with COL-I expressed around the nucleus, and COL-III expression was 
detected as a halo-like pattern (white arrows) surrounding the nucleus (Figure 3.16 B).  
 
Figure 3.14 The candidate tenogenic markers (COL-I, TMD, TC and SCX) 
expression of GDF5 (100 ng/mL) treated hMSC by immunofluorescence 
staining. 
 The extent of candidate tenogenic markers expressions were increased in 
GDF5 treated hMSC compared to the untreated control. Images were 
captured at 63X objective and a scale bar (50 µm) was depicted on the 
right bottom corner of the overlay images. 
 107 
 
 
Figure 3.15 The candidate tenogenic markers (COL-I, TMD, TC and SCX) 
expression of GDF5 (100 ng/mL) treated rbMSC by immunofluorescence 
staining. 
The extent of candidate tenogenic markers expressions were increased in 
GDF5 treated rbMSC compared to the untreated control. Images were 
captured at 63X objective and a scale bar (50 µm) was depicted on the 
right bottom corner of the overlay images. 
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Figure 3.16 Expression of collagen type-I, II and III (COL-I, COL-II and COL-III) in 
rbMSCs cultured with or without GDF5 supplement.  
A. COL-I immunofluorescence staining of rbMSCs supplemented with and 
without GDF5 (0, 5, 25, 50, 100 and 500 ng/mL, as denoted at the top 
left conner of each image). Positive expression was observed in all 
rbMSCs cultured with and without GDF5 and the expression pattern of 
COL-I was more intense around the nucleus in all rbMSCs, regardless 
of GDF5 treatment.  
B. COL-I, COL-II and COL-III immunofluorescence staining (as denoted 
on top of each image) of rbMSC treated with 100 ng/mL of GDF5. 
Only COL-I and COL-III were present in rbMSCs supplemented with 
100 ng/mL of GDF5, but no COL-II was detected. Different staining 
pattern of COL-I and COL-III was observed; with COL-I expressed 
more intense around the nucleus, and COL-III appeared as a halo-like 
pattern (white arrows) surrounding the nucleus.  
Images were captured at 10X objective and 63X objective (at bottom 
left corner of each image). 
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3.4 Discussion 
3.4.1 Cell Proliferation 
The results of this study showed that GDF5 did not appear to influence hMSC 
proliferation, which is in contrast to a previous report involving the rodent adipose 
tissue-derived MSC primary culture (Park, et al., 2010), but in consistency with a study 
which uses murine bone marrow-derived stromal immortalized cell lines (Farng, et al., 
2008). In a separate study reported recently, have shown that rodent adipose tissue-
derived MSCs had been shown to produce faster proliferation than MSCs derived from 
the bone marrow (Saka et al., 2011). Nevertheless, the data presented in this current 
study appear to be consistent with a study which uses murine bone marrow-derived 
stromal immortalized cell lines (Farng, et al., 2008). Therefore, it appears that the tissue 
origin of the MSCs may be a predetermining factor affecting cell proliferation in the 
presence of GDF5. However, this needs to be confirmed by a more robust study design.  
 
3.4.2 Candidate Tenogenic Marker Expression 
Despite the fact that GDF5 does not affect the morphological appearances of 
hMSC or rbMSC, the supplementation of GDF5 (especially at 100 ng/mL) does affect 
the expression of candidate tenogenic markers. This has been shown in the results in 
total soluble collagen assay, gene expression and protein expression 
(immunofluorescence staining).  
In the total soluble collagen experiment, a biphasic response was observed 
(significantly in rbMSC, but not significant in hMSC) where the total collagen 
expression showed a decrease at 25 ng/mL of GDF5 but an increase at 50 ng/mL of 
GDF5 (Figure 3.8). Although the observation was not significant in hMSCs total 
collagen expression, which may due to the small sample size (n=3), a similar biphasic 
response was observed in the Col-I gene expression levels in hMSCs (Figure 3.10). It is 
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suggested that this biphasic response may due to the alternate exclusion mechanism as 
shown in FGF signalling mechanism in early tendon development. Nevertheless, a more 
comprehensive experimental design is required in order to elucidate this. 
 In the gene expression experiments, the candidate tenogenic markers genes (Scx 
and Tnc) were up-regulated at day 4 of GDF5 treatment. However, at day 7, only Scx 
was persistently expressed, whereas the Tnc expression was reduced dramatically. It is 
suggested that the decrease in the Tnc gene expression is due to the function of this gene 
which is a mechanoresponsive modulator of matrix formation expressed in high 
tensional loading tissue. The expression of this gene may persistently express should the 
cells receive mechanical signals after day 4. This however, required another 
comprehensive study to resolve it.   
Further, in the current study, there was an apparent increase in the total collagen 
expression in the hMSCs cultures at 100 ng/mL of GDF-5 (Figure 3.8), with no 
significant increase in Col-III gene expression (Figure 3.10). This suggests that the 
increase in total collagen expression observed in our study is likely to be contributed 
mainly by an increase in Col-I, but the possibility of the presence of other collagens, 
e.g. Collagen type II, cannot be completely ruled out. This however, would be unlikely 
considering that other studies have shown that the expressions of these proteins are 
usually of minimal quantity (Altman et al., 2002). In regards to this, one would expect 
to observe a relatively high Col-I gene expression (at mRNA level) in the GDF5-
induced MSCs, however this was not the case in the both hMSCs and rbMSCs. This 
could be explained as the COL-I synthesis is regulated at the protein translation level, 
but not at the gene transcription level. This further alludes to the regulation of COL-I 
synthesis by the cis-acting element i.e. RNA helicase A, without affecting the 
expression of Col-I at mRNA levels (Manojlovic & Stefanovic, 2012).     
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It is critical to emphasize that the biology of GDF5 is still far from clear: how 
does GDF5 induced MSCs undergo tenogenic differentiation, and whether the GDF5-
induced MSCs undergo differentiation into tendon stem cells or tenoblast or tenocytes 
remain unclear, as currently, there are no specific markers to distinguish these 
aforementioned cells. It is speculated that the MSCs may undergo a symmetrical or an 
asymmetrical cell division upon GDF5 treatment (Figure 3.17). This speculation 
remains unresolved, as there were no specific markers to distinguish them from one 
another. Although the differentiation mechanism involved are still unknown, the 
findings of this study strongly indicate that the MSCs may undergo tenogenic 
differentiation by GDF5 treatment.  
 
Figure 3.17    A postulated scenario of a more complex tenogenic differentiation process in 
MSCs under GDF5 treatment. 
A. Symmerical cell division in the normally expected MSC tenogenic 
differentiation process. 
B. An alternative condition showing the possibility of the occurrence of 
asymmetrical cell division resulting in two cell populations: (1) the 
renewable tendon stem cells (TSC) and the mature tenocyte. 
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3.4.3 Current Limitations 
Although several limitations were identified within the present study, these were 
unfortunately unavoidable. Firstly, the overall experimental designs employed in this 
current study did not do a direct comparison between the hMSC and rbMSC. A direct 
comparison between hMSC and rbMSC would be useful, if both of these models are at 
the same level in their availability in molecular biology information. The human model 
has more advantage due to extensive molecular biology information, while the rabbit 
model has less advantage due to limited molecular biology information. Thus, in order 
to accommodate the information availability between the human and rabbit models, this 
study did not do a side by side direct comparison between hMSC and rbMSC. 
 Secondly, the use of total collagen assay to evaluate the tenogenic 
differentiation of hMSCs may not be the best method of assessment considering that 
many cells of mesenchymal in origin produce an abundance of extracellular collagen. 
The assessment of a more specific collagen, for example, type-I and type-III collagen, 
may be a more reasonable approach considering that these proteins are specific to 
tenocyte expression. However, the concentrations of these collagen types may not 
appear in sufficient quantities to be detected by conventional spectrophotometry 
analyses such as that utilized in the present study. Hence, gene expression analysis, 
which is a more specific and sensitive tool of assessment, was advocated in the present 
study. It should be noted however that gene expression analysis has its inherent 
limitation considering the fact that measurements are made at transcription level rather 
than reflecting the true level of the extracellular matrix protein that is synthesized. The 
decision to use total collagen assay may have been the most appropriate option in this 
study, since this approach has also been used in other study to evaluate the tenogenic 
differentiation of the fibroblasts (Sahoo et al., 2010). In other studies, changes in total 
collagen also appears to be correlated to the changes in the conventional hydroxyproline 
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assay, which is an indicator of the amount of tendon specific collagen (Taskiran et al., 
1999). 
 
3.5 Summary   
The use of GDF5 induces tenogenic differentiation in hMSC and rbMSC. It 
appears that GDF5 at a concentration of 100 ng/mL provides the most optimal cell 
phenotypic response, which includes an augmented level of total collagen as well as 
tenogenic markers gene and protein expression, similar to that of human (or rabbit) 
tenocyte cultures. All the factors investigated showed that rbMSC responded in a 
similar way as hMSC. Table 3.3 summarized the tenogenic response observed in hMSC 
and rbMSC in all the experiments described in this chapter.   
 
Table 3.3 A summary of GDF5 induced tenogenic response in hMSC and rbMSC. 
 
o Experiments Response Observed in 
hMSC 
Response Observed in 
rbMSC 
1 Morphological 
appearance 
No apparent morphological 
changes observed. 
 
No apparent morphological 
changes observed. 
2 Total soluble 
collagen assay 
i. 100 ng/mL of GDF5 
induced significantly 
higher amount of total 
collagen expression. 
ii. No significant differences 
were observed between 
the 50, 100 and 500 
ng/mL of GDF5 
treatment. 
i. 500 ng/mL of GDF5 
induced significantly 
higher amount of total 
collagen expression. 
ii. No significant 
differences were 
observed between the 50 
and 100 ng/mL, as well 
as between the 100 and 
500 ng/mL. 
 
3 Candidate 
tenogenic 
marker genes 
expression at 
mRA level 
 
 
i. 100 ng/mL of GDF5 
induced significantly 
(p<0.01) higher amount of 
candidate tenogenic 
marker genes expression 
(i.e. Col-I, Scx and Tnc). 
 
i. Both Col-I and Scx gene 
expression were 
significantly (p<0.05) 
up-regulated in rbMSC 
cultures treated with 50 
and 100 ng/mL of 
GDF5. 
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Table 3.3, continued  
 
  ii. The ratio of Col-I to 
Col-III expression was 
increased in hMSCs 
supplemented with 
100 ng/mL of GDF5. 
iii. Both Scx and Tnc 
expression were expressed 
in hMSCs treated with 
100 ng/mL of GDF5 at 
day 4.  
iv. Scx was persistently 
expressed in hMSCs 
treated with GDF5 from 
day 4 to day 7. 
v. Both non-tenogenic 
markers (i.e. Runx2 and 
Sox9) were significantly 
down-regulated (p<0.01) 
in hMSC treated with 
100 ng/mL of GDF5. 
 
ii. Col-I gene expression 
was significantly 
(p<0.05) and persistently 
up-regulated from day 4 
to day 27. 
iii. Scx gene expression was 
significantly up-
regulated from day 4 to 
10, but reduced at day 
27. 
4 Candidate 
tenogenic 
marker 
expression at 
protein level  
Candiadate tenogenic marker 
proteins (COL-I, TNMD, 
SCX and TNC) were 
expressed in hMSCs treated 
with 100 ng/mL of GDF5. 
Candiadate tenogenic 
marker proteins (COL-I, 
TNMD, SCX and TNC) 
were expressed in rbMSCs 
treated with 100 ng/mL of 
GDF5. 
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CHAPTER 4 
RESULTS 2: GDF5-IDUCED MESECHYMAL STEM CELLS FOR TEDO 
REPAIR – USIG I VIVO EVALUATIO I A RABBIT IFRASPIATUS 
TEDO MODEL 
 
 
 
 
 
 
 
Part of this chapter has been submitted to: 
Tan S.L., Ahmad T.S., Chan C.K., Selvaratnam L., Kamarul T. (2013) Growth 
differentiation factor 5 (GDF5)-induced marrow stromal stem cells support superior 
tendon healing in vivo: A preliminary report. PLOS O
E Submitted. 
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4.0 Results 2: GDF5-induced mesenchymal stem cells for tendon repair – using 
in vivo evaluation in a rabbit infraspinatus tendon model 
4.1 Introduction 
Collectively, the previous chapter highlighted a tenogenic inductive capacity of 
GDF5 in hMSCs and rbMSCs that may be exploited therapeutically for tendon repair. 
The GDF5 induced hMSCs and rbMSCs showed expression of tenogenic marker genes 
and proteins in vitro. To date, the use of GDF5 induced MSCs in an in vivo model has 
not been explored. Questions remain whether this tenogenic MSC (TMSC) would 
enhance tendon repair similar to that observed in other cell-based therapies which used 
tenocyte (Chen et al., 2011; Chen et al., 2007), undifferentiated MSC (Awad et al., 
1999; Juncosa-Melvin et al., 2006; Pacini et al., 2007) and tendon stem/progenitor 
(TSPC) cells (Shen et al., 2012). In instances that autologous tenocytes were used, 
improved COL-I expression (Chen, et al., 2007) and tendon remodelling (Chen, et al., 
2011) have been observed in the healing tendons. In other cases where allogeneic MSCs 
loaded scaffolds were used, restoration in structure and function of rabbit tendons was 
found (Awad, et al., 1999; Ouyang et al., 2003). Besides, clinical use of undifferentiated 
MSCs in superficial digital flexor tendon repair in racehorses has been reported with no 
ectopic bone deposition. Furthermore, the ultrasound scanning showed that tendon 
fibers were correctly oriented (Pacini, et al., 2007). In addition, allogeneic TSPC-seeded 
knitted-collagen sponge scaffold has also been shown to enhance the efficacy of rotator 
cuff tendon regeneration by differentiating into tenocytes and by secreting anti-
inflammatory cytokines that prevent immunological rejection (Shen, et al., 2012).  
 In this chapter, in vivo assessment of tendon repair potential of GDF5-induced 
MSC (TMSC) was described. To achieve this, the rabbit infraspinatus tendon was 
selected as a model to study tendon repair. This model was selected as a primary model 
due to its anatomic position where the acromion is pointed posteriorly and inferiorly 
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toward the infraspinatus tendon. This allows surgery on the infraspinatus tendon to be 
accessible and reproducible, and therefore an easy model to study the in vivo effect of 
GDF5 induced rbMSCs in tendon repair. As there is no animal model with exactly the 
same characteristics as those of humans, and no one animal species that we are aware 
represents the ‘gold standard’ for tendinopathy (Warden, 2007).  
Although anatomically different compared to human, the rabbit models have 
provided valuable information regarding the etiology, pathogenesis, as well as effective 
surgical repair techniques (Gupta & Lee, 2007). Furthermore, rabbit infraspinatus 
tendons have been used to investigate the feasibility of using an acellular matrix for the 
regeneration of rotator cuff tendon defects (Funakoshi et al., 2006). Besides, the rabbit 
model is larger in size. This makes rabbit tendons more amenable to surgery and the 
harvesting of adequate amounts of tissue for the evaluation of useful outcome measures. 
Apart from that, rabbit has cellular and tissue physiology approximates that of human 
(Fox, 1984) and they are mild-tempered and relatively easy to handle.  
This current experiment was conducted to compare the efficacy of 
GDF5-induced rbMSCs (day 4 with 100 ng/ml of GDF5-induced rbMSCs (P3) or 
tenogenic rbMSC; TMSCs) in rabbit infraspinatus tendon repair. To further strengthen 
the present study design, a side-by-side comparison to its counterparts, the 
undifferentiated MSCs and tenocytes, was conducted, apart from the control (with no 
repair).  
 
4.2 Experimental Design 
Rabbits (N=18) used for in vivo transplantation study were surgically created 
through a window defect, bilaterally on the infraspinatus tendon. Three weeks after 
defect creation, the rabbits were randomly assigned into 6 groups, and the infraspinatus 
tendon defects were repair with methods as listed in Table 4.1. At 6 weeks following 
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treatment, all the rabbits were euthanized and the infraspinatus tendons were collected 
for analysis. Figure 4.1 showed the overview of in vivo transplantation work flow. 
 
Table 4.1 Different methods were used to repair the tendon defect at three-weeks- post 
defect creation. 
All the right shoulders were repaired with different methods: suture only, 
fibrin glue (FG) only, suture with FG only, and suture with FG and 1- 2 x 10
6
 
cells (either tenocytes (P3), MSC (P3) or tenogenic MSC (TMSC, P3)). 
 
Group Type of 
repair 
Repair Method  
1 Non-cell-based Suture (S) only 3 
2 Non-cell-based Fibrin glue (FG) only  3 
3 Non-cell-based S + FG only 3 
4 Cell-based S + FG + Native tenocytes (from tendon) 3 
5 Cell-based S + FG + MSCs  3 
6 Cell-based S + FG + Tenogenic MSCs (TMSC) 3 
 
 
 
Figure 4.1  The flow chart for overall in vivo transplantation experimental design. 
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4.3 Results  
4.3.1 Mobilization Observation and Gross Observation  
All animals showed restricted movement during the three weeks post-defect 
creation. The peritendinous fibrous reaction was noticeable in all animals at three weeks 
after the defect creation. At time of harvest, all the animals showed equal bilateral range 
of motion of the shoulders. There was no detectable difference in the activity level of 
animals in each group. Macroscopically, there was no gross evidence of infection at the 
surgical site in any of the specimens (Figure 4.2). From the control (tendon defect with 
no repair) group to the repaired groups, the tendon defect area was filled with a pale 
fibrous scar (in the control and non-cell-based treatment groups) that became firmer and 
more organized in the cell-based treatment groups (Figure 4.2 A). Progressive tendon 
healing was more prominent in those treated with TMSC, where prominent tendon 
callus formation was observed (Figure 4.2 B). Early tendon callus formation suggested 
that the use of TMSC could enhance tendon neoformation. 
 
4.3.2 Microscopic Observation  
4.3.2.1 Progressive Tendon Healing as Observed by Haematoxylin and Eosin 
(H&E) Staining 
Histological appearance in haematoxylin and eosin (H&E) stained sections of 
the control tendon showed increased cellularity, randomly aligned tendon cells of more 
plump and rounded morphology which is in contrast to the normal tendon which 
showed spindle-shaped tenocytes with elongated nucleus arranged in parallel alignment 
(Figure 4.3 A and B).  
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Figure 4.2 Overview of progressive healing in tendon defects in all groups.  
(A) Macroscopic examination (Upper panel) and histological overview 
(Lower panel) of hematoxylin and eosin (H&E) stained tissue 
sections of healing tendon of all the treated and control groups. The 
grouping of the particular tendon specimens was denoted on top of 
each column of the images. FG: fibrin glue; MSC: mesenchymal 
stem cells, TMSC: tenogenic MSCs.  
(B)  Tendon callus formation was observed in the TMSC treated group. 
 This tendon callus formation indicated early neotendon formation in 
TMSC group and this was not observed in any of the other groups. 
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Figure 4.3  Microscopic evaluation of progressive healing in tendon defects in control (no 
repair) and treated groups compared to the normal tendon at six weeks 
following treatment. 
The images showed are the longitudinal sections of tendons with 
hematoxylin and eosin (H&E) stain: normal tendon (A), control (no repair) 
(B), non-cell-based treatment groups which include suture (C), fibrin glue 
(FG) (D), Suture with FG (E) and cell-based treatment groups: tenocytes 
(F), MSC (G), and tenogenic MSC (TMSC) (H); observed at 20x objective 
lens (Scale bar = 100 µm).  
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Figure 4.3, continued 
 
Inset photographs showed observation at 40x objectives to depict the cell 
nucleus morphology and the alignment of cells with the collagen fibers (Bar 
= 50 µm).   
Contrasting histological appearance was observed in the normal (A) and 
control tendon (B), where the tendon fibroblasts became more plump, 
increased in number and randomly aligned in the control group as compared 
to the spindle-shaped tenocytes with elongated nucleus arrange in parallel 
alignment in normal tendon. The treated groups showed progressive healing 
in the defect area where the tendon collagen fibers were more orientated as 
observed in the non-cell-based treatment groups compared to the control 
and in the cell-based treatment groups compared to non-cell-based treatment 
groups.  
 
Based on the histological analysis, tendon defects treated with different methods 
showed different stages of healing (early, moderate and mature healing) at six weeks 
post-surgical treatment. In normal tendon (Figure 4.3 A), spindle-shaped tenocytes with 
elongated nucleus (in blue colour) were resided parallel to the collagen fibers (in red 
colour), which were arranged in parallel alignment to the tendon’s longitudinal axis. In 
contrast to the normal tendon histology, the control tendons (Figure 4.3 B) showed high 
cellularity and collagen fibers in random orientations. In addition, cells in the control 
tendon were more plump and rounded in shape compared to that of normal tendon. In 
the non-cell-based treatment groups (tendons repaired without cells; i.e. suture only, 
fibrin glue (FG) only, and suture with FG), their histology displayed highly disorganized 
collagen fibers, plump cells with rounded nuclei, and the blood vessels was evident, 
which indicated that the tendon were at the moderate healing stage compared to the 
early healing stage in the control group (Figure 4.3 C, D and E). Whereas in the cell-
based treatment groups (i.e. tenocytes, MSC and TMSC), their histology showed 
progressive maturing of tendon healing from tenocytes to MSC to TMSC (tenocytes < 
MSC < TMSC). In these groups, the tendon defect area were resided with lesser and 
lesser cellularity, reduced in the occurrence of plump cells with rounded nuclei and an 
apparent decrease in disorganized collagen fibers as well as randomly aligned cells. 
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Within the cell-based treatment groups, TMSC group showed more mature tendon 
healing compared to that of tenocytes and MSC groups as evident by cells with more 
elongated nuclei aligned parallel to the collagen fibers which more resemble 
histological appearance of the normal tendon tissue (Figure 4.3 F, G and H). Besides, 
the collagen fibers in the TMSC group were in highly organized orientation which 
showed that the tendons were at the late stage of healing (Figure 4.3 H).  
 
4.3.2.2 Progressive Tendon Healing as Observed by Van Gieson Staining 
In the Van Gieson (VG) stained sections, collagen fibers was stained in bright 
red, while the cytoplasm, muscle and fibrin were stained in yellow, and the cell nucleus 
stained in blue (or grey). The mature collagen fibers in normal tendon was revealed in a 
deep red colour (Figure 4.4 A) and a reduced red intensity (pinkish colour) was detected 
for immature collagen fibers in all the other groups (none-cell-based and cell-based 
treatment groups). Control tendon showed a scarce distribution of collagen in the tissue 
(Figure 4.4 B). Yellowish muscle and fibrin was observed only in non-cell-based 
treatment groups. Besides, VG staining also revealed an abundance of blood vessels in 
the control and non-cell-based treatment groups. 
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Figure 4.4 Microscopic evaluation of progressive healing in tendon defects in control (no 
repair) and treated groups compared to the normal tendon at six weeks 
following treatment. 
The images showed are the longitudinal sections of tendons with Van 
Gieson (VG) stain: normal tendon (A), control (no repair) (B), non-cell-
based treatment groups: suture (C), fibrin glue (FG) (D), Suture with FG (E) 
and cell-based treatment groups: tenocytes (F) , MSC (G), and tenogenic 
MSC (TMSC) (H); observed at 20x objective lens (Scale bar = 100 µm). 
Inset photographs showed observation at 40x objectives to depict the cell 
nucleus morphology and the alignment of cells with the collagen fibers (Bar 
= 50 µm). Yellowish muscle or fibrin structure (white arrows) and evident 
of vasculature (black arrows) were observed in the control and non-cell-
based treatment groups. 
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4.3.2.3 Quality of Tendon Healing by Histological Scoring 
The Watkins (1985) and Soslowsky (1996) scoring system were used for 
histological evaluation of tendon repair. Statistical analysis showed that Watkins 
score was significantly inversely correlated to Soslowsky score (p=0.000; r=-0.931). 
They were inversely correlated because in Watkins score, the higher the score, the more 
mature healing was observed and, for the Soslowsky score, the lower the score, the 
more mature healing was observed (Figure 4.5). Kruskal-Wallis test showed that there 
were significant differences between the treatment groups when evaluated using both 
Watkins score (p=0.008) and Soslowsky score (p=0.008). Pairwise Mann-Whitney U 
tests between all the treatment groups and control group showed that there were 
significant differences between the non-cell-based treatment groups (suture, FG, and 
suture with FG) and the cell-based treatment groups (tenocytes, MSC and TMSC), in 
both Watkins and Soslowsky scores (Table 4.2); except for (i) MSC vs. TMSC in 
Watkins score, and (ii) between the tenocytes, MSCs and TMSC in Soslowsky score.  
 
 
Figure 4.5   Box-plots of histological scoring for the quality of healing in tendon defects 
in control and treated groups.  
The results showed the distribution of histological scores based on 
Watkins score (A) and Soslowsky score (B), for the control (no repair) and 
treated groups (FG:fibrin glue; S+FG: suture with FG; Teno: tenocytes). 
The histological scores obtained for both scoring methods were directly 
proportional to the methods of repair, and the quality of repair was 
increased in the cell-based groups (tenocytes, MSCs and TMSC) compared 
to the non-cell-based groups (suture, FG and suture with FG).  
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Table 4.2  A summary of Mann-Whitney U tests for pairwise comparisons between 
all the groups. 
The italic font (top right of the table) indicate the p-value for Watkins 
score and the bold font (bottom left of the table) indicate the p-value for 
both scoring showed significant differences in cell-based treatment 
groups compared to the non-cell-based treatment groups (* p<0.05).  
 
 Control 
 
Suture 
(S) 
only 
Fibrin 
Glue 
(FG)  
only 
S + FG 
 
S + FG + 
Tenocyte 
S + FG 
+ MSC 
S + FG 
+ 
TMSC 
 
Control 
 
 0.817 0.077 0.658 0.275 0.049* 0.049* 
Suture (S) 
only 
0.178  0.046* 0.105 0.046* 0.046* 0.046* 
Fibrin Glue 
(FG)  only 
0.121 0.376  0.049* 0.049* 0.049* 0.049* 
S + FG 
 
0.487 0.077 0.077  0.127 0.049* 0.049* 
S + FG + 
Tenocyte 
0.046* 0.049* 0.049* 0.077  0.049* 0.049* 
S + FG + 
MSC 
0.043* 0.046* 0.046* 0.046* 0.825  0.275 
S + FG + 
TMSC 
0.046* 0.049* 0.049* 0.049* 0.077 0.178  
 
4.3.3 Expression of Candidate Tenogenic Markers at mRA Levels Among the 
Cell-based Treated Groups 
Relative gene expression analysis was conducted to compare the mRNA levels 
of two candidate tenogenic marker genes (Col-I and Scx) among the cell-based treated 
groups. There were significant differences in the relative gene expression levels for 
Col-I and Scx of tendon repaired with tenocytes, MSC and TMSC at six weeks post-
surgical repair (Figure 4.6). In the TMSC group, the candidate tenogenic marker Scx 
(3.2±0.28) and Col-I (0.45±0.02) was significantly upregulated compared to the 
tenocytes and MSC groups.  
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Figure 4.6  Relative gene expression analysis of type I collagen (Col-I) and scleraxis 
(Scx) in cell-based treatment groups (Tenocytes, MSC and TMSC) compared 
to the control group by qPCR analysis and normalized to GAPDH (reference 
gene). 
 Both Col-I (A) and Scx (B) showed significant increase in TMSC group 
compared to tenocytes and MSC groups. (Data were presented in 
mean±SEM.) 
 
 
4.3.4 Expression of Candidate Tenogenic Markers at Protein Level Among the 
Cell-based Treated Groups  
The immunostaining of candidate tenogenic markers (COL-I, SCX, TNC and 
TNMD) revealed the tissue distribution of each protein on the tendons of normal and 
experimental groups (Figure 4.7 and Figure 4.8). The COL-I expression showed 
apparent differences in the collagen-fiber-bundles appearance between the normal, 
control and the treated groups. In normal tendons the tendon collagen-fiber-bundles 
were aligned in parallel directions, contrasting to that of control tendons, where the 
collagens fibers were highly disorganized and no collagen-fiber-bundles could be 
observed. Collagen-fiber-bundles progressively aligned into parallel direction were 
observed in all the treatment groups. The SCX expression was higher in the treatment 
groups compared to the control. Some localized expression revealed as red spots in the 
images indicated the intracellular expressions in the tendon cells which resided along 
the tendon collagen fibers, and this was noticeable in the tenocytes and TMSC groups. 
The TNC expression on the normal tendon showed a wavy pattern of the tendon 
collagen fibers. These wavy patterns were also observed in the TMSC group, and in a 
lesser extend in the tenocytes and MSC groups. TNC expression in the control group 
did not show any wavy pattern.  
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Figure 4.7  Type-I collagen (COL-I) and scleraxis (SCX) expression on normal, control 
and cell-based-treated groups (normal, control, tenocytes, MSC and TMSC; 
indicated on the left panel) captured by laser confocal microscope.  
The expression of COL-I (depicted in green) was shown by FITC (BD 
Biosciences, US) reaction and SCX (depicted in red) was shown by Texas 
red (Santa Cruz Biotechnology, California). All the tissue sections were 
counterstained with Hoescht 33342 (H33342) to detect the cell nuclei 
(depicted in blue). All the images were captured for each channel by 
sequential scanning; H33342 (first panel on the left), COL-I (second 
panel), SCX (third panel); and the merged image of all channels (last panel 
on the right). Scale bar=100µm in low magnification images (20x) and 50 
µm in high magnification images (100x).  
The tissue distribution of both COL-I and SCX on TMSC group was 
comparable to that of normal tendon. 
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Figure 4.8  Tenascin C (TC) and tenomodulin (TMD) expression on normal, control 
and cell-based-treated groups (normal, control, tenocytes, MSC and TMSC; 
indicated on the left panel) captured by laser confocal microscope.  
The expression of TNC (depicted in green) was shown by FITC (BD 
Biosciences, US) reaction and TNMD (depicted in red) was shown by 
Texas red (Santa Cruz Biotechnology, California). All the tissue sections 
were counterstained with Hoescht 33342 (H33342) to detect the cell nuclei 
(depicted in blue). All the images were captured for each channel by 
sequential scanning; H33342 (first panel on the left), TNC (second panel), 
TNMD (third panel); and the merged image of all channels (last panel on 
the right). Scale bar=100µm in low magnification images (20x) and 50 µm 
in high magnification images (100x).  
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Figure 4.8, continued 
 
The localized TNMD expression (white arrows) as fine lines on the normal 
and TMSC specimens, but its expression on the tenocyte and MSC groups 
showed more coarsening lines. The control tissue showed randomly 
distributed TNMD expression compared to the normal and cell based 
treatment groups. The wavy pattern of tendon collagen fibers can be 
observed from the expression of both TNC and TNMD. 
 
The TNMD expression was co-localized with the cells which resided along the 
tendon collagen fibers. As the mature tendon cells became elongated, and underwent 
changes in its cellular morphology, the intracellular TNMD was observed as thin lines 
aligned along the tendon fibers as depicted in the overlay images. The tissue distribution 
of TNMD on TMSC group was comparable to that of normal tendon, which showed the 
wavy pattern of the cells resided on the tendon fibers. 
 
4.4 Discussion 
The present in vivo study demonstrates that TMSC could augment tendon 
healing as compared to tenocytes and MSC. This deduction was based on the following 
findings: (1) early tendon callus formation in the TMSC group which was more 
prominent than all the other groups by macroscopic observation; (2) tendon healing in 
TMSC group showed cells that resembled tenocyte-like phenotype (i.e. cells with 
spindle-shaped and elongated nucleus) were aligned parallel to tendon’s longitudinal 
axis; (3) collagen fibers in TMSC group were in organized orientations compared to the 
randomly aligned collagen fibers in the non-cell treated groups and control group; (4) 
VG stained section showed that tendon healing in TMSC group are at the late stage of 
collagen formation (mature collagen fibers formation); (5) both Watkins (1985) and 
Soslowsky (1996) scores demonstrated that tendons of TMSC group showed better 
quality of repair compared to the non-cell based treatment groups; (6) gene expression 
analysis showed that tendon of TMSC group expressed significantly higher Col-I and 
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Scx compared to tenocyte and MSC group; and (7) all candidate tenogenic marker 
proteins were expressed in the TMSC groups with the tissue distribution comparable to 
that observed in normal tendon.  
Local tendon callus formation in the TMSC group suggested the occurrence of 
tendon neoformation in the site of repair. Previous study in tendon-bone junction repair 
in a rat model reported the observations of callus formation in the sutured tendon-bone 
junction at the site of repair at six weeks after surgery (Hibino et al., 2007). However, in 
this rabbit in vivo study, apparent tendon callus formation was observed in the TMSC 
group, but not in the suture group. This may due to the different repair model in this 
current study which is tendon-tendon repair but not tendon-bone junction repair. 
Tendon callus formation has been suggested related to the positive role play by the 
paratenon (Stein & Luekens, 1976) and intact periosteum (Hibino, et al., 2007) in case 
of tendon to bone healing. Other study in tendon-tendon healing in rat Achilles tendon 
has also observed with tendon callus formation after one week of repair with platelet 
concentrate injection (Aspenberg & Virchenko, 2004). In this current study, it is 
suggested that the positive factor inducing the tendon repair is the transplanted 
tenogenic MSC, since in the current tendon defect model did not involve paratenon or 
periosteum. 
The results of microscopic observation showed progressive tendon healing in 
tendon defect sites of different repair methods. Different stages of healing as described 
by Soslowsky and colleagues (1996) were observed in the tendon specimens of different 
repair methods in this current experiment, albeit all the tendons were harvested at the 
same recovery time. Therefore, it is suggested that the different methods used has 
accelerate tendon healing at different degree. The results of this current study also 
showed GDF5 induced MSC (TMSC group) has better effect in accelerating the tendon 
healing compared to its counter parts tenocytes and undifferentiated MSC. This was 
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further evidenced in the tissue distribution of candidate tenogenic marker proteins, 
COL-I, SCX, TNC and TNMD, on the TMSC group, which were comparable to that 
observed in the normal tendon.  
In this current experiment, the tenocytes group did not show improved tendon 
healing as observed in the TMSC group. This could be due to phenotypic drifting upon 
in vitro expansion (Bernard-Beaubois et al., 1997; Yao et al., 2006) of the limited 
number of cells obtained from the explanted tissue. In prolonged in vitro culture system, 
the isolated cells may become less proliferative and loss the expected functionality, 
ultimately, produced an inferior tendon repair when implanted to tendon defect area. A 
recent report demonstrated that GDF5 supplementation in in vitro tenocyte culture could 
augment the mRNA expression levels of extracellular matrix related genes or tenocyte 
phenotypic expression (Hogan et al., 2011); these GDF5 treated cells may produce 
enhance tendon healing when implanted in vivo. Nevertheless, this remains speculative 
and needs to be proven in a separate study. 
 
4.4.1 Study Limitation 
Several limitations were identified within the present study, these were 
unfortunately unavoidable. Firstly, only one time of recovery were studied in this 
experiment, which was 6 weeks. Previous studies in tendon repair have reported longer 
recovery time of 8 to 12 weeks (Soslowsky et al., 1996), or with more than one recovery 
time (Shen, et al., 2012). Although one recovery time at 6 weeks was used in this 
current experiment design, at this recovery time, different stages of repair discriminate 
by the different repair methods were observed. This suggested that this recovery time 
was appropriate to this current study. Further, a study in MSC-mediated tendon repair in 
rat reported at 4 weeks after surgery had also showed increased number of tenocytes and 
larger and more mature looking collagen fiber bundles (Awad, et al., 1999).   
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 Secondly, use of fluorescence and bioluminescence imaging, i.e. green 
fluorescence protein (GFP) transfected MSCs for in vivo cell tracking or the use of a 
reporter gene system consisting of enhanced GFP (eGFP) for molecular imaging would 
be of advantage. The observed tendon repair in the TMSC group (i.e. tendon callus 
formation, collagen fibres in orientated organization and candidate tenogenic markers 
expression), which was not detected in all the other groups (treated and untreated 
control), preliminarily suggested that the observed tendon repair was due to the 
implantation of TMSC at the tendon defect area. However, it remains unresolved 
whether the implanted cells (i.e. TMSC) stimulate regeneration of damage tissue by 
secretion of cytokines and chemokines when engrafted into new microenvironment or 
by their stem-like ability to differentiate (Prockop, 2007). This could possibly be 
elucidated with the reporter gene system consisting eGFP to determine whether the 
candidate tenogenic markers expression detected at the tendon defect site is from the 
implanted allogeneic cells source, or from the native TSC at tendon injury site that 
differentiated into the tendon cells. Nevertheless, the GFP-labelled MSCs, especially 
those with lentiviral-based transduction (for producing a comparatively stable and 
longer-term GFP expression), has its own limitations; especially those using the HIV-
based vectors (Van Damme et al., 2006) may induce unwanted immune response in vivo 
(Stripecke et al., 1999) as well as insertion mutagenesis (Gu et al., 2012).  
Lastly, from a translational standpoint, bipeds such as non-human primates 
represent the most ideal species to use in tendon research as they are closest to human in 
terms of anatomy and physiology. However, their use is limited by ethical consideration 
and lack of availability which results in extraordinary high cost compared to other 
laboratory animals. Among the quadrupeds, rat has been suggested as an appropriate 
model for investigating rotator cuff disease compared to other animal model (e.g. rabbit, 
cow, dog etc.) due to its shoulder anatomy where the acromion is immediately adjacent 
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and positioned over the supraspinatus tendon as in humans (Soslowsky, et al., 1996). 
However the main disadvantage of rats is their relatively smaller in size compared to 
other model such as rabbits, which make rat tendons harvesting difficult especially for 
histological or mechanical outcome measures. 
 
4.5 Summary  
This in vivo experiment showed that TMSC or GDF5 induced rbMSC resulted in 
better improvement in infraspinatus tendon healing compared to that of tenocytes and 
undifferentiated MSC. Nevertheless, this in vivo model only provided an indication of 
its potential for tendon repair; future studies are required to evaluate the most effective 
postoperative weight-bearing regime for this reconstruction model and its effect on the 
mechanical strength of the regenerated tendon tissue. Although this study suggests that 
GDF5-induced MSC may be a clinically useful adjunct treatment for tendon repair, the 
intracellular signalling pathways activated upon GDF5 treatment in MSCs, which may 
be related to the observed improvement in tendon healing, remain largely unknown. 
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CHAPTER 5  
RESULTS 3: MICROARRAY AALYSIS OF TEOGEESIS I HUMA 
BOE MARROW-DERIVED MESECHYMAL STEM CELLS: GDF5 
MODULATE CYTOSKELETAL REMODELLIG AD PROLIFERATIO I 
TEOGEIC hMSCs 
 
 
 
 
 
 
 
Part of this chapter has been submitted to: 
Tan S.L., Ahmad T.S., Selvaratnam L., Kamarul T. (2013) Identification of Pathways 
Mediating Growth Differentiation Factor 5-induced Tenogenic Differentiation in 
Human Bone Marrow Stromal Cells. Stem Cells Submitted. 
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5.0 Results 3: Microarray analysis of tenogenesis in human bone marrow-
derived mesenchymal stem cells: GDF5 modulate cytoskeletal remodelling 
and proliferation in tenogenic hMSCs 
5.1 Introduction 
Colorimetric collagen assay, gene expression analysis and immunofluorescence 
staining (as described in Chapter 3), revealed that GDF5 treatment is able to induce 
tenogenesis in both hMSC and rbMSC. Additionally, augmented tendon healing in 
rabbit infraspinatus tendon defects by the GDF5-induced rbMSC was demonstrated in 
the in vivo experiments (as described in chapter 4). Having established that the GDF5 is 
an inductive factor for tenogenesis and that the GDF5-induced rbMSC has an impact on 
tendon repair, it remained to be answered the mechanisms behind the tenogensis 
induced by GDF5. It is reasoned in this current chapter that the signals underlying 
tenogenesis might be involved the transformation of the multipotent hMSCs into the 
tenocytic-behaviour-cells. The cellular cytoskeletal remodelling plays an essential role 
in tenocytes behaviour especially in response to its high tensional loading in vivo 
environment. However, whether the cytoskeletal remodelling or other signalling 
pathway is associated with hMSC in vitro tenogenesis remains to be elucidated. To 
explore this questions, the global gene expression profiles analysis on hMSC cultured 
with and without GDF5 (100 ng/ml) was conducted. Similar to the earlier study design 
in the earlier in vitro study (Chapter 3), the primary native human tenocyte culture was 
used as a positive control for comparison with the tenogenic hMSCs. The control hMSC 
and tenocytes included in the study served as undifferentiated and differentiated 
controls, respectively, in order to increase the specificity of genes identified as regulated 
by the GDF5 treatment and associated with functional tenogenesis. Gene expression 
profiles and signalling pathways analysis were conducted using advanced microarray 
analysis, including an evaluation of the pathways affected.  
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In the actin cytoskeleton remodelling signalling, it has been described that upon 
ligand binding, it induced actin polymerization at the plasma membrane, leading to the 
formation of lamellipodia and membrane ruffles (Nobes & Hall, 1995). The members of 
rho GTPases are responsible for regulating a signal transduction pathway linking 
extracellular growth factors to the assembly of focal adhesions and actin stress fibers 
(Nobes & Hall, 1995; Ridley & Hall, 1992). Furthermore, assembly and spatial 
organization of these highly dynamic structures of polymerized actin have been 
demonstrated to play a role in the differentiation of MSC (Rodriguez et al., 2004; 
Yourek et al., 2007). Based on the microarray analysis, the rho GTPase activating 
protein 29 (ARHGAP29) was one of the up-regulated and co-expressed genes in GDF5-
induced hMSCs (both day 4 and day 10) and tenocytes; it was speculated that the 
cytoskeletal reorganization to be an important event in tenogenesis. In this current 
experiment, the actin cytoskeleton remodelling which involved in the control of cell 
shape and morphology was visualized with atomic force microscopy (AFM) live cell 
imaging and confocal laser scanning microscopy (CLSM) imaging. Various methods 
have been used to visualize the actin cytoskeleton (Small et al., 1999). The AFM 
imaging is a relatively novel and powerful tool that can be used for topographic imaging 
under physiological conditions (Radmacher et al., 1992), it is particularly suitable for 
viewing cytoskeletal remodelling in living cells with minimal sample preparation (no 
labelling, fixing or coating). The subsequent immunofluorescence imaging with CLSM 
allowed the confirmation of the cytoskeleton remodelling observed with the AFM 
analysis was the actin filaments reorganization in the differentiating hMSCs.  
In addition, immunofluorescence staining of nucleostemin (NST) was conducted 
to determine the regulation of cell proliferation in GDF5-induced hMSCs. NST is a 
regulator protein of cell proliferation (Romanova et al., 2009) predominantly associated 
with rat neural and embryonic stem cells, and some cancer cells. Despite NST being 
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reported as a marker of undifferentiated human adult bone marrow stem cells that 
involve in regulating the proliferation of these cells (Kafienah et al., 2006), recent work 
however, has demonstrate that NST is in fact expressed in many normal proliferating 
cells (Fan et al., 2006). Nevertheless, the expression of NST is generally down-
regulated in the early stage of differentiation before exit from the cell cycle (Romanova, 
et al., 2009). The expression of NST in differentiated bone marrow cells has also been 
reported as 70-90% lower than the undifferentiated cells (Kafienah, et al., 2006). 
Herein, the NST expression in GDF5-induced hMSC was evaluated to examine the 
effect of tenogenesis in hMSCs proliferation at day 4 and day 10 of induction by GDF5. 
It was demonstrated here, through the global gene expression profiles analysis of 
tenogenic hMSC that cytoskeletal remodelling and cell adhesion signalling are essential 
for hMSCs tenogenic differentiation, particularly in the expression of the earliest 
tenogenic markers in hMSC. In the event of tenogenesis, the proliferation of hMSCs 
was reduced as evidenced with the reduced in nuscleostemin expression in hMSCs 
underwent tenogenesis. Additionally, it is proposed that EMT pathway is the putative 
pathway which involved in tenogenesis.  
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5.2 Experimental Design 
Genome wide gene expressions were performed on six independent experiments 
with Affymetrix GeneChip® human gene 1.0 ST arrays (HuGene, Affymetrix Inc, 
Santa Clara, CA, USA). The global gene expression profiles for four groups of samples: 
control (untreated) hMSCs, day-4 GDF5-induced hMSCs, and day-10 GDF5-induced 
hMSCs, and human primary tenocytes cultures from hamstring tendons were evaluated. 
For all the four groups of sample, samples from six individual donors were analysed 
(six individual donors for bone marrow samples to isolate hMSCs and six individual 
donors for human hamstring tendon samples to isolate primary native human tenocyte). 
The samples collected for microarray analysis were prepared as depicted in the 
workflow in Figure 5.1. Microarray data (CEL intensity files) were then analysed with 
Limma software package for R for differentially expressed genes, and GeneGo 
Metacore™ Pathway Analysis Software (Thomson Reuters) for pathway analysis. The 
microarray data were then validated by AFM and CLSM imaging as well as 
QuantiGene® Plex 2.0 Assay. 
 
 
5.3 Results 
5.3.1 Global Gene Expression Profiles Analysis 
5.3.1.1 Quality Assessment and ormalization of Microarray Data 
Microarray data pre-processing analysis (Figure 5.2) showed that the target 
prepared hybridized efficiently and specifically onto all arrays. The signals detected for 
the 24 arrays were comparable to one another and no outlier was detected. The total 
number of features detected was 33, 297. The robust multi-array averages (RMA 
expression values) were used to normalize the values in each group (based on the signal 
intensity values). The intensities that were below background signal, absent DABG 
(detected above background) detection calls were omitted.  
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Figure 5.1 Microarray workflow from sample preparation to data analysis and 
validation. 
Total RNA were extracted from all the samples and pre-determined for 
their concentration and integrity before proceed to cDNA amplification 
and labelling. All the labelled cDNA samples were used for targets 
preparation. The prepared targets were subsequently hybridized to the 
arrays, followed by washed, stained and scanned to get the image files. 
The captured microarray image files were analysed via GCOS (Command 
Console and Expression Console; Affymetrix Inc, Santa Clara, CA, USA) 
to get the CEL intensity files. The CEL intensity files were then 
summarized via data pre-processing to get the Robust Multi-array Average 
(RMA) signals (expression values). The significantly differentially 
expressed genes were detected via Limma analysis (Smyth, 2004). 
Pathway analysis was conducted with Partek ® Genomic Suite™ 6.6 beta 
and GeneGO Metacore™ Pathway Analysis software. The microarray data 
was validated with AFM and fluorescence imaging and QuantiGene gene 
expression analysis. 
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 Figure 5.2  Pre-processing and quality control for microarray data. 
A. Positive versus negative ratio of all arrays showed the efficiency and 
specificity of the hybridization in all arrays. Ideally, the value of 
positive versus negative control should be 1. The results showed that 
the efficiency and the specificity of the hybridization in all arrays were 
in the acceptable range (≥0.8).     
B. Spike-in hybridization control plots showed similar intensity in all 
arrays. All arrays were able to detect the spike-in hybridization controls 
in accordance to their respective spike-in quantities (CreX, BioD, Bio C 
and Bio B), indicated that all arrays possessed comparable sensitivity in 
detecting the high and low abundant genes.  
C. Histogram of perfect match for all arrays showed the overall higher or 
lower intensities in all the 24 arrays, with no saturation effects. These 
were the intensities of the probes, prior to normalization and not 
combined to the probe sets yet. The results showed a typical 
distribution of signal intensities; they were never normally distributed. 
As this is a whole genome array, a lot of cell-specific genes were not 
expressed, leading to a lot of probes that gave very low (or no) signal, 
so the distribution curves of the perfect match intensities were 
positively skewed. 
D. Boxplots of log2 ratios for perfect match intensities of all arrays. 
Although some samples, e.g. “hyb02” and “hyb29” showed slightly 
thinker/longer tail than the other samples, all the arrays showed 
comparable distributions, and no sample was identified as outlier. 
E. The bar chart of the percentages of detectable above background 
(DABG) scores for present calls in all the arrays. The percentages of 
DABG ranged within less than 10% difference showed that the 
hybridization in all arrays was of superior quality and DABG among all 
the arrays were comparable. 
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The heatmap of the RMA expression values showed the distance between all the 
arrays, and none of the arrays was detected as an outlier after normalization (Figure 5.3 
A). The dendrogram plots based on the genes those that were significant in at least one 
comparison (i.e. a set of 954 probe sets) showed that the arrays were clustered into 
different clades in the distance tree according to their tissue origin, one clade for bone 
marrows derived hMSC (either with or without GDF5 treatment) and the other clade for 
tendon derived tenocytes (Figure 5.3 B and C). Furthermore, the principle component 
analysis of all 24 arrays demonstrated that the hMSCs of all donors showed the same 
shift in accordance with GDF5 treatment (Figure 5.4). This indicated that the 
discrimination of the arrays observed was not contributed by donor variations but the 
differences were due to the GDF5 supplementation and tissue origin of the cells (i.e. 
tenocytes and hMSC). Following normalization, filtering and omitting the control 
probes, a total of 27, 216 probe sets was retained (Table 5.1). These 27, 216 normalized 
intensity values of different groups were compared with the Limma package of 
Bioconductor (Smyth, 2004) to detect the differential gene expression with the corrected 
p-values for multiple testing using Benjamini-Hochberg method (Benjamini & 
Hochberg, 1995). 
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Figure 5.3  Heatmap and dendrogram of RMA expression values. 
A. The heatmap of RMA values showed comparable level of expression 
of all the genes across all the 24 arrays. The tree diagram on the 
upper panel of the heatmap showed the distances between the 
samples. The colour of the heatmap indicated the between-array 
distances. A colour bar with scales for the heatmap is included, 
indicating that red corresponds to maximum distance and green to 
minimum distance. 
B. The dendrogram plot indicates the Euclidean distance and complete 
linkage with all individual samples. 
C. The dendrogram plot indicates the Euclidean distance and complete 
linkage with average of the four groups. 
(Group 1: Control hMSC, Group 2: Day-4 GDF5-induced hMSC, 
Group 3: Day-10 GDF5-induced hMSC, Group 4: tenocytes) 
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Figure 5.4 Principle component analyses (PCA) of all 24 arrays. 
 PCA analysis was performed on all samples and all probes to 
characterize the variability present in the data. The results showed a 
distinct separation between all the groups. The PCA was visualized in 2D 
view (A) and 3D view (B), with the different colour coded for different 
groups; and the 3D view (C) with the colour coded for different 
individual donor (In the legend, individual 1 to 6 were the bone marrow 
donors and individual 7 to 12 were the tendon donors). Image B and C 
showed that the arrays were grouped according to their experimental 
groups (treatment) but not according to the donor variation. (Group 1: 
Control hMSC, Group 2: Day-4 GDF5-induced hMSC, Group 3: Day-10 
GDF5-induced hMSC, Group 4: tenocytes) 
 
 
Table 5.1 Summary of total number of probe sets or genes before and after data 
normalization and filtering. 
 
Probe Sets Total 
1. Estimated number of genes on array 28,869 
2. Total distinct probe sets on the array 764,885 
3. Positive control probe sets on the array 1,195 
4. Negative control probe sets on the array 2,904 
 
5. Total number of probe sets detected on chip 33,297 
6. Total number of probe sets detected on chip but do not have a 
present DABG detection call 
 
1,320 
7. Total number of probe sets detected on chip after omitted control 
probe sets and probe sets without a present DABG detection call 
 
27,878 
8. Number of probe sets omitted after data filtering 662 
9. Total number of probe sets used to assess differentially 
expressed genes 
 27,216 
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5.3.1.2 Tenogenic Gene Expression Profiles Regulated by GDF5 Treatment 
The results of Limma package of Bioconductor analysis showed that the 
corrected p-value discovered slightly higher number of significant differentially 
expressed genes at p<0.05 than the uncorrected p-value at p<0.001 (Table 5.2; 
Appendix J), except for Group 1 vs 2. The corrected p-values provided a better control 
in the false discovery rate, thus the significant gene lists obtained based on the corrected 
p-value were used for the subsequent analysis (i.e. pathway analysis).  
Table 5.2  A summary of the number of differentially expressed probe sets.  
 Uncorrected p-value <0.001 Corrected p-value<0.05 
 Log-ratio < -1 Log-ratio > 1 Log-ratio < -1 Log-ratio > 1 
Group 1 vs 4 168 159 204 182 
Group 2 vs 4 211 185 268 212 
Group 3 vs 4 324 264 400 291 
Group 1 vs 3 139 98 152 119 
Group 2 vs 3 50 8 50 8 
Group 1 vs 2 19 22 12 19 
(Group 1: Control hMSC, Group 2: Day-4 GDF5-induced hMSC, Group 3: Day-10 
GDF5-induced hMSC, Group 4: tenocytes) 
 
 
 The significantly up- and down- regulated genes were presented in the Venn 
diagrams to show the overlap between all the comparisons with: (1) control hMSC 
(Group 1; Figure 5.5 A) and (2) tenocytes (Group 4; Figure 5.5 B). The Venn diagrams 
showed 9 genes (as compared to control hMSC; Figure 5.5 A) and 236 genes (as 
compared to tenocytes; Figure 5.5 B) associated with tenogenesis by GDF5 treatment; 
of these 3 were up-regulated and 6 were down-regulated when compared to control 
hMSC (Figure 5.5 A); and 130 were up-regulated and 106 were down-regulated when 
compared between tenocytes to hMSCs (Figure 5.5 B). In addition, numerous genes 
associated with tenogenesis which were modulated by GDF5 were identified in 
GDF5-induced hMSCs; both day 4 (21 up-regulated, 24 down-regulated) and day 10 
(17 up-regulated, 9 down-regulated). The genes displayed the most significant changes 
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in expression patterns in the GDF5-induced hMSCs and in tenocytes were listed in 
Table 5.3 with their respective log2 ratio (log2 fold change). 
 
 
Figure 5.5  An overview of significant overlap of differentially expressed genes 
observed between the GDF5-treated groups (Group 2 and 3) and the 
tenocytes group (group 4) in Venn diagrams. 
The microarray experiments were designed to detect differential 
expression of transcripts with GDF5 treatment and were compared with 
Venn diagrams. The list of the significantly (corrected p-value) up- and 
down- regulated genes, were used to detect the altered candidate 
tenogenesis genes within the GDF5-treated groups (Group 2 and 3) as 
depicted in the intersections or uniqueness; between all comparisons with 
control hMSC (as depicted in A) and tenocytes compared to all the other 
groups (as depicted in B). 
 The numbers in each section or intersections of the circles represented 
the total number of significantly differentially up- or down- regulated 
genes for the pairwise comparisons (as denoted above or below each 
circle). The numbers in green and red fonts indicated the significantly up- 
and down-regulated genes, respectively. (G1: Control hMSC; G2: Day-4 
GDF5-induced hMSC; G3: Day-10 GDF5-induced hMSC; G4: 
tenocytes) 
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Table 5.3 The most significantly altered genes in the GDF5-induced hMSC and tenocytes (LR: log2 ratio, p-value: corrected p-value).  
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 Among the significantly co-expressed genes by GDF5-induced hMSCs and 
tenocytes, asporin (ASPN) and integrin alpha 8 (ITGA8) were found to be among the 
top most up- and down- regulated genes, respectively (Table 5.3). Besides, 
neurofilament medium polypeptide (NEFM) was among the most significantly down-
regulated genes in day-4 and day-10 GDF5-induced hMSCs, although not appeared to 
be the top most down-regulated genes in tenocytes, it was significantly down-regulated 
in tenocytes. Besides, the rho GTPase activating protein 29 (ARHGAP29) and 
chemokine (C-C motif) ligand 2 (CCL2) were up-regulated and co-expressed in all the 
GDF5 treated hMSCs and tenocytes. These genes have been reported to associate with 
actin cytoskeleton reorganization (stress fibers formation) (Stamatovic et al., 2003). 
Overall, all the co-expressed genes were involved direct or indirectly with collagen 
fibrillogenesis (Velling et al., 2002) and cytoskeletal remodelling signalling (Moon & 
Zheng, 2003; Stamatovic, et al., 2003). Therefore, these findings suggested a crucial 
role played by collagen fibrillogenesis and cytoskeletal remodelling in directing hMSC 
into tenogenic cell fate. A complete list of genes significantly modulated during 
tenogenesis by GDF5 treatment can be found in Appendix K.  
 
5.3.1.3 Tenogenesis Pathways Associated with GDF5-induced hMSC 
In this section, the complex signalling mechanisms involved in GDF5-induced 
hMSCs (day 4 and day 10) and in native tenocytes, as captured by pathway analysis are 
presented (Table 5.4). The pathway analysis was based on the significantly up- or down- 
regulated gene lists where corrected-p<0.05 and at least fold change of 2 (or log2 ratio at 
least 1.0 for up-regulated genes) or fold change less than 0.5 (or log2 ratio less than -1.0 
for down-regulated genes). A total of 8 pathways (p<0.001) were regulated at day 4 of 
induction by GDF5.  
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Table 5.4 Pathways regulated by GDF5-induced tenogensis in hMSC. 
Pathway regulated in hMSC at day 4 of 100 ng/ml GDF5 treatment (Total= 8 pathways) 
Pathway name Genes involved p-value 
Cholesterol biosynthesis FDPS↑, SC4MOL↑, ERG1↑ 3.603E-04 
Glycolysis and gluconeogenesis p.3 / Human version ENO↓, ENO2↓ 6.822E-04 
Glycolysis and gluconeogenesis p.3 ENO↓, ENO2↓ 6.822E-04 
Immune response_TREM1 signalling pathway PI3K reg class IA↑, CCL2↑ 4.092E-03 
Immune response_IL-17 signalling pathways PI3K reg class IA↑, CCL2↑ 4.229E-03 
Glycolysis and gluconeogenesis (short map) ENO2↓ 5.096E-03 
Development_VEGF signaling via VEGFR2 - generic 
cascades 
PI3K reg class IA↑, CCL2↑  8.143E-03 
Regulation of lipid metabolism_Insulin regulation of fatty acid 
methabolism 
PI3K reg class IA↑, FADS2↑ 9.105E-03 
 
Pathway regulated in hMSC at day 10 of 100 ng/ml GDF5 treatment (Total= 21 pathways) 
Pathway name Genes involved p-value 
Cell cycle_Role of APC in cell cycle regulation PLK1↓, BUBR1↓, Aurora-A↓, Cyclin A↓, Cyclin B↓, Nek2A↓, Securin↓, APC↓, 
CDC18L(CDC6)↑  
3.540E-10  
Cell cycle_The metaphase checkpoint Survivin↓, Aurora-A↓, Nek2A↓, PLK1↓, BUB1↓, BUBR1↓, AF15q14↓, CENP-F↓ 2.731E-08 
Cell cycle_Chromosome condensation in prometaphase Cyclin A↓, Cyclin B↓, CAP-G↓, Aurora-A↓, CAP-G/G2↓, Condensin↓, TOP2↓ 3.203E-07 
Cholesterol Biosynthesis IDI1↑, HMGCS1↑, HMDH↑, ERG1↑, FDPS↑, SC4MOL↑, SC5D↑ 2.325E-04 
Cell cycle_Initiation of mitosis PLK1↓, Wee1↓, FOXM1↓, Cyclin B2↓ 3.811E-04 
Immune response_Antiviral actions of Interferons OAS1↑, OAS2↑, OAS3↑, 2′-5′-oligoadenylate synthetase↑, MxA↑ 7.921E-04 
Cell cycle_Role of Nek in cell cycle regulation PI3K reg class IA↑, Nek2A↓, tubulin beta↑, Aurora-A↓ 1.004E-03 
Cell cycle_Spindle assembly and chromosome separation Anaphase-promoting complex (APC)↓, Nek2A↓, Securin↓, Aurora-A↓ 1.130E-03 
Development_Angiopoietin - Tie2 signaling Angiopoietin 3↑, PI3K reg class IA↑, Grb14↑, Survivin↓  1.415E-03 
Development_TGF-beta-dependent induction of EMT via 
SMADs 
Endothelin-1↓, SMAD3↓, ID2↓, E-cadherin↑  1.415E-03 
Cytoskeleton remodeling_Keratin filaments Tubulin beta↑, Keratin 14↑, Keratin 16↑, Kereatin 17↑ 1.575E-03 
Cell cycle_Regulation of G1/S transition (part 1) Anaphase-promoting complex (APC) ↓, PP2A regulatory↑, SMAD3↓, Cyclin A↓, 
CDK6↑ 
1.931E-03 
Cell cycle_Cell cycle (generic schema) CDK6↑, CyclinA↓, Cyclin B↓  3.038E-03 
 153 
 
Table 5.4 continued   
   
Immune response_NF-AT signaling and leukocyte interactions NF-AT1↑, cPAL2↑, Ca(II) channel↑, Eotaxin↑  3.914E-03 
Immune response _CCR3 signaling in eosinophils Eotaxin↑, Eotaxin 3↑, Rac2↓, MyHC↑, Myosin II ↑ 4.553E-03 
Arachidonic acid production FADS1↑, PA24A↑, cPLA2↑, PLA2↑ 5.290E-03 
DNA damage_ATM / ATR regulation of G2 / M checkpoint Wee1↓, Cyclin A↓, Cyclin B↓ 5.643E-03 
Cell cycle_Transition and termination of DNA replication Cyclin A↓, TOP1 alpha↓, TOP2↓ 6.966E-03 
Immune response_Innate immune response to RNA viral 
infection 
TLR3↓, RIG-I↓, MDA-5↓ 6.966E-03 
Cell cycle_Role of SCF complex in cell cycle regulation APC↓, PLK1↓, Wee1↓ 7.690E-03 
Immune response_TREM1 signaling pathway TLR4↓, PI3K reg class IA↑, CCL2↑, NFATC2↑  9.488E-03 
 
Pathway regulated in tenocytes (Total= 18 pathways) 
Pathway name Genes involved p-value 
Immune response_Alternative complement pathway C3↑, C3a↑, iC3b↑, C3c↑, C3dg↑, C3b↑, C5 convertase (C3bBb)↑, Clusterin↑ 1.129E-07 
Immune response_Lectin induced complement pathway C3↑, C3a↑, C3b↑, C3c↑, C3dg↑, iC3b↑, DAF↑, C5 convertase (C2aC4bC3b)↑  7.265E-07 
Immune response_Classical complement pathway C3↑, C3a↑, C3b↑, C3c↑, C3dg↑, iC3b↑, DAF↑, C5 convertase (C2aC4bC3b)↑ 1.166E-06 
Development_Regulation of epithelial-to-mesenchymal 
transition (EMT) 
HGF↓, WNT↓, Jagged1↓, TGF-beta 3↑, Endothelin-1↓, ENDRA↓, ACTA2 ↓ 5.553E-05 
Immune response_MIF-mediated glucocorticoid regulation I-kB↑, NFKBIA↑, IL-8↑, VCAM↓ 3.282E-04 
Development_TGF-beta-dependent induction of EMT via 
SMADs 
Endothelin-1↓ , TGF-beta↑, TGF-beta 3↑, Jagged1↓ 2.010E-03 
Transcription_Role of AP-1 in regulation of cellular 
metabolism 
ITGA2↑, TSG-6↑, GCL cat↑, GCL reg↑ 2.733E-03 
Apoptosis and survival_Lymphotoxin-beta receptor signaling IL-8↑, I-kB↑, VCAM↓, SDF-1↓  3.951E-03 
Cell adhesion_Ephrin signaling Ephrin-B↓, Ephrin-B receptors↑, Ephrin-B receptor 1↑, Ephrin-A receptors↓ 5.075E-03 
Immune response_PGE2 signaling in immune response PGE2R2↑, PGES↓, IL-8↑,  HGF↓ 5.075E-03 
Development_TGF-beta-dependent induction of EMT via 
RhoA,  PI3K and ILK. 
TGF-beta 3↑, ACTA2↓, I-kB↑, Actin↓ 5.492E-03 
Immune response_Histamine H1 receptor signaling in immune 
response 
IL-8↑, VCAM1↓, NFKBIA↑, I-kB↑  6.394E-03 
Muscle contraction_Relaxin signaling pathway Endothelin-1↓, PDE4D↑, NFKBIA↑, I-kB↑ 6.394E-03 
Development_PEDF signaling PEDF (serpinF1)↑, NFKBIA↑, c-IAP2↑, BDNF↓ 6.881E-03 
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Table 5.4 continued   
   
Development_Cross-talk between VEGF and Angiopoietin 1 
signaling pathways 
VCAM1↓, I-kB↑, Angiopoietin 1↓  7.347E-03 
Development_S1P2 and S1P3 receptors in cell proliferation 
and differentiation 
ACTA2↓, Transgelin↓, Actin↓ 7.347E-03 
Immune response_HMGB1/RAGE signaling pathway VCAM1↓, I-kB↑, NFKBIA↑, IL-8↑ 9.068E-03 
Muscle contraction_GPCRs in the regulation of smooth 
muscle tone 
 Endothelin-1↓, ENDRA↓, PGE2R2↑, MRLC↓, Myosin II↓   9.278E-03 
   
Pathway regulated in GDF5-induced hMSC (day 4 and day 10) (Total= 3 pathways) 
 
Pathway name 
 
Change 
p-value 
GDF5-induced 
hMSC (Day 4) 
GDF5-induced 
hMSC (Day 10) 
Day 10 vs day 4 
Development_Angiopoietin - Tie2 signaling + 5.622E-2 1.415E-3 8.316E-2 
Development_TGF-beta-dependent induction of EMT via SMADs + 5.622E-2 1.415E-3 8.316E-2 
Immune response_IL-13 signaling via JAK-STAT + 7.019E-2 2.393E-2 5.175E-3 
     
   
Pathway regulated in GDF5-induced hMSC (day 4 and day 10) and tenocytes (Total= 11 pathways) 
 
Pathway name 
 
Change 
p-value 
GDF5-induced 
hMSC (Day 4) 
GDF5-induced 
hMSC (Day 10) 
Tenocytes 
Glycolysis and gluconeogenesis p.3 / Human version - 6.822E-4 4.463E-2 5.296E-2 
Glycolysis and gluconeogenesis p.3 - 6.822E-4 4.463E-2 5.296E-2 
Cell cycle_Role of Nek in cell cycle regulation + 5.152E-2 1.004E-3 8.790E-2 
Development_Angiopoietin - Tie2 signaling + 5.622E-2 1.415E-3 1.024E-1 
Development_TGF-beta-dependent induction of EMT via SMADs + 5.622E-2 1.415E-3 2.010E-3 
Immune response_TREM1 signaling pathway + 4.092E-3 9.488E-3 1.313E-2 
Immune response_IL-17 signaling pathways + 4.229E-3 2.078E-1 1.390E-2 
Glycolysis and gluconeogenesis (short map) - 5.096E-3 6.630E-2 2.738E-1 
Development_PEDF signaling + 7.787E-2 5.030E-1 6.881E-3 
Development_VEGF signaling via VEGFR2 - generic cascades + 8.143E-3 1.155E-1 3.765E-1 
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Table 5.4 continued     
     
Regulation of lipid metabolism_Insulin regulation of fatty acid methabolism + 9.105E-3 3.592E-1 7.538E-1 
     
   
Pathway regulated in tenocytes compared to GDF5-induced hMSC (day 4 and day 10) (Total= 41 pathways) 
 
Pathway name 
 
Change 
p-value 
Tenocytes vs control 
hMSC 
Tenocytes vs GDF5-
induced hMSC 
(Day4) 
Tenocytes vs GDF5-
induced hMSC 
(Day 10) 
Cell cycle_Chromosome condensation in prometaphase + 2.806E-1 1.132E-7 2.303E-12 
Cell cycle_Role of APC in cell cycle regulation + 3.948E-1 1.365E-1 1.134E-8 
Cell cycle_Initiation of mitosis + 5.699E-2 8.134E-6 1.519E-8 
Immune response_Alternative complement pathway + 1.129E-7 1.866E-1 7.618E-4 
Immune response_Lectin induced complement pathway + 7.265E-7 2.614E-1 1.259E-2 
Immune response_Classical complement pathway + 1.166E-6 2.840E-1 1.602E-2 
Development_TGF-beta-dependent induction of EMT via SMADs + 2.010E-3 1.576E-1 4.825E-6 
Development_Regulation of epithelial-to-mesenchymal transition (EMT) - 5.553E-5 2.906E-4 1.190E-5 
Immune response_MIF-mediated glucocorticoid regulation + 3.282E-4 6.401E-5 2.618E-5 
Immune response_Histamine H1 receptor signaling in immune response + 6.394E-3 4.521E-5 2.313E-3 
Cell adhesion_ECM remodeling + 4.671E-2 7.675E-5 6.418E-4 
Cell cycle_Role of Nek in cell cycle regulation + 8.790E-2 1.365E-1 2.501E-4 
DNA damage_ATM/ATR regulation of G1/S checkpoint + 3.948E-1 1.365E-1 2.501E-4 
Cell cycle_Sister chromatid cohesion + 2.918E-1 9.471E-3 3.251E-4 
GTP metabolism - 5.128E-2 7.298E-4 6.803E-2 
Transcription_Role of AP-1 in regulation of cellular metabolism + 2.733E-3 9.389E-4 2.968E-1 
Cell cycle_Role of SCF complex in cell cycle regulation + 3.656E-1 4.481E-1 1.245E-3 
Apoptosis and survival_Lymphotoxin-beta receptor signaling + 3.951E-3 1.491E-3 1.179E-1 
Transcription_Role of VDR in regulation of genes involved in osteoporosis - 6.889E-2 3.513E-1 1.683E-3 
Immune response_IL-1 signaling pathway + 3.059E-2 1.842E-3 1.306E-1 
Development_TGF-beta-dependent induction of EMT via RhoA,  PI3K and 
ILK. 
+ 5.492E-3 6.578E-2 1.851E-3 
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↑ Up-regulated; ↓ Down-regulated 
Table 5.4 continued 
     
Development_NOTCH1-mediated pathway for NF-KB activity modulation + 1.546E-2 4.689E-3 2.597E-3 
Immune response_Gastrin in inflammatory response + 2.216E-2 2.639E-3 1.348E-1 
Immune response_HMGB1/RAGE signaling pathway + 9.068E-3 4.206E-3 1.729E-2 
Cell adhesion_Cell-matrix glycoconjugates + 1.174E-1 4.104E-2 4.270E-3 
Airway smooth muscle contraction in asthma - 5.606E-2 1.041E-1 5.062E-3 
Cell adhesion_Ephrin signaling + 5.075E-3 1.269E-2 3.898E-2 
Immune response_PGE2 signaling in immune response + 5.075E-3 1.269E-2 1.372E-1 
Immune response_Role of PKR in stress-induced antiviral cell response + 5.853E-2 5.753E-3 2.229E-1 
Cell adhesion_Tight junctions + 1.803E-2 5.772E-3 2.754E-1 
Cell adhesion_Cadherin-mediated cell adhesion + 6.113E-2 1.507E-2 5.953E-3 
Muscle contraction_Delta-type opioid receptor in smooth muscle 
contraction 
- 6.113E-2 1.507E-2 5.953E-3 
Development_S1P2 and S1P3 receptors in cell proliferation and 
differentiation 
- 7.347E-3 1.507E-2 5.953E-3 
Muscle contraction_Relaxin signaling pathway + 6.394E-3 1.582E-2 1.574E-1 
Development_PEDF signaling + 6.881E-3 6.341E-1 5.080E-2 
Immune response_IL-17 signaling pathways + 1.390E-2 7.148E-3 2.804E-2 
Development_Cross-talk between VEGF and Angiopoietin 1 signaling 
pathways 
+ 7.347E-3 1.507E-2 3.704E-2 
Cell adhesion_PLAU signaling + 1.226E-1 7.691E-3 2.455E-2 
Transport_Macropinocytosis regulation by growth factors + 7.437E-2 3.841E-2 8.979E-3 
Muscle contraction_GPCRs in the regulation of smooth muscle tone - 9.278E-3 2.627E-2 9.435E-3 
Apoptosis and survival_Granzyme A signaling + 3.755E-1 2.220E-2 9.983E-3 
Cell cycle_Chromosome condensation in prometaphase + 2.806E-1 1.132E-7 2.303E-12 
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Of particular relevance is the activation of vascular endothelial growth factor 
(VEGF) signalling via VEGFR2 generic cascade. VEGF is found expressed in tendon 
sheath fibroblasts and the expression of VEGF is increased in early tendon healing 
process (Bidder et al., 2000). Besides, it has been suggested as one of the important 
regulators of gene activation (Kjaer, 2004). Activation of this pathway may thus 
potentially be involved in early stage of tenogenesis induced by GDF5. Besides, a 
down-regulation in the glycolysis and gluconeogenesis pathway was found. Although, 
there is no study available focusing on the role of glycolysis during early hMSC 
differentiation, this observation can be explained by MSCs are more glycolytic than 
differentiated fibroblasts (Funes et al., 2007). 
At day 10 of GDF5 treatment, a total of 21 pathways (p<0.001) were regulated, 
among which cell cycle related signalling pathways (i.e. the metaphase checkpoint 
signalling, chromosome condensation in prometaphase signalling, initiation of mitosis 
signalling as well as spindle assembly and chromosome separation signalling) were 
down-regulated and development related TGF-β-dependent induction of EMT via 
SMADs signalling, angiopoietin - Tie2 signalling, cytoskeleton remodelling keratin 
filaments signalling, arachidonic acid production signalling were activated. Extensive 
cell-cell contact or depletion of nutrients from the culture medium has been shown to 
induce transient/reversible growth arrest (or cell cycle arrest). However, a more 
physiological mechanism, a reciprocal regulation of cell proliferation and differentiation 
occurs (Owen et al., 1990), when cells undergo differentiation. The growth arrest in the 
G1 phase of the cell cycle has been reported to be associated with expression of the 
differentiated phenotype in many cell types (Filipak et al., 1989; Myster & Duronio, 
2000; Nadal-Ginard, 1978); and the stem cells must growth arrest (predifferentiation 
growth arrest) at a distinct cell cycle state prior to differentiation (Filipak, et al., 1989). 
Thus, the down-regulation of cell cycle related pathways at day 10 of GDF5 treatment 
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was not unexpected. Whereas, the developmental related pathway, EMT pathway in 
particular, plays crucial roles in the formation of body plan (a characteristic process of 
vertebrate gastrulation) (Behr et al., 2005) and in the differentiation process of multiple 
tissue and organs (Thiery et al., 2009). The occurrence of EMT has been reported in 
mesodermal fate program, where the somites (one of the transient structures) will 
undergo secondary EMT, leading to the generation of mesenchymal cells that 
differentiate into specific cell types, i.e. tendon (Acloque et al., 2009; Thiery, et al., 
2009). In addition, amniotic epithelial cells can stepwise differentiate in vitro into 
tenocytes through EMT (Barboni et al., 2012). Therefore, it is suggested that the EMT 
may be required for the adult stem cells (ie. hMSC) to differentiate into tenogenic 
lineage. Angiopoietin - Tie2 signalling pathway has been demonstrated to play a critical 
role in the maintenance of hematopoietic stem cells in a quiescent state in the bone 
marrow niche (Arai et al., 2004) and it also has a protective effect on MSC which is 
crucial to MSC survival (Liu et al., 2008). The activation of angiopoietin - Tie2 
signalling together with the down regulation of cell cycle related pathway, may suggest 
that the angiopoietin - Tie2 signalling plays a protective role when the hMSC exit the 
cell cycle and undergo differentiation. Rapid keratin-network adaptation has recently 
been reported to be crucial in migrating cells and for adaptation to varying environment 
conditions for example, during development or under mechanical stress in epithelia 
(Kolsch et al., 2010) and hepatocyte (Galarneau et al., 2007; Loranger et al., 1997). The 
activation of cytoskeleton remodelling related keratin filaments signalling in this current 
experiment may suggest a crucial role of keratin filament reorganization in hMSCs 
during early tenogenic differentiation. The arachidonic acid production signalling is 
suggested to play an important role in tenocyte behaviour (Cilli et al., 2004; Khan et al., 
2005). This is because the arachidonic acid is an initial molecule in a cascade that 
involved phospholipase A2 (PLA2) and produces prostaglandin-E2 (PGE2) (Kaiser, 
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1999). This PGE2 has an effect in the proliferation and collagen production of human 
tendon fibroblast (Cilli, et al., 2004). Thus, the activation of arachidonic acid signalling 
in the GDF5-induced hMSCs may play an essential role in collagen production during 
tenogenesis. Further, cytosolic PLA2 (cPLA2) and secretory PLA2 (sPLA2) are involved 
in the production of other inflammatory mediators, apart from the PGE2. Therefore, this 
could possibly explain the occurrence of the immune response pathways identified in 
this current experiment (Table 5.4). 
The GDF5-induced hMSC (day 4 and 10) and tenocytes together showed 
regulation of 11 pathways. Down-regulation of glycolysis signalling in the 
GDF5-induced hMSCs is thereby relevant to tenogenesis, as the tenocytes also 
demonstrated a down-regulation in the glycolysis signalling, similar to that observed in 
the day-4 GDF5-induced hMSC. This again explained that the hMSCs are more 
glycolytic than primary human tenocytes. Thus, upon induction by GDF5, the hMSCs 
underwent tenogenesis, which subsequently exhibited lower glycolytic activities than 
the control hMSCs. In addition, of particular relevance was the activation of 
development related angiopoietin - Tie2 signalling, TGF-beta-dependent induction of 
EMT via SMADs, VEGF signalling via VEGFR2 and pigment epithelium-derived 
factor (PEDF) signalling. It is suggested that activation of these pathways would 
promotes tenogenic differentiation. The activation of PEDF signalling was relevant for 
it has a crucial role in angiogenesis inhibition (Bouck, 2002). Activation of this pathway 
may potentially be involved in the response of hMSC to the angiogenesis effect of 
GDF5 (Yamashita et al., 1997). It is important to emphasize that tenomodulin, as one of 
the tenogenic markers, is also an anti-angiogenic molecule (Oshima et al., 2003; 
Shukunami et al., 2005). In addition, the PEDF is a new identified adipokine. At 
physiological concentration, this protein also inhibits adipocyte differentiation, and 
down regulates the adipocyte markers (Wang et al., 2009). Therefore, the activation of 
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this PEDF signalling pathway was suggested to be crucial to promote tenogenesis in 
GDF5-induced hMSCs via inhibition on both angiogenesis and adipogenic 
differentiation. Furthermore, the cell adhesion signalling and cytoskeletal remodelling 
signalling were also activated in the GDF5-induced hMSCs and in native tenocytes (not 
shown in table); despite at a lower significance level (p=0.01 and p=0.05, respectively). 
These pathways were associated with tenocyte behaviour as cell adhesion and 
cytoskeletal remodelling are particularly important in the survival of the tendon cells 
which reside in the high tensional loading tissue.  
As an extension to determine the pathways associated with the late tenogenic 
differentiation or mature tenocytes, the significantly up- or down regulated gene lists 
obtained from comparing tenocytes to GDF5-induced hMSC were analyzed. In matured 
tenocytes, the activated pathways were: (i) development related TGF-β-dependent 
induction of EMT via SMADs signalling, TGF-β-dependent induction of EMT via 
RhoA, PI3K and ILK signalling, PEDF signalling, cross-talk between VEGF and 
angiopoietin 1 signalling, (ii) cell adhesion related ECM remodelling signalling, cell-
matrix glycoconjugates signalling, Ephrin signalling, tight junctions signalling, 
cadherin-mediated cell adhesion signalling, PLAU signalling and (iii) cell cycle related 
(i.e. chromosome condensation in prometaphase signalling, role of APC in cell cycle 
regulation signalling, initiation of mitosis signalling, ATM/ATR regulation of G1/S 
checkpoint signalling, sister chromatid cohesion signalling and  role of SCF complex in 
cell cycle regulation signalling) pathways. Whereas, the down-regulated pathways were 
muscle contraction delta-type opioid receptor in smooth muscle signalling, muscle 
contraction related GPCRs in the regulation of smooth muscle tone signalling, and 
development related S1P2 and S1P3 receptors in cell proliferation and differentiation 
signalling. The activated pathways which were development related were consistent to 
the pathways identified from the day-4 or day-10 GDF5-induced hMSCs, except the 
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PEDF signalling. PEDF signalling was only up-regulated at in the tenocytes. This 
suggests that the PEDF signalling may be involved in the late tenogenic differentiation 
or in mature tenocytes phenotypes. However, in contrary to the effect of day 10 GDF5 
treatment (or early tenogenesis), the cell cycle related pathways were up-regulated in 
the mature tenocytes. Activation of cell cycle signalling in tenocytes suggests that active 
maintenance of cell-cycle as an important aspect of the differentiated tenocytes and 
there may be a temporal coupling between withdrawal from the cell cycle and tenogenic 
differentiation as previously described in stem cells differentiation events (Filipak, et 
al., 1989; Myster & Duronio, 2000). A reciprocal and functionally coupled relationship 
between proliferation and differentiation has been demonstrated in fetal calvarial 
derived osteoblasts (Owen, et al., 1990). It is, therefore, postulated that there is a 
reciprocal mechanism for coordinating the temporal sequence of cell cycle and 
differentiation events during tenogenesis, which remains to be explored.  
Apart from the development and cell cycle related signalling, the activated 
pathways also involved ECM remodelling signalling and cell adhesion signalling which 
were two crucial phenotypes that the mature tenocytes must possess. These 
characteristics are crucial for the tenocytes to maintain its integrity and physical 
resistance to mechanical stress in their native tendon tissue. Hence, the conversion of 
biochemical signals (GDF5 induction) into the cytoskeletal remodelling is important for 
maturation of tenogenic hMSCs, especially in cytoskeletal-ECM linkage. The pathways 
related to ECM remodelling via direct or indirect connections between internal actin 
cytoskeleton and ECM in tenocytes were such as cell adhesion related integrin inside-
out signalling, cytoskeleton remodelling signalling and regulation of actin cytoskeleton 
by Rho GTPases signalling, which involved significantly regulated transcripts, i.e. type-
I collagen, alpha-2/beta-1 integrin, alpha-10/beta-1 integrin, actin and laminin 1. The 
regulation of actin cytoskeleton by Rho GTPases signalling has been implicated in 
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lamellipodium and stress fiber formation in mammalian cells (Kaibuchi et al., 1999; 
Nobes & Hall, 1995). Activation of this pathway may thus potentially be involved in the 
lamellipodium and stress fiber formation in the mature tenocytes. Other cell adhesion 
related pathways activated in the mature tenocytes (cell-matrix glycoconjugates, ephrin 
signalling, tight junctions, cadherin-mediated cell adhesion and PLAU signalling) also 
play an important role in cytoskeleton-ECM linkage in tenocytes. Down regulation of 
muscle contraction and development related signalling were consistent with mature 
tenocyte phenotype.  
 
5.3.1.4 Candidate Tenogenic and on-Tenogenic Markers Expression Profiles 
Apart from the most significantly up- or down- regulated genes and pathways, 
the changes in the expression profiles in ECM related genes as well as candidate 
tenogenic and non-tenogenic marker genes in GDF5-induced hMSCs were also 
analysed. Graphical representation of log2 ratios detected by microarray analysis is 
shown in Figure 5.6. Among these genes, type-I collagen alpha 1 (Col-I a1), type-II 
collagen alpha 1 (Col-II), type-III collagen alpha 1 (Col-III a1) and matrix 
metallopeptidase 3 (Mmp3) were related to ECM;  thrombospondin 4 (Thbs4), mohawk 
homeobox (Mkx), tenomodulin (Tnmd), scleraxis (Scx) and tenascin C (Tnc) were 
candidate tenogenic marker genes; peroxisome proliferator-activated receptor gamma 
(Pparg), SRY (Sex determining region Y)-box 9 (Sox9), cartilage oligomeric matrix 
protein (Comp), Runt-related transcription factor 2 (Runx2), bone gamma-
carboxyglutamate protein (Bglap) and alkaline phosphatase liver (Alpl) were the non-
tenogenic marker genes; and c-fos induced growth factor (Figf or Vegf-d) were related 
to chondrogenesis (Bluteau et al., 2007), osteogenesis (Orlandini et al., 2006) and 
tenocyte proliferation (Luo et al., 2009).  
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Figure 5.6   Expression levels of the ECM related, candidate tenogenic and non-tenogenic marker genes based on microarray analysis. 
 The graphical representation of genes (n=16) displaying changes in expression patterns in hMSC in response to GDF5 treatment with their 
respective log2 ratio based on microarray analysis. The genes which showed at least fold change of 2 (log2 ratio=1, red dotted line) and fold 
change of less than 0.5 (log2 ratio=-1, green dotted line) were regarded as significantly up- and down- regulated genes respectively. 
 164 
 
The Col-I and Col-III were significantly up-regulated in the day-10 GDF5-
induced hMSCs, among the ECM related genes. A down-regulation of Col-I in 
tenocytes indicated that the production of Col-I were reduced in mature tenocytes 
compared to the control hMSC and the early differentiating tenogenic hMSCs. 
Nevertheless, the Mmp3, which play a role in the normal maintenance and remodelling 
of tendon ECM, was up-regulated in the tenocytes, but weakly expressed in the GDF5-
induced hMSCs.  
Among the tenogenic marker genes, only Tnc was detected as up-regulated in 
the GDF5-induced hMSCs. Whereas in the mature tenocytes, the Thbs4 and Mkx was 
detected as highly up-regulated transcript compared to the other genes. The expression 
level of Tnc in tenocytes was higher than the control hMSCs despite not being above the 
cut-off level. The non-tenogenic marker genes were generally weakly expressed among 
the GDF5-induced hMSC and tenocytes, except for Comp and Runx2. The expression 
levels of Comp was significantly up-regulated in day-10 GDF5-induced hMSC, while 
the Runx2 was significantly down regulated in tenocytes. The rest of the other genes, 
including the Figf, were detected as weakly expressed and not significantly up- or 
down- regulated. 
 
5.3.2 AFM and CLSM Imaging in hMSCs During Tenogenesis 
5.3.2.1 Cytoskeletal Remodelling in GDF5-induced hMSCs 
The control hMSCs, day-4 GDF5-induced hMSCs, day-10 GDF5-induced 
hMSCs and tenocytes were cultured in respective media and scanned with AFM 
imaging. Upon differentiation, there were evident differences in the topography between 
undifferentiated hMSCs and their GDF5-induced counterparts (Figure 5.7). Overall, the 
scanning in topography revealed a higher height scale in control hMSCs as compared to 
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that of the GDF5 treated hMSCs and tenocytes, which may particularly related to their 
cytoskeleton organization.  
 
Figure 5.7   Cytoskeleton reorganization in hMSCs visualized by AFM. 
Representative AFM topography scanning of control hMSCs (left upper), 
hMSCs at day 4 of induction by GDF5 (right upper), hMSCs at day 10 of 
induction by GDF5 (left lower) and tenocyte. In the topography images, 
brighter colour indicated higher distance off of substrate (cover slip). The 
panel on the right side of each image indicated the height scale (z-scale) of 
the topography. There was a marked difference in the topography 
(cytoskeleton organization) of the control hMSCs compared to the hMSCs 
exposed to GDF5. The topography of control hMSCs had a larger z-scale; 
apparently possessed higher morphology. Both control hMSCs and day-4 
GDF5-induced hMSCs showed detailed tree-like web structure of 
presumably the actin network under the cell membrane especially at the 
leading edges which strongly attached on the cover slip (black arrowheads). 
The GDF5-induced hMSCs possessed more flatten morphology because 
they adhered more strongly via the stress fibers that could be visualized just 
under the surface of the cell membrane (white arrowheads). The detailed 
structure of presumably the actin cytoskeleton (actin bundles or stress 
fibers) could be observed in the day-10 GDF5-induced hMSCs and 
tenocytes. 
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At day-4 GDF5-induced hMSCs, similar cell surface topography to that of 
control hMSCs were observed, with a tree-like web structure of presumably actin 
network. There was a tremendous change in cell surface topography of day-10 GDF5-
induced hMSCs. The day-10 GDF5-induced hMSCs showed similar cell surface 
topography to that of tenocytes, which both revealed bundle structure of presumably the 
stress fibers at the leading edge. These results suggests that the hMSCs underwent 
tenogenesis and continued reorganizing their cytoskeleton which allowed them to 
adhere more strongly to the substrate (cover slip) and subsequently displayed a more 
flatten morphology compared to the control hMSCs. To further confirm that the 
structures visualized under AFM were actin filaments, fluorescence imaging was 
conducted. 
  The fluorescence images obtained by CLSM (Figure 5.8) shadowed those 
images obtained by AFM imaging (Figure 5.7). The CLSM analysis demonstrated that 
the GDF5-induced hMSCs possessed stress fiber arrays which localised primarily next 
to the cell attachment site (Figure 5.8). However the abundance of this stress fiber 
arrays appeared low in the control hMSCs, which displayed more cortical cytoplasmic 
actin (or actin filament meshwork). Following extended GDF5 treatment on day 10, 
hMSCs displayed long, thin stress fibres, similar to that in tenocytes. These 
observations suggested that GDF5-induced a reorganization of actin structures which 
involved F-actin polymerization and restructuring of cortical actin elements to newly 
formed stress fibres. 
 
5.3.2.2 Down Regulation of ucleostemin in Early Stage of Tenogenesis in hMSCs  
The nucleostemin (NST) expression was decreased in day-4 and day-10 GDF5-
induced hMSCs (Figure 5.8), but persistently expressed in the untreated hMSC (at day 4 
and day 10). The NST expression was also remained high in tenocytes.  
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Figure 5.8  Actin cytoskeleton reorganization and nucleostemin (ST) expression in 
hMSCs upon induction by GDF5 captured with confocal laser scanning 
microscope.   
 Representative images of sequential scanning: nucleus stained with 
Hoescht 33342 (first panel on the left), nucleostemin (NST) (with indirect 
FITC stain; second panel) and actin fibres (direct staining which 
specifically stained cellular F-actin; third panel) and the merged image of 
all channels (last panel on the right). Scale bar=50µm (at 100x objective). 
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GDF5-induced hMSCs showed a reduction in the NST expression, which is 
parallel with the cytoskeletal reorganization. This finding suggests that the proliferation 
of hMSCs was reduced upon tenogenic differentiations.  
 
 
5.3.2.3 Gene Expression Validation with QuantiGene® Plex 2.0 Assay 
In order to validate the gene expression profiling results from microarray 
analysis, selected candidate tenogenic marker and non-tenogenic marker genes were 
quantified using QuantiGene® Plex 2.0 Assay (n=6). Among the 12 targets measured, 
only 9 targets were detected above the limit of detection (LOD). Three targets (Col2a1, 
Figf and Tnmd) were detected as absent calls in all the samples, hence were excluded 
from fold change analysis. The rest of the other 9 targets were detected in all the 
samples (all the 6 samples in each group), except Scx and Mmp3 were only detected in 3 
samples among the 6 samples measured (Figure 5.9).  
 
Figure 5.9   Expression levels of selected candidate tenogenic and non-tenogenic marker 
genes (n=9) based on microarray and QuantiGene® Plex 2.0 Assay. 
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Figure 5.9, continued 
 
(A) The graphical representation of genes expression patterns in hMSCs in 
response to induction by GDF5; with their respective log2 ratio based on 
microarray analysis.  
(B) Gene expression profiles independently validated using QuantiGene® 
Plex assay presented in log2 ratio. Expression variation for each gene 
was visualized with standard deviation. 
 
 
The gene expression levels detected with QuantiGene® Plex assay was 
relatively higher compared to that of microarray analysis. Overall, the gene expression 
profiles obtained from QuantiGene® Plex assay were consistent with the microarray 
results in Tnc, Mmp3, Runx2 and Alpl, but showed some differences in the expression 
profiles for Scx, Pparγ, Sox9, Comp and Bglap. Considering that Scx and Mmp3 were 
derived from three biological samples compared to that of microarray which was 
derived from six bioloigical samples, the variation in the expression profiles was not 
unexpected. Whereas the Pparγ, Sox9 and Bglap were all weakly expressed genes, thus 
the differences detected may result from the detection limit and sensitivity of the 
different platforms, which subsequently affected interplatform reproducibility of 
differentially expressed genes. Nonetheless, the discordant results could also be due to 
the probes (for each quantitative platform used) were probing different sequence 
locations in the genes (in Pparγ, Sox9 and Bglap). This discordant gene expression data, 
however, could only be minimized if probes of different platforms are custom designed 
to detect the same location of the genes. From these results, collectively, the microarray 
data has been validated with the QuantiGene® Plex assay thus supporting the use and 
interpretation of expression profiles and pathways information based on the microarray 
results.  
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5.4 Discussion 
Herein, the molecular signalling pathways regulated during GDF5-induced 
tenogenesis were identified. Firstly, the top differentially expressed genes in GDF5-
induced hMSCs and tenocytes were identified, i.e. ASPN, ARHGAP29 and CCL2 were 
the up-regulated genes; ENO2, STC1, ACAN, C7orf69, NEFM and ITGA8 were the 
consistently down-regulated in GDF5-induced hMSCs and tenocytes. Secondly, through 
the global gene expression profiles analysis, several pathways were identified as 
important pathways for tenogenesis: (i) the glycolysis and gluconeogenesis signalling 
pathways were down regulated upon GDF5 treatment in hMSC and in tenocytes; (ii)The 
cell cycle related signalling pathways were also down-regulated in the day-10 GDF5-
induced hMSCs; (iii) The activated pathways which may be crucial in tenogenesis were 
angiopoietin-Tie2 signalling, TGF-beta-dependent induction of EMT via SMADS 
signalling, PEDF signalling and VEGF signalling via VEGFR2; (iii) The cell adhesion 
and cytoskeleton remodelling signalling pathways were identified as important 
pathways at the late tenogenic differentiation stage or in mature tenocytes; (iv) the EMT 
pathway is identified as the putative pathway which is involved in GDF5-induced 
tenogenesis. Thirdly, among the candidate tenogenic marker genes, Col-I, Col-III and 
Tnc were up-regulated in the day-10 GDF5-induced hMSCs; while the Runx2 was the 
down-regulated non-tenogenic marker genes. Contradictory, Comp was also up-
regulated in day-10 GDF5-induced hMSCs. Fourthly, the AFM and fluorescence 
imaging evidence the cytoskeletal remodelling events in the GDF5-induced hMSCs. 
Fifthly, a reduction in the proliferation of GDF5-induced hMSCs was evidenced by 
reduced NST expression in GDF5-induced hMSCs. Lastly, the QuantiGene® Plex 2.0 
Assay validated the expression of the candidate tenogenic and non-tenogenic marker 
genes and showed consistent results with microarray analysis, except: (i) the Pparγ 
which was detected weakly expressed in all groups in microarray analysis, was detected 
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as up-regulated in the day-10 GDF5-induced group; (ii) the Comp were detected as up-
regulated in day-4 GDF5-induced hMSCs compared to weakly expressed as detected in 
microarray analysis; and (iii) the Bglap were detected as up-regulated in tenocytes 
compared to weakly expressed as detected in microarray analysis. 
Aspn is among the top up-regulated transcript which co-expressed in the GDF5-
induced hMSCs and in tenocytes. This gene has been reported as one of the top 
molecular markers expressed in human mature tendon (Jelinsky et al., 2010). Thus, 
Aspn may play a crucial role from the early tenogenesis to the late mature tenocyte. In 
contrary to the occurrence in mature tendon, the Aspn has also been demonstrated with a 
role in osteoblast-driven collagen mineralization, which increases the Osterix and Runx2 
expression (Kalamajski et al., 2009). However, in this current study, the expression of 
Runx2 was not up-regulated, suggesting that the asporin might play other role in the 
GDF5-induced hMSCs rather than promoting the osteoblastic function. Further, asporin 
has been reported as a negative regulator of TGF-β in cartilage, which inhibits TGF-β-
induced expression of cartilage matrix genes in ATDC5 cells (Kizawa et al., 2005), and 
in in vitro mouse model for chondrogenesis (Shukunami et al., 1997; Shukunami et al., 
1996). Conversely, in articular cartilage cells, knockdown of asporin increases the 
expression of cartilage markers and TGF-β1; in turn, TGF-β1 stimulates asporin 
expression; which suggested the asporin and TGF-β1 form a regulatory feedback loop 
(Nakajima et al., 2007). The high abundance of asporin expression detected in the 
GDF5-induced hMSCs and tenocytes may thus play a role to suppress the chondrogenic 
phenotype while promoting the tenogenic expression, i.e. Tnc expression, in the 
differentiating hMSCs.  
A previous study reported in human tendon found that Thbs4, Tnmd, Dcn and 
Mkx were among the top molecular markers of mature human tendon (Jelinsky, et al., 
2010). Consistent to that reported by Jelinsky and colleagues (2010), this current 
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experiment also found Thbs4 and Mkx as the top most up-regulated transcripts in 
tenocytes, apart from Aspn. However, the Thbs4 and Mkx were not up-regulated in the 
GDF5-induced hMSCs. Previous study in murine mesenchymal stem cell line 
C3H10T1/2 (clone 8) reported that an unknown mechanism, which associated with 
BMP type I receptor (BMPR-I i.e. ALK3), is involved in inhibiting BMP12-induced 
Thbs4 mRNA expression (Berasi et al., 2011). Therefore, it is suggested that a similar 
BMPR-mediated signalling may be involved and resulted in the low mRNA expression 
of Thbs4 in the GDF5-induced hMSCs. In addition, it has been reported that an 
establishment of the muscle-tendon junction is required for the elevated level of Thbs4 
in tendon cells (Charvet et al., 2012). The Mkx is a late tenogenic marker, which will 
only be elevated in mature tenocyte (Ito et al., 2010; Liu et al., 2010), hence, not up-
regulated in the GDF5-induced tenogenic hMSCs. 
Cytoskeletal remodelling signalling and cell adhesion signalling were identified 
as essential signalling pathways for hMSCs tenogenic differentiation, particularly in the 
expression of the earliest tenogenic markers in hMSC. Development of the cellular 
cytoskeleton during the tenogenic differentiation has been shown by previous study in 
uniaxial-cyclic-stretched hMSCs, with observations of actin stress fibers in the stretched 
hMSCs (Morita et al., 2012). This effect however, was also observed in this current 
experiment in the GDF5-induced hMSCs. Therefore, it is suggested that the 
cytoskeleton remodelling is an essential event in tenogenesis and for the tenocyte 
phenotypic expression. 
In the event of tenogenesis, the proliferation of hMSCs was reduced as 
evidenced with the reduced in NST expression in hMSCs undergoing tenogenesis. This 
finding is therefore relevant to the pathway analysis which demonstrated a down-
regulation in the cell cycle related signalling pathways in the GDF5-induced hMSCs. 
The available evidence reported that growth arrest in G1 phase of the cell cycle is 
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associated with expression of the differentiated phenotype in many cell types (Hong & 
Yaffe, 2006; Nadal-Ginard, 1978). Hence, it is suggested that a temporal coupling of 
cell cycle arrest and terminal differentiation occurs during the tenogenic differentiation 
in hMSCs. However, a more comprehensive study is required in order to show how the 
temporal and reciprocal coordination of cell-cycle arrest and tenogenic differentiation is 
achieved. This would subsequently contribute to the identification of known 
developmental regulators or pathways that directly link these two events, particularly in 
hMSC tenogenic differentiation. 
 
5.4.1 Study Limitation 
A possible limitation of this study model is that the hMSCs derived from the 
elderly donors (bone marrow donor) were compared to the tenocytes derived from the 
young donors (hamstring tendon donors). While this current study being invaluable in 
the understanding of the molecular mechanisms in human MSCs tenogenesis, it remain 
unknown whether the similar observation would be seen if hMSCs and tenocytes 
derived from the young donors of same age group were used. The bone marrow samples 
collected in this study were obtained from the patients undergoing intramedullary 
nailing, which majority of them were from elderly group. It has been reported that the 
cells from aged population may have reduced ability to self-renew and differentiate 
(Kretlow et al., 2008; Roobrouck et al., 2008). However, in this study, the MSCs 
derived from elderly donors were not compared to the tenocytes derived from the aged 
donors. This alludes to the observation of inferior cell biological characteristics in 
tenocytes derived from elderly donors (Klatte-Schulz et al., 2012). Thus, support the use 
of tenocytes from young donors for a better positive control cells, albeit the use the 
hMSCs from the elderly donors for tenogenic differentiation experiments. Thereby, this 
in vitro model is useful for the understanding of MSC tenogenesis. 
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Another possible limitation in this current experiment is that the assessment of 
cytoskeleton rearrangement by CLSM were not conducted on the same area or same 
sample scanned by AFM. Ideally, a better experimental approach to evidence the AFM 
topography results is to assess the same area scanned by AFM for CLSM imaging. 
However, due to the limitation in the equipment used in the current experiment, the 
assessment of cytoskeleton rearrangement on the same cell or same scanned area by the 
AFM was not possible. Nevertheless, the samples independently prepared for AFM and 
CLSM in the current experiment allowed an independent validation of AFM results by 
CLSM. Further, the independent sample preparation for AFM and CLSM imaging 
allowed the advantages of minimally prepared cultured cells (i.e. without any staining) 
to be used for AFM live cell imaging, hence reflected closer to the physiological 
condition. Nonetheless, the AFM instrument used for live cells imaging in this study, 
does not have the analysis module for quantifying or measuring the cellular elasticity, 
which would otherwise greatly improve the strength of the AFM imaging data, 
especially in evaluating the changes in cytoskeleton organization. 
 
5.5 Summary  
In conclusion, this study shed light on the possible signalling pathways involved 
in GDF5-induced hMSC tenogenesis and showed that the cytoskeleton remodelling 
occurred in the early tenogenic differentiation parallel with a reduction in cell 
proliferation. The top most up- or down- regulated genes identified in early tenogenenic 
hMSCs or in late mature tenocytes can potentially to be used as molecular markers in 
future studies related to tenogenic differentiation. Nevertheless, much remains to be 
explored about the tenogenesis events in hMSCs, for instance, the cell adhesion force 
change during the MSC-to-tenocyte differentiation. 
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6.0 DISCUSSIO 
6.1 Summary of the Findings  
Collectively, this study consists of three main parts. Firstly, the in vitro study of 
tenogenic inducing effects of GDF5 in hMSCs and rbMSCs was conducted. The cell 
proliferation experiments showed no significant differences in the cell proliferation rate 
between the hMSCs cultured at different concentrations of GDF5 (0, 5, 25, 50, 100 and 
500 ng/ml). In determining the potential for tenogenic differentiation, the total collagen 
assays revealed that GDF5 elicited a biphasic response in both hMSCs and rbMSCs at 
the gradient concentrations tested. The hMSCs cultured at 100 ng/mL of GDF5 
demonstrated a significant increase in total collagen levels comparable to that of 
tenocyte culture (p<0.05). On the other hand, despite only showing a significant 
increase in total collagen level in cultures supplemented with 500 ng/ml of GDF5, 
rbMSC showed no significant difference to hMSCs at 100 ng/mL of GDF5.  
Furthermore, hMSCs cultured at 100 ng/mL of GDF5 demonstrated significant up-
regulation in the candidate tenogenic marker genes (Scx, Tnc and Col-I; p<0.05) whilst 
a significant down-regulation of the non-tenogenic marker genes (Runx2 and Sox 9; 
p<0.05) at day 7 was observed. Similarly, in rbMSCs, a significant up-regulation in Scx 
and Col-I gene expression levels were detected at 100 ng/ml of GDF5. 
Immunofluorescence staining also revealed an increase in COL-I, TNMD, TNC and 
SCX expression in day 4 hMSCs and rbMSCs cultures treated with 100 ng/ml of GDF5. 
However, a significant down-regulation (p<0.05) in the Scx gene expression levels in 
rbMSCs at day 27 was detected despite having a significantly persistent Col-I up-
regulation throughout day 4 to day 27.  
Secondly, an in vivo pilot study in a rabbit infraspinatus tendon model was 
conducted to evaluate the potential of using tenogenically differentiated MSCs (TMSC; 
at the optimized response dosage of 100 ng/mL of GDF5) in clinical applications. H&E 
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and VG staining revealed significant differences in the quality of repair between the 
non-cell-based treatment groups (tendons repaired without cells; i.e. suture only, fibrin 
glue (FG) only, and suture with FG) and the cell-based treatment groups (i.e. tenocytes, 
MSC and TMSC). The TMSCs treated group displayed more mature tendon healing as 
compared to that of tenocytes and MSC groups with prominent tendon callus formation. 
Besides, improved healing in TMSC was also evidenced by cells with more elongated 
nuclei aligned parallel to the collagen fibers which more resemble histological 
appearance of the normal tendon tissue. In addition, the collagen fibers in the TMSC 
group were in highly organized orientation which showed that the tendons were at the 
late stage of healing process. Further analysis by comparing the gene expressions and 
protein expressions in cell-based treatment groups showed augmented gene expression 
levels (Scx and Col-I) and higher intensity in protein expression (COL-I, SCX, TNC and 
TNMD) in the tendon repaired with TMSC.  
Lastly, the differentially expressed genes between the control hMSCs (G1) and 
hMSCs cultured at 100 ng/mL GDF5 for 4 days (G2), hMSCs cultured at 100 ng/mL 
GDF5 at 10 days (G3), and native tenocyte cultures (G4) were identified and the 
signaling pathways potentially involved in tenogenesis events were also identified. In 
this global gene expression analysis, a list of 27,216 genes was analyzed. Significant 
differences in 954 (3.51% of the overall human transcriptome) genes were observed at 
corrected p-values (Corr p) of less than 0.05 (using Benjamini-Hochberg correction to 
control the false discovery rate). When these significant gene lists were analyzed with 
GeneGo Metacore™ Pathway Analysis, these genes were identified to be involved in 
specific pathways (i.e. cytoskeleton remodeling, cell adhesion, and extracellular matrix 
related pathways) that are closely related to the native behavior of tenocytes in vivo such 
as the adhesion of tenocytes to the tendon collagen fibers for survival under high 
tensional loading environment. In addition, several signaling pathways which may be 
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crucial for tendon development were identified, i.e. development related TGF-β-
dependent induction of EMT via SMADs signalling, TGF-β-dependent induction of 
EMT via RhoA, PI3K and ILK signalling, PEDF signalling, cross-talk between VEGF 
and angiopoietin 1 signalling pathways. Further, the cytoskeleton remodeling in GDF5-
induced hMSCs were evidenced with AFM and CSLM imaging. CSLM also revealed a 
reduction in NST expression in the differentiating hMSCs which indicated a reduced 
cell proliferation rate in the GDF5-induced hMSCs. The microarray data was validated 
with independent QuantiGene® Plex assay thus supporting the use and interpretation of 
the inferred gene expression profiles and pathways information. 
 
6.2 GDF5-induced Tenogenesis in MSC 
The findings of the in vitro studies in hMSCs and rbMSCs appeared to be 
supported by a previous study by Park and colleagues (2010) which demonstrated that 
at 100 ng/mL of GDF5 there was a significant increase in TNMD and TNC expression 
at protein level, compared to that of 10 ng/mL or lesser (Park et al., 2010). Further, the 
biphasic response in the total collagen expression where an observation of a decrease at 
25 ng/ml and an increased at 50 ng/ml of GDF5 (Figure 4.3 A), was similar to that 
reported in bovine chondrocyte COL-I expression at low concentration of GDF5 (Appel 
et al., 2009). This could possibly be explained as the GDF5 has a biphasic effect in 
inducing the collagen expression, particularly the COL-I expression, hence promoting 
differentiation into different phenotypes (chondrocytes and tenocytes) at different 
concentration levels of GDF5 and there is an alternate exclusion mechanism occurs 
(when differentiation into one cell fate (i.e. chondrocytes) is blocked, the other (i.e. 
tenocytes) is adopted). Nevertheless, a more comprehensive study, which includes 
analysis at protein level, is required in order to evidence this. 
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 In the qRT-PCR analysis, the results showed an up-regulation in Col-I, Scx and 
Tnc gene expression at mRNA levels in day 4 GDF5-induced hMSCs. These genes 
were continuously up-regulated to day 7 of induction by GDF5, except Tnc which 
showed a down-regulation. However, in comparison to the microarray and the 
QuantiGene® Plex assay, the Tnc expression was up-regulated at day 10 of induction by 
GDF-5. The temporal expression profile observed in this study was however similar to 
that observed in a rodent MSC model, which demonstrated a down-regulation of Tnc on 
day 6 upon GDF-5 treatment which eventually increased on day 9 and day 12 (Park, et 
al., 2010). Since Tnc is a late tenogenic marker, hence the up-regulation of this gene in 
the hMSCs at the latter time point (day 10) is particularly relevant. This finding was 
consistent to that observed in other study in rodent MSC model (Park, et al., 2010). The 
increased expression of this gene at a late phase of tendon development has also 
recently been documented in a study comparing the Tnc expression in tendon from the 
embryonic period to that observed at day 14 postnatal (Liu et al., 2011). The most 
studied function of Tnc is its modulation of cell adhesion and cell spreading (Chiquet-
Ehrismann & Tucker, 2004). The up-regulation in the Tnc expression may be related to 
its function in regulating cell shapes through the suppression of focal adhesion kinase 
and RhoA activity, which both have an influence on the actin cytoskeleton (Chiquet-
Ehrismann & Tucker, 2004; Chiquet et al., 2003). It is hypothesized that the up-
regulation of the Tnc may be involved in releasing tensile stress to avoid overstretching 
when the hMCS actively reorganized their cytoskeletal or forming the stress fiber upon 
induction by GDF5. 
 The increase in Scx and Col-I gene expression at mRNA level is an expected 
outcome of tenogenic MSC differentiation process. However, it is interesting to note 
that Dcn expression was not up-regulated during tenogenic differentiation (neither in the 
qRT-PCR, microarray nor QuantiGene® Plex assay), which may have been related to 
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the monolayer conditions used in this experiment (Yao et al., 2006). Culture conditions 
play a critical role in modulating the synthesis, assembly and organization of 
extracellular matrix components. In a 3D environment, Dcn is also able to modulate 
BMP/TGFβ pathway through interaction with lipoprotein-receptor related protein 
(Cabello-Verrugio & Brandan, 2007) and regulates matrix organization and mechanical 
characteristics of the three dimensional collagen matrices (Ferdous et al., 2007). This 
nonetheless may not be the case in the present study, as previous studies have shown 
that an increase in Dcn expression in monolayer rodent MSC cultures is not unexpected 
(Park, et al., 2010). 
Nevertheless, while this current study has determined the tenogenic phenotype 
of the GDF5-induced MSCs, it will thus be an important line of future investigation to 
examine how stable is the GDF5-induced tenogenic MSCs. Are the GDF5-induced 
MSCs ‘permanently’ committed to the tenogenic lineage? Will the GDF5-induced 
tenogenic MSCs undergo trans-differentiation when cultured in the trilineage 
differentiation medium (i.e. adipogenic, osteogenic and chondrogenic medium)? Would 
the GDF5-induced MSCs persistently maintain their tenogenic phenotype after the 
initial treatment with GDF5? In addition, this current study was focused on the gene 
expression at mRNA level, the expression at protein level was only determined 
qualitatively with immunostaining analysis. Hence, based on the findings of gene 
expression analysis at mRNA level of this study,  future study should focused and 
explored further at protein expression analysis, in order to reveal the biological 
significant of the changes detected in this current study. 
 
6.3 Effect of Tenogenic-MSCs in Tendon Regeneration 
The results of the pilot study found significant improvement in tendon defects 
repaired with TMSC. The tendon callus formation, occurrence of the tenocyte-like cells 
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with elongated nucleus and collagen fibers in parallel orientation to tendon’s long axis 
were only observed in the TMSC repaired tendon but not in that of the control tendon. 
This indicates that the injected TMSC were capable of producing tendon matrix, thus 
may have been integrated into the repair tissue. However, this would require a cell 
tracking study to further support this finding.  
It is plausible that the improved tendon healing observed in the TMSC repair 
group was resultant from the active involvement of TMSC in tendon healing process, 
such as, inflammation, proliferation, differentiation and ECM remodeling. When 
implanted into tendon defect area, the behavior of TMSC at the repair site is postulated 
directed by a complex set of micro-environment factors (soluble and substrate bound 
cues in the ECM and intracellular signaling) in the defect area. TMSC eventually 
participated in tendon repair in two speculative manners: (i) by proliferation to 
appropriate number of cells and subsequent differentiation into mature tenocytes for 
tendon healing, and (ii) by mediating the behavior of cells involved in the repair process 
through paracrine signaling, similar to that previously reported foe MSC in wound 
healing (Chen et al., 2008b; Wu et al., 2007). It is suggested that TMSC secreted trophic 
factors that are highly stimulatory to tendon ECM production, i.e. TGFβ (Beredjiklian et 
al., 2003) and BMP2 (Thomopoulos et al., 2012), which can play a role in regulating 
differentiation and healing kinetics (Sharma & Snedeker, 2012). However, the 
interaction between TMSC paracrine signaling and ECM cues and how they affect 
progenitor cell differentiation at the healing tendon remain to be elucidated. 
Paracrine factors plays a crucial role in tenogenic differentiation (Barboni, et al., 
2012; Sharma & Snedeker, 2012) and tendon healing (Chen et al., 2008a). Although it 
remain unclear of the exact paracrine system involved in TMSC induced tendon 
healing, current study indicated that the TMSC able to improve tendon healing better 
compared to its counterparts (repair by tenocytes nad undifferentiated MSC). As an 
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extension from this current study, future study should explore further with the use of a 
reporter gene system consisting of eGFP for molecular imaging. This ultimately would 
allow the determination of whether the observed tendon healing occurred due to the 
differentiation capability of the implanted TMSCs into mature tenocytes or by the 
secretion of cytokines and chemokines by the implanted TMSC at the repair site. 
Conversely, the native tenocytes from the surrounding of tendon defect area may release 
the paracrine factors which influence the implanted TMSC to enhance tendon healing, 
e.g. by ECM remodelling. Apart from in vivo study, this could also possibly be tested in 
an in vitro co-culture system of GDF5-induced MSCs and tenocytes; by seeding one 
cell type in the transwell chambers and the other in the plate wells, to elucidate the 
potential mutual or reciprocal effects of these two cell types. 
Apart from the paracrine effect, from this current study, question remains that 
whether or not the FG matrix provides another stimulating effect on the TMSC or 
tenocytes. Although previous study have shown that FG may be used as an injectable 
scaffold to deliver more viable cells directly into infacted myocardium (Christman et al., 
2004), the effect of the fibrin matrix on the injected TMSCs have not been explored.    
 
6.4 Potential Therapeutic Approaches 
 
The observation from the current temporal experiment indicates that it may be 
appropriate to utilize the GDF-5 induced hMSC collected at day 4 for further clinical 
application, in view of the fact that the hMSCs has already been differentiated into 
tenocytes, as indicated by the significant up-regulation of the candidate tenogenic 
marker gene and protein expression at this time point.   
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7.0 COCLUSIO 
The results of this study demonstrated that the GDF5-induced hMSCs 
differentiated along the tenogenic lineage as evidenced by the colorimetric assay, qRT-
PCR, and immunofluorescent staining. The results of the in vivo experiments suggest 
that GDF5-induced rbMSCs were superior in promoting tendon repair as compared to 
its counterpart, the undifferentiated rbMSCs and tenocytes. This finding supports the 
idea that tenogenic differentiated MSC may be a preferred source of cells in cell based 
therapy for tendon repair in the future. Further, the newly identified high abundant 
genes in the global gene expression analysis may be used as tenogenic differentiation 
markers in future studies. The identified signaling pathways which were involved in 
hMSCs tenogenesis would provide a better understanding of the molecular events in 
tendon formation. This ultimately may allow enhancement in future tendon treatment 
strategies.  
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APPE
DIX A1 
University of Malaya Medical Centre (UMMC) Ethics Approval Letter 
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APPE
DIX A2 
Donors Demographic Details  
 
Table 1 Basic demographics and the origin of tissue samples for hMSCs cultures from 
the donors. 
 
 
 
 
 
 
 
 
 
 
 
 
Donor Age 
(year) 
Gender Sampling Site Experiments 
1 (h79) 53 Female Bone marrow from femur For comparison with rbMSC 
characteristics. 
2 (h63) 60 Female Bone marrow from tibia  
3 (h65) 74 Female Bone marrow from tibia  
4 (h9) 69 Male Bone marrow from femur For in vitro tenogenic differentiation 
with GDF-5 induction in hMSC 
(collagen assay and qPCR). 
5 (h19) 67 Female Bone marrow from femur 
6 (h23) 75 Male Bone marrow from femur 
7 (hST1) 19 Male Hamstring tendon As positive control for in vitro tenogenic 
differentiation of hMSC (collagen assay 
and qPCR). 
8 (0217m) 28 Male Hamstring tendon 
9 (0223b) 21 Male Hamstring tendon 
10 (h78) 63 Female Bone marrow from femur For in vitro tenogenic differentiation 
with GDF-5 induction in hMSC 
(microarray analysis) and imaging 
analysis. 
11 (h79) 53 Female Bone marrow from tibia  
12 (h74) 75 Female Bone marrow from tibia  
13 (h76) 62 Female Bone marrow from tibia  
14 (h83) 85 Female Bone marrow from femur 
15 (h90) 65 Female Bone marrow from tibia  
16  (02h23) 21 Male Hamstring tendon As positive control for in vitro tenogenic 
differentiation of hMSC (microarray 
analysis) and imaging analysis. 
17 (02h16) 20 Male Hamstring tendon 
18 (02h27) 29 Female Hamstring tendon 
19 (02h33) 26 Male Hamstring tendon 
20 (02h07) 23 Male Hamstring tendon 
21 (02h17) 28 Male Hamstring tendon 
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Animal Care and Use Committee, Faculty of Medicine, University of Malaya 
Ethics Approval Letter 
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APPE
DIX C 
Preparation of Trilineage Differentiation Medium 
I. Preparing StemPro® Osteogenesis Differentiation medium (Invitrogen, 
Carlsbad, California, USA) 
 
Osteogenesis differentiation medium Final 
Conc. 
For 
100 ml 
StemPro® Osteocyte/Chondrocyte Differentiation Basal medium 1X 90 ml 
StemPro® Osteogenesis supplement 1X 10 ml 
Gentamicin (10 mg/ml) 5 µg/ml 50 µl 
 
II. Preparing StemPro® Adipogenesis Differentiation medium (Invitrogen, 
Carlsbad, California, USA) 
 
Osteogenesis differentiation medium Final 
Conc. 
For 
100 ml 
StemPro® Adipocyte Differentiation Basal medium 1X 90 ml 
StemPro® Adipogenesis supplement 1X 10 ml 
Gentamicin (10 mg/ml) 5 µg/ml 50 µl 
 
III. Preparing standard chondrogenesis differentiation medium  
Standard chondrogenesis medium were prepared according to standard method 
previously described by Mackay et al. 1998 (Tissue Engineering (1998) 4(4): 415) 
as follow: 
 
DMEM-high glucose supplemented with 10 ng/ml TGF-β3 (Invitrogen-Gibco, 
USA), 100nM dexamethasone (Sigma–Aldrich, USA), 50 µg/ml ascorbic acid-2-
phosphate (Sigma–Aldrich, USA), 100 µg/ml sodium pyruvate (Invitrogen-Gibco, 
USA), 40 µg/ml proline (Sigma–Aldrich, USA) and 1X ITS (Sigma–Aldrich, 
USA). 
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APPE
DIX D 
Optimization of Primers for qRT-PCR 
Protocol: 
To determine the optimal annealing temperature of each primer set, gradient PCR was 
conducted. 2 µL of each dilution was added to 20 µL of PCR reaction mixture, 
containing 10 uL iQ
TM
 SYBR® Green Supermix (Bio-Rad Laboratories, Inc., Hercules, 
CA), 0.6 µL cDNA samples, and 0.2 µM of each primer (forward and reverse primers; 
Table 2.4). The amplification protocol was as follows: an initial denaturation and 
activation step at 95
o
C for 30 s followed by 40 cycles of 95
o
C for 15 s and gradient 
temperature ranging from 55
 o
C to 65
o
C for 45 s. Following amplification, a melting 
curve program was carried out to confirm the presence of a single product (55-95
o
C 
with a heating rate of 0.5
o
C per second and a continuous fluorescence measurement). 
Data was analysed with the CFX manager software. The optimum annealing 
temperature was determined based on the cycle threshold (Ct) value at different 
annealing temperature. Primers used for qRT-PCR in rabbit samples, which derived 
from human or other animal sequences, were checked for its specificity via DNA 
sequencing analysis. 
 
Sequencing results of primers used for rabbit qRT-PCR: 
>glyceraldehyde_3_phosphate_dehydrogenase_1st_BASE_248889_A1_A_f.ab1 
GNGCGAGGGCAGTCATCCCTGAGCTGACGGGAAGCTCACTGGCATGGCCTTCCGTGTCCCCACTGCCA
ACGTGTCAGTGGTGGACCTGACCTGCCGTCTAGAAAAACCTGCCAAATATGATGACATCAAGAAGGTG
GTGAAGCAGGCGTCGGAGA 
 
>scleraxis_homolog_B_1st_BASE_248891_B1_B_f.ab1 
NNNNNNNNNNNCGCAACNTCTCATCCTTGGAGAGCTTGCGGTTCGGCGGGCTTCGGTGGGGATCAG
CGTGCGCAGCGCCGTGAAGGCCGTGTTCACGCTGTTGGTGCGGTCTCGCTCGCGCGCGTTCGCCGTGT
GCCGCTG 
 
>collagen_type I_alpha 1_1st_BASE_248893_E1_E_f.ab1 
NNTGTCAGGCTCCTGGCTCTCCTGGTGACAAGGTCCCTCTGGAGCCTCTGGTCCTGCTGGTCCCCGAGG
TCCCCCTGGCTCTGCTGGTGCTCCTGGCAAAGATGGACTCAACGGTCTCCCTGGCCCCATTGGGCCCCC
TGGTCCTCGCGGTCGCACTGGTGATGCTGGTCCTGTTGGTCCCCCCGGCCCTCCTGGACCTCCTGGTCC
CCCTGGTCCTCCCAGCGCTGGTTCGACTTCAGCTTCCTGCCCCAGCCACCTCAAGAGAAGGCTCACGAT
GGTGGCCGCTACTACCGGGCTGATGATGCCAATTGTGGTTCGA 
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APPE
DIX E1 
Electropherogram of Total R
A Samples Used for Microarray Experiment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample 2 
Conc:  
1412.50 
ng/µl 
RIN: 8.40 
rRNA ratio: 
1.85 
Sample 6 
Conc:  
1251.67 
ng/µl 
RIN: 8.70 
rRNA ratio: 
1.63 
Sample 4 
Conc:  
2411.37 
ng/µl 
RIN: 9.10 
rRNA ratio: 
1.65 
Sample 5 
Conc:  
3370.61 
ng/µl 
RIN: 9.20 
rRNA ratio: 
1.37 
Sample 46 
Conc:  
986.74 
ng/µl 
RIN: 8.60 
rRNA ratio: 
1.88 
Sample 47 
Conc:  
535.34 
ng/µl 
RIN: 9.00 
rRNA ratio: 
2.06 
Sample 28 
Conc:  
190.17 
ng/µl 
RIN: 7.60 
rRNA ratio: 
2.04 
Sample 27 
Conc:  
488.63 
ng/µl 
RIN: 8.40 
rRNA ratio: 
1.62 
Sample 12 
Conc:  
496.63 
ng/µl 
RIN: 9.00 
rRNA ratio: 
1.58 
Sample 11 
Conc:  
493.19 
ng/µl 
RIN: 9.00 
rRNA ratio: 
1.71 
Sample 7 
Conc:  
928.95 
ng/µl 
RIN: 8.30 
rRNA ratio: 
1.70 
Sample 16 
Conc:  
488.58 
ng/µl 
RIN: 8.80 
rRNA ratio: 
1.80 
Sample 17 
Conc:  
396.79 
ng/µl 
RIN: 9.00 
rRNA ratio: 
1.83 
Sample 15 
Conc:  
168.09 
ng/µl 
RIN: 8.70 
rRNA ratio: 
1.78 
Sample 8 
Conc:  
498.15 
ng/µl 
RIN: 9.00 
rRNA ratio: 
1.81 
Sample 10 
Conc:  
1276.98 
ng/µl 
RIN: 9.00 
rRNA ratio: 
1.97 
Sample 14 
Conc:  
324.42 
ng/µl 
RIN: 9.10 
rRNA ratio: 
1.76 
Sample 19 
Conc:  
131.03 
ng/µl 
RIN: 8.10 
rRNA ratio: 
1.52 
Sample 20 
Conc:  
164.78 
ng/µl 
RIN: 7.30 
rRNA ratio: 
1.40 
Sample 18 
Conc:  
92.39 
ng/µl 
RIN: 8.70 
rRNA ratio: 
1.59 
Sample 29 
Conc:  
207.415 
ng/µl 
RIN: 8.80 
rRNA ratio: 
1.69 
Sample 34 
Conc:  
155.79 
ng/µl 
RIN: 7.40 
rRNA ratio: 
1.43 
Sample 35 
Conc:  
206.42 
ng/µl 
RIN: 8.30 
rRNA ratio: 
1.29 
Sample 37 
Conc:  
117.77 
ng/µl 
RIN: 9.40 
rRNA ratio: 
1.85 
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APPE
DIX E2 
Quality and Integrity of Total R
A Samples and Their Respective cD
A 
Concentration Amplified From 200 ng of Total R
A 
The quality control tests of total RNA was conducted with Agilent Bioanalyzer 
and Nanodrop spectrophotometry. In this study, only total RNA with high purity and 
integrity (with no evidence of degradation) were used for the microarray experiment in 
order to prevent any false positive or false negative results contributed by the low 
quality total RNA. Overall, the integrity of total RNA samples as indicated by RIN was 
8.62±0.56; and the purity as indicated by A260/A280 ratios was 2.10±0.03, to ensured 
excellent amplification for microarray hybridization. Two hundred nanogram of total 
RNA were used and the concentrations of cDNA after amplification by the Applaus™ 
WT-Amp ST System (NuGEN Technologies, Inc, San Carlos, CA, USA) for microarray 
target preparation were as indicated in the table below.  
 
Sample 

o 
Total R
A 
concentration (ng/µl) 
Ratio 
A260/A280 
R
A Integrity 

umber (RI
) 
Concentration of 
cD
A (µg/µl) 
2 2266.1 2.10 8.40 1.250 
4 1209.7 2.08 9.10 0.625 
5 2171.9 2.08 9.20 0.500 
6 1698.4 2.10 8.70 0.417 
7 411.1 2.07 8.30 0.357 
8 202.9 2.08 9.00 0.313 
10 584.3 2.07 9.00 0.250 
11 284.8 2.09 9.00 0.227 
12 177.1 2.09 9.00 0.208 
14 116.7 2.10 9.10 0.179 
15 138.1 2.10 8.70 0.167 
16 175.8 2.10 8.80 0.156 
17 127.4 2.09 9.00 0.147 
18 53.9 2.20 8.70 0.139 
19 41.2 2.19 8.10 0.132 
20 52.6 2.14 7.30 0.125 
27 93.6 2.10 8.40 0.093 
28 140.2 2.10 7.60 0.089 
29 113.0 2.10 8.80 0.086 
34 141.1 2.10 7.40 0.074 
35 302.6 2.10 8.30 0.071 
37 94.3 2.10 9.40 0.068 
46 1327 2.10 8.60 0.054 
47 584 2.10 9.00 0.053 
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APPE
DIX F 
QuantiGene® Plex 2.0 Assay (11904 Human) Reagent System 
Bead 

umber 
Gene 
Symbol 
Genbank 
Accession 
o 
Seq 
Length 
Probe set 
region Type Target 
ame 
13 RUNX2 NM_004348 5720 648-1082 Target Runt-related transcription factor 2 
14 MMP3 NM_002422 1828 1119-1775 Target Matrix metallopeptidase 3 
20 SCXA NM_001008271 606 251-574 Target Homo sapiens scleraxis homolog A (mouse) (SCXA) 
21 COMP NM_000095 2471 1420-1842 Target Homo sapiens cartilage oligomeric matrix protein (COMP), mRNA 
25 PGK1 NM_000291 2439 1609-2233 HKG Phosphoglycerate kinase 1 (Medium High abundant HKG) 
27 COL2A1 NM_001844 5087 1788-2258 Target Type-II alpha 1 (primary osteoarthritis, spomdyloepiphyseal dysplasia, congenital) 
30 FIGF NM_004469 2128 835-1476 Target c-fos induced growth factor (vascular endothelial growth factor D) 
34 HPRT1 NM_000194 1435 102-646 HKG Hypoxanthine phophoribosyltransferase 1 (Medium abundant HKG) 
43 ALPL NM_000478 2596 1075-1617 Target Alkaline phosphatase, liver/bone/kidney 
44 BGLAP NM_199173 552 113-477 Target Bone gamma-carboxyglutamate (gla) protein 
45 PPARG NM_005037 1818 567-1044 Target Peroxisome proliferative activated receptor, gamma 
46 TNC NM_002160 8605 2687-3165 Target Tenascin C 
53 SOX9 NM_000346 3963 1607-2274 Target SRY(Sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal) 
56 TNMD NM_022144 1360 301-1020 Target Homo sapiens tenomodulin (TNMD) 
57 TBP NM_003194 1921 277-822 HKG TATA box binding protein (Low abundant HKG) 
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APPE
DIX G1 
Unstained Control Used to Adjust the PMT Voltage for Flow Cytometry Analysis 
1. Dot plot of an example of unstained control used to adjust the PMT voltage: 
 
 
 
2. PMT voltages were adjusted with the unstained control tube before recording the 
single-stained control (with BD CompBead). 
Histograms of fluorescence signals detected for the unstained control after adjusted 
the PMT voltage:  
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APPE
DIX G2 
Examples of the Gated Histogram of Single-stained Controls (BD CompBead) 
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APPE
DIX H 
Preparation of Staining Solutions 
I. Preparing 1% (w/v) Eosin Y Stain  
Eosin Y   10.0 g 
Distilled water  200 ml 
95% ethanol  800 ml 
All the components were mixed to dissolve and the stock solution was stored at 
room temperature. The eosin solution was filtered prior to use. 
 
II. Preparing Oil Red O Stain 
An oil red O stock solution was prepared by adding 300 mg of Oil Red O powder to 
100 mL of 99% isopropanol. This stock solution is only stable for one year from 
the date it was made. 
In the fume hood, 3 parts of Oil Red O stock solution was mixed with 2 parts of 
deionized water. The mixture was incubated for 10 min at room temperature. This 
working solution must be prepared prior to use because it is only stable for 2 hours. 
The Oil Red O working solution was completely filtered through the Whatman 
filter paper in a funnel above a vessel before used for staining. 
III. Preparing Safranin O and Fast green Stain 
1. Modified Weigert’s iron hematoxylin 
Stock solution A (This stock solution is only stable for 4 months): 
Hematoxylin   10.0 g 
80% Ethanol   500.0 ml 
 
Stock solution B (This stock solution is only stable for 4 months): 
Ferric chloride   20.0 g 
Distilled water   475.0 ml 
Hydrochloride acid (36.5-38%) 5.0 ml 
 
Working Modified Weigert’s iron hematoxylin (This working solution is only 
stable for 1 week) 
Equal parts of stock A and B were mixed. 
 
2. 1.0% acid-alcohol 
70% ethanol   500.0 ml 
Hydrochloride acid (36.5-38%) 5.0 ml 
 
3. 0.02% Fast green 
Fast green   0.05 g 
Distilled water   250.0 ml 
 
4. 1.0% acetic acid 
70% ethanol  100.0 ml 
Acetic acid, glacial 1.0 ml 
 
5. 1% safranin O 
Safranin O  2.5 g 
Distilled water   250.0 ml 
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APPE
DIX I1 
Comparison of hMSCs and rbMSCs Phenotypic Expression 
 
 
The hMSCs and rbMSCs were stained with antibodies against the indicated antigens 
(labeled on top of the figures) and analyzed by flow cytometry. Representative 
histograms are displayed. The y axis indicated the event count, and the x axis indicated 
the mean fluorescence intensity in a log (10
0 
to 10
5
) scale. The isotype control 
histograms are shown above their respective stained sample histograms. The results 
showed that rbMSCs expressed CD29, CD44, CD73, CD81, CD90, but do not 
expressed CD34, CD45, CD177 and HLA-DR.  
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APPE
DIX I2 
Expression of CD105, CD166, CD14 and CD19 on hMSCs 
 
Representative histograms are displayed. The y axis indicated the event count, and the x 
axis indicated the mean fluorescence intensity in a log (10
0 
to 10
5
) scale. The isotype 
control histograms are shown above their respective stained sample histograms. The 
results showed that hMSCs expressed CD105 and CD166 but does not expressed CD14 
and CD19. Representative histograms illustrate relative number of cells vs. mean 
fluorescence intensity. 
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APPE
DIX J 
Volcano Plots of Log2-ratios vs –Log10 p-value for Uncorrected p-value (Left) and the Corrected p-value (Right) 
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APPE
DIX K 
List of Genes Modulated in hMSCs by GDF5 Treatment and Genes Modulated in 
Tenocytes (Total: 954 genes) 
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